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Background: Hypoxia (a pathologically low oxygen level) is a well-established driver of aggressive behaviour 
in prostate cancer (PCa), the second most common cancer in men worldwide. MicroRNAs (microRNAs) are 
short non-coding RNA molecules that are essential for many cell processes by regulating gene expression 
post-transcriptionally. In prostate cancer, several microRNAs are abnormally expressed but the relationship 
between microRNAs and the hypoxic response has not been extensively studied. The primary objective of 
this thesis was to investigate the expression and functional role of microRNAs in response to hypoxia in 
prostate cancer. 
 
Methods: Three laboratory models of hypoxia were utilised: (i) in vitro PCa cell line culture at 0.1% oxygen, 
(ii) 3D cell spheroid culture, and (iii) an in vivo murine tumour xenograft experiment. MicroRNA expression 
was monitored by RT-qPCR to establish a list of hypoxia-responsive microRNAs. The effect on mRNA targets 
was determined by RT-qPCR, western blot and luciferase assay following transient transfection to over-
express the microRNAs. For miRNAs that were upregulated by hypoxia in all three models, functional 
bioassays were used to examine the effect on PCa cell proliferation, migration and invasion. Regulation of 
miRNA expression by DNA methylation was explored by pyrosequencing.  The laboratory work was 
complemented by in silico and next-generation sequencing (NGS) analyses of data collected from human 
prostate tumours, including prostate cancer datasets archived in The Cancer Genome Atlas (TCGA) 
repository. Bioinformatics analyses was also utilised in collaborative work investigating the impact of 
androgen receptor variants (ARV) on gene expression. Finally, a systematic review and meta-analysis on 
the role of appetite-regulating hormones in prostate cancer development was performed.   
 
Results: The hypoxic models generated novel data demonstrating that miR-210, miR-21 and miR-196a were 
upregulated by hypoxia. In the case of miR-210 and miR-21, functional assays showed they could contribute 
to tumour progression by regulation of an adhesion protein (NCAM) and by increasing clonogenicity and 
migration, respectively. In silico TCGA analyses revealed that the expression of both microRNAs correlated 
significantly with markers of hypoxia and tumour aggressiveness in clinical samples, providing strong 
evidence for their role in prostate tumour progression. NGS data analyses and methylation analysis 
generated results to show how bioinformatics can identify key networks of cellular signalling associated 
with hypoxia and epigenetic regulation of microRNA expression. Collaborative bioinformatics analyses also 
utilised NGS data to demonstrate how ARV can contribute to prostate cancer progression. The systematic 
review revealed that obesity related hormones may also be important in prostate cancer development.  
 
Conclusions: This thesis provides evidence that microRNAs play a crucial role in the progression of prostate 
cancer through hypoxia-related mechanisms. The data presented builds upon previous research of 
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microRNA function in prostate cancer by presenting novel results linking individual microRNAs with 
hypoxia-associated tumour progression. Increasing our understanding of the functionality of specific 
microRNAs in prostate cancer will be crucial in developing this exciting field of research so that it can inform 
precision medicine and improve patient outcome. This work provides evidence that microRNA profiling has 


























Chapter 1: General Introduction 
1.1 Prostate cancer 
1.1. I. Structure and function of the prostate  
The prostate is a small gland of the male reproductive system of most mammals, which is located under 
the bladder and wraps partially around the urethra. In humans, the prostate is about the size of a walnut 
and consists of three anatomical zones: the peripheral zone, the central zone, and the transition zone. The 
peripheral zone is the largest (accounting for around 65% of the prostate) followed by the central zone 
(around 25%) and the transitional zone (5-10%) (McNeal, 1981). The prostate is an exocrine gland, its 
secretions mix with fluid from the seminal vesicles and sperm from the testes, and it contributes 30-35% 
of the fluid in ejaculate. The prostate is highly muscular and its contractions propel the ejaculate. Like other 
glands, histologically it contains pouches (acini) of secretory cells (Figure 1). These secretory cells are also 
known as luminal cells, since they are the innermost cells within the lumen of the acini, and they are 
enveloped within a basal cell layer and basal lamina, which together comprises the basement membrane. 
The acini are embedded within layers of smooth muscle. Histologically, the three zones appear very similar 
but have distinct enzymatic and receptor profiles, for instance the androgen receptor is enriched in the 
peripheral zone and most prostate tumours arise from this zone (Al Kadhi et al., 2017). 
 
            
Figure 1. Diagram of a prostatic acinar. Luminal cells secrete seminal fluid into the lumen, encapsulated by a layer of 
basal cells and the basal lamina membrane, nested within the stromal network and components of the extracellular 
matrix (such as laminin and collagen).  
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The prostate is not a vital organ but has an essential function in reproduction. Prostatic secretions are 
critical for effective fertilisation, as they contain prostate specific antigen (PSA) which counteracts clotting 
factors from the seminal fluid, allowing the sperm to migrate up the uterus from the cervix. Prostatic 
secretions are also alkaline, which buffers and protects sperm in the acidic environment of the vagina. The 
prostate also acts as a filter, removing toxins from the seminal fluids to protect sperm and promote 
effective impregnation (Verze, Cai and Lorenzetti, 2016). Moreover, the prostate produces an essential 
enzyme, 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT) (Randall, 1994). 
Testosterone and DHT are androgens (sex hormones produced by the gonads and adrenal glands) that 
stimulate the androgen receptor (AR), although DHT is over ten times more potent an agonist. The AR is 
widely expressed across the body and androgens regulate a myriad of body functions including cognition, 
mood, bone and muscle function, libido, and puberty. With ageing, the accumulation of toxins in the 
prostate, due to its filter function, affects production of 5-alpha-reductase which is evident by a decline in 
libido and also increases the risk of prostate cancer (PCa) (Bain & Bain, 2007). There are two sphincter 
muscles in the urethra, at the base of the prostate (external lower sphincter) and at the intersection with 
the bladder (internal upper sphincter), which act as valves and allow the flow of either ejaculate or urine. 
Abnormalities in prostate function, such as hyperplasia, cancer, prostate enlargement, or surgeries, can 
damage the sphincters resulting in loss of integrity of the sphincter muscles and causing urinary 
incontinence or retrograde ejaculation (ejaculatory fluid entering the bladder) (Mobley, Feibus and Baum, 
2015). 
1.1. II. Carcinogenesis  
Carcinogenesis refers to the transformation of a healthy cell into a cancer cell via mutations that affect 
specific processes, giving rise to cells with specific features or “hallmarks”, and causing the cell to become 
deregulated and proliferate uncontrollably within its tissue. The hallmarks of cancer are: 1) Genome 
instability and mutation (ineffective repair pathways causing an accumulation of unrepaired damage). 2) 
Sustained proliferative signalling in the absence of growth factors. 3) Evasion of growth suppressors. 4) 
Suppression of cell death pathways. 5) Replicative immortality (due to a constitutively active telomerase). 
6) Angiogenesis (beckoning of blood vessels). 7) Capacity for invasion, extravasation and metastasis. 8) 
Reprogramming of cellular energetics (abnormal metabolism). 9) Tumour-promoting inflammation. 10) 
Subversion of immune surveillance (hiding from immune cells) (Hanahan and Weinberg, 2011).  
A healthy cell transforms into a cancer cell by relatively simultaneous mutations occurring in these key 
pathways (driver mutations). Due to the combination of genome instability, an accumulation of DNA-
damaging agents such as toxic by-products of metabolism, and the inhibition of cell death, the transformed 
cell continues to acquire mutations, resulting in increasingly malignant phenotypes. Therefore, as tumours 
grow the cancer cells often become more aggressive as they acquire additional mutations, and tumour 
aggressiveness can sometimes be a function of time. However, the rate of progression is highly dynamic 
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and depends on the types of initial mutations (for instance, determining the propensity for metastasis) as 
well as the individual environment of the tumour. As an illustration of this phenomenon, in most cases PCa 
is indolent (slow growing), although a small subset will rapidly grow and metastasise. Increased 
understanding of the genetics of PCa is necessary to understand why some tumours turn out to be more 
dangerous than others (Shao et al., 2009). 
1.1. III. Epidemiology and risk factors 
Despite being indolent in the majority of diagnoses, PCa is now the second most common cancer in men 
worldwide. The high prevalence of total disease makes PCa the fifth-leading cause of male cancer deaths 
worldwide (Ferlay et al., 2015). Moreover, the global incidence of PCa is predicted to increase to 1.7 million 
new cases and 499,000 new deaths by 2030, due to population increase and ageing alone, without 
considering the increase in risk-associated lifestyle factors and behaviours (Ferlay et al., 2010). 
Interestingly, the incidence across populations varies hugely, up to 30-fold across certain registries. The 
highest observed incidence is in USA Blacks, followed by France, then Australia. The striking differences in 
incidence are partly due to genetic susceptibility, for example, there is a particularly high incidence in some 
populations of African descent, although critical individual germline mutations have not been identified. 
Populations with the highest mortality are Trinidad and Tobago (44 deaths per 100,000 people per year), 
followed by USA Blacks (25 deaths per 100,000), Cuba (23.5 deaths per 100,000), and South Africa (22.4 
deaths per 100,000). Asia has the lowest rates of incidence and mortality in the world (Torre et al., 2015). 
In the UK, over 11,000 men died from PCa in 2016 (Cancer Research UK, 2019). The differences in incidence 
and mortality rates also reflect differences in diagnostic practices, genetic and lifestyle differences, and 
most importantly the differences in the treatment options available. Therefore, improvements in PCa 
treatments and prevention strategies could negate the natural increase in incidence due to population 
growth and ageing. 
There are several confirmed risk factors for PCa: older age (above 60 years) (Glass, Cary and Cooperberg, 
2013), black race/ethnicity (Thompson et al., 2006), and a family history of PCa (Brawley, 2012). Although 
not considered confirmed risk factors by the World Health Organization (WHO), certain lifestyle factors 
may increase the risk of PCa, such as a high consumption of red meat and animal fats, obesity, and physical 
inactivity. Increasingly unhealthy “Western” lifestyles, ageing populations, and better treatments for major 
killers such as cardiovascular disease and breast cancer, is responsible for the increasing relative incidence 
in PCa (Torre et al., 2015).  
Chapter 6 is a Systematic Review and Meta-Analysis, which I wrote to address whether certain appetite-
regulating (and obesity-related) hormones associate with the risk of PCa or the risk of an advanced or lethal 
form of the disease.  
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1.1. IV. Classification of prostate tumours 
As previously mentioned, the majority of prostate tumours do not necessarily pose a threat to the patient’s 
life (thus not considered “high-risk”). Yet, despite a vast number of published studies analysing the 
aetiology and treatment of PCa, there is not yet a consensus on what comprises a “high-risk” tumour. 
Accurate identification of high-risk tumours is paramount to ensure early intervention, and prevent over 
treatment of indolent tumours. The following sections discuss the various classification measures, to 
introduce the biochemical progression of PCa, to introduce diagnostic methods, and to highlight that new 
diagnostic tools are needed to supplement these approaches.  
The most common means of tumour classification is to measure the physical extent of the tumour (tumour-
node-metastasis (TNM) scale) or by histological examination alone (Gleason grading). Gleason grading 
scores the tumour as a sum of the two most common histological patterns, from 1 (well-differentiated 
cells) to 10 (de-differentiated cells with highly deteriorated tissue structure) (Figure 2). However, what is 
deemed a “high-risk” tumour varies considerably between these approaches, and despite extensive work 
to improve the stratification of PCa subtypes, significant heterogeneity in prognosis is observed within the 
“high-risk” groups (Chang et al., 2014). This was demonstrated by a study that compared the different 
classification schemas, to prediction the 5-year relapse-free survival outcomes of a PCa cohort. The 
different classification schemas produced probabilities ranging from 49-80% (Yossepowitch et al, 2007).  
Evidently, there is a need for more accurate diagnosis of the most aggressive cancer phenotypes. A new 
“grade group” system (which distinguishes between the two types of Gleason grade 7: 3+4 and 4+3) was 
designed to determine more accurately the patients prognosis, since 4+3 has been correlated with 
significantly poorer outcomes (Pierorazio et al., 2013). Furthermore, Gleason grade is utilised when PCa 
has reached the stage where biopsy is required, so earlier biomarkers of PCa development would therefore 




Figure 2. The original Gleason Grade diagram, drawn by Dr. Donald Gleason in 1966. Histological classification of 
cancer progression from well-differentiated to poorly-differentiated (grades 1-5), with details on histological 
appearance at each grade. From (American Urological Association, 2019), usage rights: non-commercial use. Adapted 
with text from (Chen and Zhou, 2016) 
 
1.1. V. Screening and biomarkers 
As with most cancers, early diagnosis greatly improves PCa prognosis. To improve early detection, PCa 
screening was widely employed in the late 1980s and 1990s in many high-income countries such as the 
USA, for men over the age of 60 years. This involved the routine measurement of serum levels of PSA, 
which serves as a marker of prostatic overgrowth (i.e., cancer). PSA screening in the USA lead to a steep 
increase in the number of cases diagnosed, which then tailed off slightly as the bulk of cases had been 
diagnosed (Center et al., 2012). However, the PSA test, while highly specific for prostate cells and indicative 
of prostate cell masses, is not specific to cancer cells. For instance, PSA levels are increased during the 
presence of benign prostatic hyperplasia (BPH, a non-cancerous type of cyst) and by low-risk tumours. A 
large proportion of the cases diagnosed by PSA screening in these populations turned out to be low-risk, 
indolent tumours. Considering the prostate is an inessential organ, arguably these tumours would be best 
left untreated unless noticeable symptoms develop that would indicate tumour progression to a high-risk 
state and puts the patient at risk of metastasis. PSA screening is thus associated with the over-diagnosis of 
indolent tumours, and a large study estimated that 23-42% of screening-detected PCa were indolent 
(Draisma et al., 2009). These patients typically undergo a transurethral or transrectal biopsy, which has 
high risk of serious side effects: urinary incontinence, impotence, or sepsis. Furthermore, there are 
conflicting reports on the actual efficacy of PSA screening in terms of its effect on reducing PCa-specific 
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mortality. Initial evidence from the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial, which gathered mortality results after 13 years of follow-up, reported that screening was associated 
with reduced PCa-specific mortality (Andriole et al., 2012). However, an analysis of eight European 
countries found no improvement in mortality rate associated with PSA screening (Schröder et al., 2012). 
Based on this, PSA screening for PCa is now not in practice in any country in the world, at least for men 
with average risk. However, it is important to note that PSA testing remains the single best way to monitor 
biochemical recurrence following primary treatment for PCa. That is, its prostate cell specificity makes it 
ideal for monitoring tumour recurrence following surgical removal of the entire prostate. 
A promising approach to improve the identification of “high-risk” tumours is the use of cellular markers 
measured at biopsy. A set of protein biomarkers that could predict “high-risk” patients’ response to 
androgen deprivation therapy (ADT) were identified, including P16, Ki-67, MDM2, Cox-2, and PKA (Roach, 
Waldman and Pollack, 2009). Subsequently, a four-gene signature was identified that predicted 
biochemical recurrence and lethal metastasis, by expression of PTEN, SMAD4, cyclin D1, and secreted 
phosphoprotein 1 (Roach, Waldman and Pollack, 2009). A panel of cell cycle markers was validated using 
advanced PCa specimens, as able to accurately predict post-RP outcomes. This panel included markers of 
proliferation and PI3K/PTEN signalling, as well as copy number variations, and the authors proposed it be 
used in addition to Gleason scoring to assess aggressiveness. Several gene expression panels measuring 
gene expression in biopsy cores by RT-qPCR have been marketed to indicate “high risk” tumour behaviour, 
such as the 46-gene panel Prolaris test and the 17-gene panel Oncotype DX test, by Myriad Genetics (Salt 
Lake City, Utah) and Genomic Health (Redwood City, California), respectively (Cooperberg et al., 2013). 
One of the most promising new biomarkers of PCa is the prostate cancer gene 3 (PCA3), a long non-coding 
RNA. This reliably correlates with histopathological features such as tumour volume and positive surgical 
margins and can distinguish tumours of Gleason score 6 from ≥7, and stage pT0/2 from pT3/4. PCA3 is 
reliably cancer-specific, although it is not specific to prostate cells, and so could be biased by the presence 
of tumour cells from other tissues (whereas PSA is tissue-specific but not cancer-specific). PCA3 is detected 
from the urine and is thus non-invasive (Cooperberg et al., 2013). Therefore, attention is increasingly 
focused on monitoring cellular features as well as global tumour parameters, and liquid biopsies are ideal 
since they do not require an invasive biopsy procedure.  
In summary, despite advances in clinical classification and screening methods, many patients who present 
with a seemingly localised tumour still die each year from PCa, and arguably represent the true “high-risk” 
cases. Since the diagnostic procedures are unpleasant and risky, there is a clear need for biomarkers that 




1.1. VI. Genomics and molecular subtypes 
Compared to other cancers, PCa has a relatively low occurrence of germline mutations although notably, 
germline BRCA2 mutation confers a 5-7 times increased risk of PCa and BRCA1 mutation confers a 3.8 time 
risk in men younger than 65 years old (Attard et al., 2016). There may also be an increased risk of PCa for 
men with defects in the DNA repair enzymes CHEK2, NBS1, PALB2, and BRIP1, although the associations 
are not strong (Attard et al., 2016). 
The most common genetic aberration in PCa is fusion of E26 transformation-specific (ETS) transcription 
family members (ERG, FLI1 and ETV1) with the 5’ region of androgen response genes. In particular, fusion 
of TMPRSS2 and ERG genes which occurs in approximately 50% of PCa. ETS transcription factors regulate 
growth-related pathways such as the cell cycle, migration and differentiation. Therefore, deletions or 
translocations that place oncogenic ERG downstream of TMPRSS2 causes ERG to become androgen 
responsive (Lara et al., 2016). Aberrations in PTEN are also highly common and associate with poor 
prognosis; around 10% of PCa have mutations in PTEN, it is deleted in 10-70% of tumours removed by RP, 
and in over 50% of metastatic PCa (Roviello et al., 2016). Genome-wide association studies (GWAS) of PCa 
have implicated numerous SNPs, such as 8q24, which affects the expression of c-Myc (Attard et al., 2016). 
Notably, two recent and very large sequencing studies have demonstrated molecular subtypes of localised 
and metastatic PCa. As part of The Cancer Genome Atlas (TCGA) database of cancer genomics, a cohort of 
333 primary prostate carcinomas were analysed by RNA-seq, DNA-seq, methylation array, reverse phase 
protein lysate microarray (RPPA) as well as histopathological features. Tumour data was normalised to non-
tumour tissue (from the same patient’s organ) to determine differentially expressed genes and mutational 
and epigenetic events. In TCGA prostate adenocarcinoma (PRAD) cohort, 74% of the tumours sequenced 
could be categorised into seven subtypes, defined by specific gene fusions (ERG, ETV1 or ETV4, FLI1) or 
mutations (SPOP, FOXA1, IDH1). Twenty-five percent of the tumours had mutations in PI3K and MAPK 
signalling pathways, and DNA damage response genes were inactivated in 19% of the tumours. However, 
a limitation of this cohort is that all were localised tumours. A similar approach was subsequently employed 
to analyse 150 metastatic samples (Robinson et al., 2015). Similarly, 40-60% of the tumours had 
abnormalities in the androgen receptor, ETS genes, TP53, and PTEN, with the latter two notably enriched 
compared to primary PCa. Again, BRCA1, BRCA2 and ATM (DNA-damage response mediators) were 
increased in this metastatic cohort compared to primary PCa. This study also revealed novel aberrations in 
PIK3CA/B, R-spondin, BRAF/RAF1, APC, b-catenin, and ZBTB16/PLZF. Opportunely, 89% of the tumours 
presented aberrations that are already clinically targetable, such as in the androgen receptor or other 
cancer-associated genes, and 8% of cases had actionable germline mutations (Robinson et al., 2015). 
Recently, further analysis of 360 metastatic samples identified an immunogenic subtype characterised by 
loss of CDK12 (due to biallelic inactivating mutations) meaning that they may be targetable by checkpoint 
blocking agents (Wu et al., 2018). 
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1.1. VII. Epigenetics 
1.1. VII. a)  Epigenetic modifications 
Epigenetics refers to heritable DNA modifications that do not involve changes to the sequence, such as the 
addition of chemical groups to DNA or to the histones that it envelopes, or changes in the configuration of 
secondary or tertiary DNA structure (nucleosomes and chromatin)(Figure 3). Epigenetic modification can 
be broadly categorised into: 1) DNA methylation, 2) ATP-dependent chromatin re-modelling, and 3) post-
translational histone modifications (including the replacement of canonical histones, with variants that 
affect nucleosome-stability and higher-order chromatin structure and dynamics) (Portela and Esteller, 
2010).  
The most studied epigenetic modification is DNA methylation, which occurs on cytosines when adjacent to 
guanine (a “CpG” site). The fifth carbon is methylated by the action of a DNA methyltransferase (DNMT) 
enzyme using S-adenosyl-methionine (SAM) as the methyl-donor. DNA methylation induces transcriptional 
silencing via two mechanisms. Firstly, it repels transcriptional activators that cannot bind their target 
regions when methylated, and secondly it recruits transcriptional repressors that have affinity for 
methylated DNA (proteins with a Methylation-Binding Domain, MBD). MBD-containing proteins may have 
a positive or negative effect on transcription; they can have direct transcription activating or repressing 
effects, chromatic modifying effects such as influencing nucleosome structure or histone modification, or 
act as scaffolds to recruit other factors (Portela and Esteller, 2010).  
1.1. VII. b)  DNA methylation of CpG islands, promoters, and genes 
There are clusters of CpG sites dotted across the genome, known as CpG islands (>200 base pair long 
sequences with over 50% GC content, and an observed/expected CpG ratio of >60%). CpG island 
methylation is essential for genomic imprinting, for example when hypermethylation of a gene on one 
allele may silence its expression while the other allele is hypomethylated to produce monoallelic 
expression, or when testis-specific genes are suppressed using DNA methylation in non-testis tissue. DNA 
methylation also regulates X chromosome inactivation in females, and often occurs at CpG islands within 
repetitive elements, such as those with repeated copies of retroviral elements or transposons, here it is 
essential for the repression of pro-viral DNA and intra-genomic parasites (Portela and Esteller, 2010).  CpG 
islands not associated with imprinted genes are normally unmethyated and CpG island methylation is not 
generally utilised as a mechanism of somatic gene regulation. However, at non-CpG island regions, and 
particularly at promoter regions, methylation provides a rapid and reversible means of somatic gene 
regulation (Jones, 2012).  
Generally, the methylation of promoters is associated with transcriptional repression. However, the effect 
of methylation of gene body regions is more complex. While transcription initiation is blocked by DNA 
methylation, elongation is not and may even be enhanced by it, and most studies have reported that gene 
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body methylation was associated with increased expression of the gene (Portela and Esteller, 2010)(Jones, 
2012)(Irwin et al., 2016). However, inhibitory effects have also been observed, which could be because the 
gene body often contains functional elements that are stabilised by methylation, including alternative 
promoters, repetitive elements, enhancers, transcription factor binding sites, and intron-exon binding 
sites, which have an enrichment of nucleosomes (Yang et al., 2014). Therefore, hypermethylation could be 
important to silence these elements to prevent intragenic transcription initiation, and it may regulate 
splicing. It also affects DNA architecture; a large bioinformatics study reported that reduced methylation 
at gene bodies increased chromatic accessibility and occupancy of the histone variant H2A.Z, and it induced 
changes in histone modifications (Yang et al., 2014). H2A.Z is associated with both transcriptional activation 
and repression, and its occupancy in DNA has also been linked with poising genes for rapid induction. It 
also plays a role in recruiting the polycomb repressive complex 2, which catalyses di- and tri-methylation 








Figure 3. Epigenetic modifications influence the structure of chromatin. The double helix of DNA is coiled around histone 
proteins in nucleosomes (secondary structure) and further wound into a tertiary structure called chromatin. The addition of 
methyl groups influences the binding of transcription factors, whereas the addition of acetyl (or other) groups to histone 
tails increases the physical accessibility of the DNA. Image from Wikipedia commons free media repository (use rights: 




1.1. VII. c)  DNA methylation in cancer and prostate cancer 
Changes in epigenetics are critical in mediating cell malignancy. Cancer cells commonly display a global 
reduction in DNA methylation, mainly attributed to changes at repetitive elements, which comprise just 
under 50% of the genome. This can lead to activation of these normally dormant regions, as well as 
destabilising the structure of chromatin and leading to genome and chromosome instability and thus 
increasing the rate of detrimental mutations and translocations. At the same time however, 
hypermethylation is observed at the promoters of tumour-suppressors (Pan et al., 2018)(Ehrlich, 2002).  
PCa is no exception and the promoter of numerous tumour-suppressors were hypermethylated and 
accordingly downregulated in PCa cell lines relative to non-cancer fibroblasts (APC, MGMT, GPX3, TIMP2, 
GSTP1, PTGS2, DKK3, RASSF1 and TNFRSF10D) (Kamińska et al., 2019). Treating cells with a demethylating 
agent (5-aza-2’-deoxycytidine) increased expression of several mesenchymal markers in vitro in PCa, 
including TWIST1, SNAI1, SNAI2, ZEB1 and CD146 (Dudzik et al., 2019). Recently,  a novel diagnostic panel 
was also validated which could accurately predict patient outcome after surgical removal of the prostate, 
which included three methylation markers (Strand et al., 2019). Therefore, the importance of the 
epigenome as well as the mutational landscape in PCa development is emerging.  
 
1.1 VII. Prostate cancer treatment  
1.1. VII. Active surveillance, radiotherapy, and radical prostatectomy 
As discussed in section 1.1. IV, classification systems vary although PCa can be broadly categorised into 
clinical states: the localised tumour, the non-castrate rising PSA state, non-castrate metastatic state, and 
finally the castrate-resistant metastatic state (mCRPC), which for most men is lethal within two years 
(Figure 2). These states will define the clinical management decisions, and are based on an assessment of 
the risk that the tumour is expected to pose. The journal of the National Cancer Institute in the USA 
reported that 94% of newly diagnosed men had low-risk disease (stage T1 or T2). These tumours are 
considered as having favourable long-term oncologic outcomes (Shao et al., 2009). A localised tumour that 
is deemed unthreatening is usually monitored over several years (by PSA level, imaging, or biopsies) and 
left untreated unless the tumour proves to be developing rapidly. This is known as “active surveillance” 
and effectively manages the majority of prostate tumours. If a localised tumour is diagnosed at a high TNM 
stage or Gleason grade, grows during active surveillance, becomes symptomatic, or if the patient prefers 
to intervene, the primary tumour will be treated by surgery, chemotherapy, or external beam radiotherapy 
(hereafter referred to as radiotherapy) (Keyes et al., 2013).  
Radiotherapy is administered at an optimal dose of 75Gy or above, often in parallel with chemotherapy 
(Roach, 2007). Brachytherapy, delivery of doses directly to the target area using a sealed radiation source, 
can be added to the treatment plan instead of a full course of radiotherapy, to improve outcomes and 
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reduce off-target damage (Keyes et al., 2013). Unfortunately, radiotherapy is associated with a 50% 
increase in the risk of subsequent urological associated malignancies (Wallis et al., 2016). Patients also 
typically develop digestive diseases and circulatory defects following radiotherapy, as well as an increased 
risk of cardiovascular disease (Baker, Moulder and Hopewell, 2011)(Shadad et al., 2013). 
Surgical removal of the tumour, or if large, the entire prostate (radical prostatectomy, RP) is performed via 
retropubic or perineal entry. RP usually includes removal of adjacent lymph nodes (extended pelvic lymph 
node dissection). There are numerous unpleasant side effects of RP, including urinary incontinence and 
increased frequency of urination, and erectile dysfunction (Frey, Sønksen and Fode, 2014).  
Tumours that continue to grow despite primary treatment (locally advanced), or recur locally or 
systemically, can receive a different course of treatment (salvage treatment), for instance introducing 
radiotherapy after surgery. It has been estimated that approximately 15% of PCa diagnoses are high-risk 
and destined to progress to mCRPC, which is considered incurable although RP plus a combination of 
chemotherapies can delay tumour progression and prolong the patient’s life (Bastian et al., 2012)(Keyes et 
al., 2013). 
1.1. VII. Androgen deprivation (hormone) therapy  
It has been known for over 200 years that the prostate depends on secretions from the testes. In 1786, the 
surgeon John Hunter noted while analysing cadaveric dissections, that: ‘‘The prostate and Cowper’s glands, 
and those of the urethra, which in the perfect male are soft and bulky, with a secretion salt to the taste, in 
the castrated animal are small, flabby, tough and ligamentous, and have little secretion’’ (Zuckerman, 
1936). In the 1940s, Huggins and Hodges confirmed that prostate cells are dependent on androgens 
secreted by the testes, and that PCa cells upregulate this pathway to proliferate irrespective of circulating 
levels of androgens (Huggins and Hodges, 1941). To this day, inhibition of the androgen receptor (AR) and 
its downstream signalling pathway remains the backbone of PCa therapy.  
Upregulation of AR signalling ranges from overexpression of AR, production of intra-tumoural androgens, 
and mutations in AR that relax its ligand binding specificity or even abolish the requirement for a ligand. 
PCa patients typically receive a combination of treatments that inhibit circulating testicular androgens by 
physical or chemical castration (by luteinising hormone-releasing hormone (LHRH) analogue or antagonist 
which both reduce serum testosterone levels) plus an inhibitor of the AR, which together are known as 
combined androgen blockage or androgen deprivation therapy (ADT) (Heinlein and Chang, 2004)(Demir et 
al., 2014). If a man present with a high-stage (locally advanced) tumour, the standard treatment is ADT plus 
RP or radiotherapy. At the discretion of the clinician, ADT can be short or long-term, or intermittent or 
continuous. A robust and continuous course may be necessary to abolish completely the tumour although 
this worsens side effects.  
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AR inhibitors have been the focus of PCa treatment and there are three generation of inhibitors that have 
been developed, mainly agents that compete with androgens for the ligand-binding domain. AR is a nuclear 
factor with a ligand-binding domain (LBD), DNA-binding domain (DBD), and N-terminal domain (NTD). In 
the basal state, the LBD binds the DBD, maintaining it in an inactive form until a ligand sequesters it (at 
which point AR dimerises, translocates to the nucleus, and binds DNA at androgen response elements 
(ARE)). To achieve combined androgen blockage, AR inhibitors are prescribed with abiraterone acetate, an 
inhibitor of the steroid biosynthesis enzyme CYP17A1 that was approved in 2011 and which inhibits 
intratumoural androgen synthesis (Denmeade and Isaacs, 2002).  
Three generations of AR inhibitors have been developed; the first one and two target the LBD and some 
newer agents have additional affinity for the other domains.  The first AR antagonist was flutamide, which 
was approved for medical use in 1983. An improved AR inhibitor, bicalutamide, was approved for use in 
1995 and has been prescribed to millions of men with PCa worldwide. However, PCa was observed to 
quickly develop resistance to bicalutamide and there were concerns that it was exerting an agonist effect 
in some circumstances. A second generation antiandrogen, enzalutamide was developed (formerly 
MDV3100) and received FDA approval in 2012. Enzalutamide has superior affinity for the LBD, and 
additionally inhibits its nuclear translocation and DNA binding, blocks coactivator recruitment, and has no 
known agonist activity.  
Despite the specificity of enzalutamide, as previously mentioned some PCa cells express splice variants of 
the AR that lack the ligand-binding domain and are thus constitutively active. Furthermore, the AR variants 
are insensitive to bicalutamide and enzalutamide which target the LBD. These pathological variants are 
observed in CRPC at a 20 fold higher level than hormone-sensitive PCa, associate with the ability of PCa to 
grow in the absence of androgens in vitro and in vivo, and are closely associated with poor prognosis in 
patients (Wadosky and Koochekpour, 2017). Chapter 6 reports a project by a research group in Strasbourg, 
on which I collaborated during a visit in 2018.  
A third (next) generation anti-androgens is under development to target pathological AR variants and 
specifically focusing on agents that can bind the NTD. Since this region is highly disordered and does not 
have a “pocket”, it is notoriously difficult to design an agent that can bind it. However, a drug called EPI-
001 (ralaniten) was developed which is a mixture of four stereoisomers, and can bind the activation region 
of the NTD (Brand et al., 2015). EPI-001 inhibits nuclear translocation, prevents interactions with its 
cofactors, and blocks binding to the androgen response elements (ARE) of DNA. Thus, it functions by 
multiple mechanisms to efficiently prevent transcriptional activity and it is effective against all variants of 
AR. EP-001 had excellent effects on xenograft models and no known side effects on other pathways 
although in the end it was not marketed. Its successor, EPI-506 was then developed and is composed of a 
derivative of bisphenol A and a prodrug of ralaniten (EPI-002), which is one of the stereoisomers of EPI-
001. EP-506 passed Phase I clinical trials although was halted due to side effects (Ito and Sadar, 2018).  
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Other next generation antiandrogens include galeterone, orteronel, and apalutamide. Galeterone is a tri-
modal agent that inhibits CYP17A1, antagonises AR (via LBD), and promotes degradation of the AR protein 
(Alyamani et al., 2017). Orteronel is an androgen biosynthesis inhibitor that antagonises CYP17A1. 
Apalutamide (ARN-509) is a LBD-binding AR antagonist which chemical similarity to enzalutamide but 
improved AR affinity and reduced distribution in the central nervous system and thus fewer off target 
effects. Apalutamide was approved for non-metastatic PCa in February 2018 (Al-Salama, 2018), although 
galeterone and orteronel were discontinued by manufacturer Takeda in 2018, since the results of their 
phase III trials showed that neither improved overall survival. Therefore, it is still only LBD-targeting AR 
inhibitors that are currently available to patients.   
Due to the side effects of ADT, another subject of debate is the optimal treatment model. The use of 
intermittent versus continuous treatment was investigated to prevent ADT resistance, and to lessen toxic 
side-effects. One randomised control trial found that intermittent doses were as effective as continuous 
treatment to improve survival outcome, albeit with a short follow-up period (Crook et al., 2012). However, 
a second study reported that intermittent ADT did not improve survival outcome in comparison to 
continuous dosing, although non-cancer related deaths were improved, indicating reduced toxicity 
(Hussain et al., 2013). Long-term treatment with ADT appears to be superior to short-term dosing, long-
term treatments were associated with improved disease-specific survival in three large randomised 
controlled trials, although differences were not highly significant and cannot be considered definitive (Bolla 
et al., 2009)(Horwitz et al., 2008). Therefore, while attempts have been made to reduce toxicities 
associated with ADT, including intermittent and shorter-duration dosing, these cannot be confirmed to be 
as effective as the standard 3-year continuous treatment. However, some physicians still consider the 
differences between treatment groups, which were modest at best, as negligible and they therefore do not 
recognise the benefit of ADT for longer than 6-months.  
Furthermore, long-term systemic ADT has highly unfavourable side effects, including: decreased bone 
mineral density and weakening, dyslipidaemia, insomnia, muscle loss (and as a result of the associated 
increase in adiposity: insulin resistance and increased risk of diabetes), decreased libido and sexual 
dysfunction, hot flashes, anaemia, fatigue, and gynecomastia (growth of breast tissue) (Horwitz et al., 
2008). It may also be associated with an increased risk of cardiovascular disease although this is contested; 
a meta-analysis of observational studies found significant effect on combined risk (Bosco et al., 2015) 
whereas a meta-analysis of RCTs found no association (Nguyen et al., 2011). Inclusion of a GnRH 
(gonadotropin-releasing hormone) antagonist in the treatment plan may reduce the risk of cardiotoxic side 
effects (Hammerer and Manka, 2019).  
Therefore, it is necessary to develop novel treatments for PCa that can be localised to the prostate and 
reduce the reliance on ADT.  
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1.1. VIII. Castration-resistant prostate cancer (CRPC) 
On top of the unpleasant side effects, ADT is invariably associated with the emergence of resistance, after 
a latency period of approximately 2 years. PCa cells that have developed insensitivity to AR inhibition are 
known as androgen-independent, or castration-resistant PCa (CRPC) (Shen and Abate-Shen, 2010)(Crea et 
al>, 2015). At this point, treatment typically consists of secondary anti-androgen treatment (e.g. 
enzalutamide following the failure of bicalutamide) combined with non-hormonal therapies (see section 
1.1. IV). Over 90% of CRPC metastasise, normally to the bone, causing acute pain due to the associated 
skeletal compression and fractures. Currently, metastatic CRPC (mCRPC) has a median survival expectancy 
of 9-13 months (Kirby, Hirst and Crawford, 2011). Therefore, CRPC is considered incurable although 
treatments have prolonged patients’ lives. This means that the vast majority of men who received 
hormone-therapy eventually died from their PCa. 
1.1. IV. Non-hormone chemotherapies  
To improve tumour reduction, ADT is normally combined with non-hormonal therapies. Several are generic 
anti-cancer agents that are approved for multiple cancer types, such as the taxanes docetaxel and 
cabazitaxel. Taxanes are a class of generic anti-cancer agents that target rapidly dividing cancer cells by 
binding intracellular microtubules to promote or inhibit the assembly of tubulin into microtubules, 
preventing mitosis and inducing apoptosis. Cabazitaxel is a newer agent with better efficacy and thus a 
lower occurrence of resistance and can provide a back-up if the patient does not respond to docetaxel. The 
alkylating agent carboplatin is also often prescribed and damages mitotic cells by crosslinking DNA (Quinn 
et al>, 2017).  
Prednisone is a corticosteroid that acts as an immunosuppressant, and reduces the inflammation, oedema 
and pain associated with metastasis. Corticosteroids have been prescribed to patients with metastasis for 
over 30 years and prednisone is now commonly administered in combination with abiraterone and 
enzalutamide to patients with mCRPC (Fizazi et al., 2017). It has the additional benefit of reducing 
mineralocorticoid excess due to abiraterone (Kato et al., 2018). Everolimus is an analog of rapamycin and 
inhibits mTOR. Since PTEN was shown to regulate AR signalling, and the Akt/mTOR pathway becomes 
essential when PTEN is inactive or deleted, there is accumulating evidence that the addition of everolimus 
could reduce AR independence. Indeed, a Phase II result reported that everolimus improved the treatment 
of CRPC when in combination with bicalutamide (Chow et al., 2016). In vitro and preclinical studies have 
also shown that the combination of EPI-002 with the mTOR inhibitor BEZ235 reduced the proliferation of 
enzalutamide resistant PCa cells, which are thought to be driven by AR-V7 signalling and the expression of 
AR-V7 target genes was also reduced (Kato et al., 2016). Thus, increasing attention is being focused on 
achieving synthetic lethality by mTOR inhibition.  
There are two non-hormonal options that were specifically developed for mCRPC: Sipuleucel-T and 
Radium-233. Sipuleucel-T is a form of immunotherapy, it is a personalised anti-cancer vaccine for mCRPC. 
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The patient’s dendritic cells are isolated from the blood, exposed to a cancer antigen harvested from the 
tumour, and re-introduced by injection. The principle is to mount a systemic immune response, targeted 
to the patient’s cancer cells. Sipuleucel-T was associated with a 4.1 month increase in median survival at 
phase III trial (Kantoff et al>, 2010). Currently, Sipuleucel-T for PCa is the only form of cancer 
immunotherapy that has ever demonstrated efficacy at Phase III. As a treatment for skeletal metastasis, 
radium-233 (alpharadin) was developed. Radium-233 has chemical similarity to calcium and is absorbed 
into the bones where it emits short-range alpha radiation, and acts as a targeted radiotherapy. Radium-
233 increased overall survival by 2.8 months at phase III trial (Parker et al., 2013).  
Therefore, while advanced therapies have been developed that can statistically significantly increase a 
patient’s survival; realistically the increases are modest (a few more months at most). Plus, the patient is 
likely to suffer from additional side effects which range from headaches, fatigue, and pain, to 
cardiovascular disease, infection, and respiratory disease which may themselves be fatal. More research is 
needed, particularly genetic-based investigations, to allow improvements in the current management of 
PCa, either by earlier detection or better understanding of the mechanisms of resistance to therapy and 
relapse.   





Figure 4. Clinical stages of prostate cancer ranging from indolent and/or localised to metastatic castration-resistant, 
with treatment options. Typical treatments for localised PCa at the neoadjuvant (initial) stage is active surveillance; 
end (adjuvant) and salvage (upon relapse) stages are surgery and radiotherapy, treatments for prostate cancer not 
responsive to primary therapy and progressing (either as androgen dependence (pink) or not (blue)) leading to 
progressive metastatic castration resistant prostate cancer include anti-androgen, taxane, radio-, or immuno-therapy.  
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1.1. VIII. Summary 
The prognosis for men with PCa is heterogeneous; in the majority of cases the tumour follows an indolent 
course although in some cases the disease is aggressive and progresses to metastases and death. 
Therefore, the majority of tumours can be managed by “watchful waiting” although if locally advanced the 
patient may receive hormone-based therapy targeting the androgen receptor (AR). Androgens are growth 
factors that regulate prostate cell proliferation in both the physiological and cancer state. Androgens 
activate the AR and this signalling pathway becomes upregulated in PCa to permit excessive proliferation. 
Inhibition of the AR is the mainstay for PCa treatment, sometimes accompanied by traditional cytotoxic 
agents. However, although this is initially effective at abolishing the tumour, patients inevitably develop 
resistance and relapse with the incurable CRPC. It is imperative to understand why PCa relapses following 
ADT, for the development of new treatments that can supplement ADT in order to prevent drug resistance. 
To some extent, relapse is due to mutational events such as the upregulation of AR variants that are 
insensitive to LBD-targeting agents. Potentially, changes observed in the tumour microenvironment also 
contribute, to drive a selection of the most deadly cancer cells.  
 
1.2 Hypoxia 
Hypoxia refers to a reduced oxygen concentration, relative to the levels in other tissues in the body or 
relative to the tissue under healthy conditions. Mild hypoxia occurs in many tissues at physiological levels 
and can often be essential for its function. However, excessive or inappropriate hypoxia can become 
pathological and have deleterious consequences in the body (Taylor and Colgan, 2017). 
1.2. I. Physiological hypoxic niches 
Physiological hypoxia occurs naturally in many tissues due to their structure. For example, in the bone 
marrow, oxygen delivery is extremely low due to its impermeable structure and lack of vascularisation. 
Here, hypoxia is important to protect the haematopoietic stem cell populations from oxidative stress, to 
which stem cells are highly sensitive. In the kidney, a high metabolic activity produces hypoxia and this is 
important to regulate erythropoietin synthesis. Similarly, the cells of the germinal centres of secondary 
lymphoid tissues have a high metabolic activity and thus high oxygen demand, which produces a mild 
hypoxia that protects resident immune cells. Furthermore, germinal centres are the location where mature 
B cells proliferate, differentiate and obtain mutations in genes encoding antibodies (giving rise to B cell 
clones), and since this process is highly oxygen consuming, hypoxia increases further during clonal 
expansion and this favours B cell behaviour and phenotype. In the intestinal wall, the mucosal layer on the 
luminal face is relatively impermeable to oxygen, which creates a gradient between the anaerobic lumen 
and intestinal lamina propria (a highly vascularised connective layer beneath the intestinal epithelium). 
This helps to improve the barrier protection of the intestinal wall, and regulates the activity of immune 
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cells that are recruited to break down components of the intestinal microbiome and particles of digested 
food. The placenta becomes hypoxic as it grows, which is necessary to inhibit maternal immune cells and 
protect the semi-allogenic trophoblasts of the developing foetus (granting it immune privilege). Here, 
hypoxia has a dampening effect on the maternal T cells, as it induces expression of programmed cell death 
1 ligand 1 (PDL1) which inactivates their cytotoxic activity and induces apoptosis (Taylor and Colgan, 2017). 
1.2. II. Pathological hypoxia 
Physiological hypoxia tends to be mild and relatively consistent; however, pathological hypoxia is severe 
and often chaotic and fluctuating. The causes of pathological hypoxia depend on the tissue and the 
outcomes are similarly varied and context-dependent. Pathological hypoxia may occur due to acute or 
chronic inflammation, reduced blood flow (including ischaemia), reduced vascularisation, increased oxygen 
consumption, thrombosis, infection, and tumorigenesis. 
Importantly, due to extensive crosstalk between hypoxic signalling and inflammatory signalling, 
pathological hypoxia can cause immune cell dysfunction and further drive disease progression. Acute 
inflammation results in the accumulation of immune cells, mainly monocytes and neutrophils and 
extensive metabolic reprogramming which drastically increases oxygen consumption and is known as 
“inflammatory hypoxia”. However, while in the intestinal mucosa this is beneficial, high numbers of 
activated neutrophils has been shown to be damaging to the lung epithelium and in this context a similar 
degree of hypoxia has pathological consequences. In chronically inflamed tissues, hypoxia is either pro- or 
anti-inflammatory depending on the context. For example, during irritable bowel syndrome the 
inflammation suppresses vasculature, increasing hypoxia (and ultimately leading to fibrosis), while in 
mucosal immune cells hypoxia increases their activity and survival. Many studies have now shown that the 
overall effect of pharmacological activation of hypoxic signalling is anti-inflammatory (Taylor and Colgan, 
2017). Pathological hypoxia also occurs in tissues infected by pathogenic bacteria, due to the high rate of 
oxygen consumption by the bacteria, local inflammation, and the presence of impermeable biofilms. Here, 
hypoxia can have the dual effect of suppressing immune cell activity and promoting the virulence of the 
pathogen (Taylor and Colgan, 2017). 
1.2. III. Tumour hypoxia   
Hypoxia develops in solid tumours due to the deregulated proliferation of cancer cells away from their 
blood supply (from around 180μm) and the increasingly chaotic and leaky structure of tumour vasculature 
(Fraga et al., 2015). In normal tissues the oxygen tension is between 40-60mmHg, however in solid tumours 
it drops as low as 10mmHg (McKeown, 2014).  
Across all cancers, tumour hypoxia predicts poor patient outcome. Firstly, this is because hypoxia impedes 
treatments; poorly-vascularised regions have reduced delivery of chemotherapies and poorly-oxygenised 
regions are less sensitive to ionising radiation therapy (Saggar et al., 2013)(Harrison et al., 2002). Secondly, 
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hypoxia is a stress condition that induces profound changes at the cellular level that are associated with 
increased malignancy. There are four distinct types of tumour hypoxia which may exert different responses 
within the tumour: chronic hypoxia (diffusion-limited), acute/intermittent/cycling hypoxia (caused by 
temporary, local disturbances such as vascular collapse), anaemic hypoxia (due to reduced haemoglobin), 
and toxic hypoxia (inability of cells to utilise oxygen due to poisoning) (Bayer and Vaupel, 2012; 
Manoochehri Khoshinani, Afshar and Najafi, 2016).  
 
1.2. IV. Hypoxia-inducible factor (HIF) signalling  
The hypoxic response is governed by the hypoxia-inducible factor (HIF) transcription factors. Since hypoxia 
is involved in the pathogenesis of many diseases, the effects of HIF activation has been extensively studied 
in many tissues. The general HIF signaling pathway is outlined below.  
 
HIF is a heterodimer composed of an alpha and beta subunit (also known as the aryl hydrocarbon receptor 
nuclear translocator (ARNT)). The alpha subunit (HIFα) has three isoforms (HIF-1/2/3) which have slightly 
different expression patterns and downstream targets. The alpha subunit is the rate-limiting subunit; both 
subunits are expressed constitutively although the alpha subunit is targeted for proteolytic degradation 
when cellular oxygen is sufficient. During normoxia, HIFα is hydroxylated at two proline residues (P402 and 
P564) by prolyl-hydroxylase domain-containing enzymes (PHDs) which allows it to bind the von Hippel-
Lindau tumour suppressor protein (pVHL). pVHL mediates an interaction with the Elongin B/C-Cul2 
ubiquitin ligase complex, which ubiquitylates them and targets them for proteasomal degradation. 
Additionally, factor inhibiting HIF (FIH) hydroxylates an asparagine residue on HIFα, which prevents 
interaction with its coactivator p300 (p300/CBP). PHD and FIH require oxygen as cofactor and therefore, 
during hypoxia HIFα is not hydroxylated and degraded, but interacts with p300 and translocates to the 
nucleus where it functions as a transcription factor and binding at androgen response elements of DNA 
(ARE). PHDs are also regulated negatively (e.g. by succinate, fumarate, reactive oxygen species (ROS) and 
nitric oxide (NO)) and positively (e.g. by ferrous iron (Fe2+), 2-oxoglutarate (2-OG), and cysteine), allowing 






























Figure 5. Oxygen-dependent regulation of HIFα. Inspired by a figure from (Araos, Sleeman and Garvalov, 2018a). Oxygen-
dependent PHD and FIH hydroxylate HIFα on proline and asparagine, pVHL binds the hydroxylated residues and recruits an 
ubiquitin ligase (Ub. Lig.) that ubiquitylates HIFα, targeting it for degradation by the proteasome. In the absence of oxygen, 
PHD and FIH are inactive and HIFα translocates to the nucleus and transcribes genes with a HIF response element (HRE) in 
the promoter. PHD is positively regulated by Fe2+, 2-OG, and cysteine; and negatively by succinate, ROS, fumarate, and NO. 
30 
 
Therefore, HIF is an essential component of the response to cellular stress and bioenergetics, and 
furthermore numerous growth factor signalling pathways affect HIF. For instance, platelet-derived growth 
factor (PDGF), insulin-like growth factor, insulin, and heregulin all upregulate HIFα transcription or 
translation. Phosphorylation of HIFα is also a vital means of regulating its activity, both positively and 
negatively. Ras-ERK (MAPK) signalling regulates HIF activity, by p42/p44 or p38 MAPK phosphorylation of 
HIFα or p300. Phosphorylation by glycogen synthase kinase 3β (GSK-3β) and polo-like kinase 3 (Plk3) reduce 
HIF transcription factor activity, while phosphorylation by the double strand break sensor ataxia-
telangiectasia mutated (ATM) increases its activity. In cancer cells, activation of phosphatidylinositol 4,5-
bisphosphate 3-kinase, Akt and mammalian target of rapamycin (PI3K/Akt/mTOR) regulated levels of HIFα 
at both the gene expression and protein level. Furthermore, HIFα is regulated post-translationally by 
modifications such as acetylation (for instance by p300/CBP-associated factor (PCAF)), which is associated 
with the transcription of specific target genes.  HIF-α stability is additionally regulated by factors that 
mediate its ubiquitination or association with the proteasome. For example, E3 ubiquitin ligase hypoxia-
associated factor (HAF) ubiquitylates HIF-1α regardless of oxygen levels, and translation initiation factor 
eIF3e promotes degradation of HIF2α. Receptor for activated C kinase 1 (RACK1) mediates the degradation 
of both HIF1α and HIF2α by recruiting Elongin C, however this can be inhibited by heat shock protein 90 
(HSP90) which increases the stability of HIF during stress conditions such as acidosis. Basic helix-loop-helix 
family, member e41 (BHLHE41 or SHARP1) increases proteosomal degradation of HIF1/2α, and ubiquitin 
C-terminal hydrolase-L1 (UCHL1) stabilises HIF-1α by de-ubiquitination (Araos, Sleeman and Garvalov, 
2018a). 
Therefore, more than a guardian of oxygen homeostasis, HIF functions as a master integrator of oxygen 
levels, DNA damage and cellular stress, growth signalling, and metabolic status. Abnormal HIF signalling 
could thus have far-reaching consequences in terms of cell dynamics and behaviour.  
 
1.2. V. Hypoxic Signalling and Cancer Progression 
Considering that HIF is at the centre of the stress response network, it is unsurprising that hypoxia affects 
pathways that are involved in cancer, including angiogenesis, proliferation, metabolism, epithelial-
mesenchymal-transition (EMT), and motility and metastasis.  
Hypoxia facilitates angiogenesis by inducing expression of vascular-endothelial growth factor (VEGF) and 
SDF-1. It regulates the metabolic enzymes GLUT-1, GLUT-3 and glycolytic enzymes, and apoptosis via BNIP-
3, p53, TGF-β and bFGF, as well as epithelial-mesenchymal-transition via E-cadherin, ZEB-1 and ZEB-2, TCF3, 
CXCR4, LOX, MMP-2, and MMP-9. A protein responsible for regulating intra- and extracellular pH, CAIX, is 
also a direct target of HIF. Moreover, hypoxia reduces proliferation, which protects the cell from traditional 
chemotherapies that target rapidly dividing cells. Furthermore, the hypoxic microenvironment intrinsically 
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selects for apoptosis-resistant cancer cells and may directly suppress apoptosis to permit proliferation 
despite an accumulation of mutations. This leads to clonal evolution and increasingly abnormal phenotypes 
(Harris, 2002)(Jang et al., 2010). 
Figure 6 illustrates how the activation of different cancer-associated pathways by hypoxia produces a cell 
that is stem-like, resistant to chemo- and radiotherapy, capable of metastasis, and stimulates an increased 
blood supply for nutrients, and through which it can escape from the primary tumour and enter the 






Figure 6. Schematic overview of the links between hypoxia and the cancer-associated pathways. Inspired by a figure from 
(Muz et al., 2015). Hypoxia increases tumour vascularisation via upregulation of vascular-endothelial growth factor (VEGF) 
and its receptor 2 (VEGF-R2), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), bromodomain-containing 
factor 1 (BDF-1), angiopoietin 1 and 2 (ANG-1/2), and matrix metalloproteinases (MMPs). Migration is facilitated by 
upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), carbonic anhydrase IX (CAIX), MMPs, 
integrins, stromal cell-derived factor 1 (SDF1), and C-X-C motif chemokine receptor 4 (CXCR4). The cell cycle is blocked by 
upregulation of cyclin dependent kinase (CDK) inhibitors p21 and p27. Cell morphology is altered to facilitate EMT by changes 




1.1. V. a) Epithelial-Mesenchymal-Transition 
Epithelial-mesenchymal-transition (EMT) is a dynamic morphogenic program that is important during 
development, in which cells exhibit profound plasticity, and de-differentiate and acquire mesenchymal 
features. Crucially, they lose polarity and intercellular adhesion, and demonstrate increased motility, 
migration and invasive capabilities. This process is utilised by cancer cells and is key to metastatic spread. 
HIF can upregulate the expression of the transcription factors that drive EMT and have established 
oncogenic potential: Snail, Slug, ZEB1/2, and Twist (Puisieux, Brabletz and Caramel, 2014). By inactivating 
PHD3, stabilisation of HIF-1α and HIF-2α caused upregulation of TGFα/SMAD/EGFR signalling and lead to 
EMT and metastasis, in lung cancer cells. Furthermore, hypoxia has been shown to increase EMT through 
activation of Notch, Hedgehog, integrin-linked kinase, and NF-κB signalling (Araos, Sleeman and Garvalov, 
2018a). Importantly, during hypoxia cancer cells may be encouraged to enter EMT as a result of changes in 
neighbouring, non-cancer cells. Hypoxia increased the secretion of IL-1β by infiltrating macrophages, which 
then upregulated HIF-1α in proximal, but normoxic, hepatocellular carcinoma cells (Zhang et al., 2018). 
Furthermore, hepatocellular carcinoma cells increased expression and secretion of high mobility group box 
1 (HMGB1) in response to hypoxia, and this induced macrophages to infiltrate and produce IL-6. The IL-6 
secreted by macrophages in turn increased EMT in the hepatocellular carcinoma cells. This was confirmed 
by silencing of HMGB1, which inhibited macrophage infiltration, EMT, and metastasis in tumour xenografts 
(Jiang et al., 2018).  
1.2. V. b) Extracellular Matrix Remodelling  
The extracellular matrix (ECM) refers to the network of macromolecules that provide structural and 
biochemical support to cells, including collagens, glycoproteins, and enzymes. Alterations in the ECM as 
well as the basement membrane facilitate cancer cell motility and extravasation. Hypoxia and HIFs 
upregulate many enzymes that can play a role in remodelling of the ECM, such as matrix 
metalloproteinases (MMPs), lysyl oxidases (LOX), procollagen lysyl hydroxylases (PLODs), collagen prolyl-
4-hydroxylases (P4Hs), and cathepsins. Collagens vastly increase in the ECM during cancer, affecting cancer 
cell polarity, migration, and motility. Moreover, hypoxia is associated with fibrosis in tumours, as well as 
immune reactivity, which is an independent predictor of patient relapse and disease-free survival. The 
properties of the ECM determine the type and effect of cancer-associated fibrosis (Gilkes, Semenza and 
Wirtz, 2014). Hypoxia also downregulates tissue inhibitor of metalloproteinases 2 (TIMP2)(Rankin and 
Giaccia, 2016). In fact, P4HA1/2 and PLOD1/2 were essential for hypoxic-mediated metastasis of orthotopic 
breast cancer xenografts (Gilkes et al., 2013).  
The stroma refers to cells that provide a connective and supportive network, that do not have the specific 
function of the organ, in this case as glandular cells. The main cell type is fibroblasts, and these play a crucial 
role in tumour development. Cancer cells interact with neighbouring fibroblasts, which then become 
reprogrammed (known as cancer-associated fibroblasts, CAFs). Interestingly, hypoxic tumour cells secrete 
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soluble factors that can recruit fibroblasts and facilitate their conversion into CAFs. The microenvironment 
similarly promotes unwanted behaviours in the CAFs themselves, the upregulation of HIF in CAFs increased 
growth and metastasis of breast cancer xenografts. Research into the effect of hypoxia on CAFs is currently 
emerging and has shown that HIF1α causes the upregulation of ECM modellers P4HA1/2 and PLOD2. 
Moreover, culturing breast cancer cells in the ECM derived from hypoxic fibroblasts increased the cancer 
cells’ migration (Gilkes, Semenza and Wirtz, 2014). However, another study reported conversely that 
hypoxia negatively regulated CAFs, CAFs were deactivated and unable to remodel the ECM when cultured 
in hypoxic conditions, and knocking down PHD2 activity in CAFs co-transplanted with breast cancer cells, 
was associated with reduced metastasis. Overall, this highlights that the effect of hypoxia depends on the 
type of CAF and type of tumour, and may also depend on the degree or duration of hypoxia as methods 
were highly varied in these studies, from the overexpression of HIF to hypoxic culture at various O2 
concentrations (Araos, Sleeman and Garvalov, 2018a). 
Notably, inhibition of angiogenesis as a treatment strategy has been associated with subsequent hypoxia, 
with detrimental effects on the ECM including increased collagen, hyaluronic acid, and sulphated 
glycosaminoglycans, and these were specifically correlated with increased metastasis in murine models of 
colorectal and pancreatic cancer (Aguilera et al., 2014; Rahbari et al., 2016). Finally, it is important to 
mention that the interaction between the cancer cell and ECM is dynamic and bi-directional. Biglycan in 
the ECM acted on gastric endothelial cells to increase HIF1α expression via NF-κB to increase migration and 
invasion, and extracellular matrix protein 1 (ECM1) increased HIF1α via integrin β4, FAK and SOX2 signalling 
to affect glucose metabolism and metastasis (Hu et al., 2016; Gan et al., 2018).  
Therefore, both the ECM and neighbouring fibroblasts are highly sensitive and responsive to hypoxia, and 
this is pivotal in creating a microenvironment that is further conducive to tumour progression.  
1.2. V c) Immune suppression  
One hurdle that all cancers must overcome in order to progress is to escape destruction by the immune 
system. HIF-1α-dependent signalling contributes to this in several ways. Cancerous cells are normally 
detected by CD8+ cytotoxic T lymphocytes (CTLs) and natural killer cells, which attempt to eradicate the 
cancer cell by secreting cytotoxic granules towards the cell membrane. These granules contain granzymes, 
which activate both caspase-dependent and independent apoptosis (Lieberman, 2003). HIF signalling 
directly counteracts this by inhibiting apoptosis (Greijer and van der Wall, 2004), and inducing autophagy 
and STAT3 signalling which confers additional resistance to CTL-mediated lysis (Noman et al., 2011)(Noman 
et al., 2009). Expression of miRNA miR-210 during hypoxia was shown to encourage escape from CTL-
mediated cytotoxicity, in melanoma and non-small cell lung carcinoma (Noman et al., 2012). In a 
hepatocellular carcinoma cell line, hypoxia promoted an immunosuppressive phenotype. These results 
suggest that HIF inhibition would be a useful addition to a treatment strategy to counteract immune 
suppression. Unfortunately, HIF1α was essential for effective CD8+ CTL immune infiltration of the tumour 
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and cytotoxicity in a mouse model of melanoma and lung carcinoma, suggesting that HIF inhibition would 
prevent immune destruction (Palazon et al., 2017). Immune checkpoint inhibitors, agents that block the 
receptors on cancer cells that repress immune recognition, such as CTLA-4-, PD-1-, and PD-L1 inhibitors, 
have shown marked success in tumours such as melanoma and lung cancer, but no success in cancers such 
as PCa due to the hypoxic microenvironment. Murine models have indicated that CTLs are rarely able to 
infiltrate hypoxic areas, and those that do, struggle to survive the hostile environment of low pH, low levels 
of glucose, amino acids and other nutrients, and the high concentrations of inhibitory ligands such as PD-
L1 and inhibitory cytokines such as TGF-β, and extracellular adenosine (Chouaib et al., 2017). However, use 
of a hypoxia-activated prodrug (TH-302/evofosfamide) was able to disrupt hypoxia and eradicated over 
80% of PCa tumours in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, when in 
combination with immune checkpoint inhibitors (Jayaprakash et al., 2018). This reinforces the importance 
of targeting hypoxia in effective chemo- and immunotherapies. 
Thus, while reduction in hypoxia has been shown to increase the efficacy of therapies, HIF is unlikely to 
provide a robust therapeutic target due to its promiscuous role and complicated interaction with immune 
cells. Successful approaches have utilised hypoxia-activated pro-drugs, and better characterisation of the 
critical downstream mediators of HIF activity in this context should be explored, with the view to clinical 
applications.  
1.2. V. d) Stemness  
A hypoxic microenvironment is conducive to cells with a stem-like phenotype and this has huge 
implications for the development and treatment of cancer. Until recently, there were two schools of 
thought to explain the heterogeneous nature of tumours and the process of metastasis: the classic 
stochastic model (also known as the clonal evolution model) and the more recent hierarchical model (also 
known as the cancer stem cell (CSC) model). The stochastic model argues that tumour cells acquire a 
specific set of somatic mutations to obtain metastatic capability, and by this logic all cells in the tumour 
possess the potential to drive cancer progression. The hierarchical model makes a distinction between cells 
with a unique potential to generate malignant colonies and drive cancer progression and metastasis 
(tumour-initiating cells), and those that have differentiated from them and are cancerous but do not have 
sufficient pluripotency to increase malignancy. This is also known as the CSC model as these tumour-
initiating cells share physiological similarity to stem cells and may in fact be transformed stem cells. 
Traditionally, the stochastic model proposed that normal somatic cells accumulate mutations in at least 
five pathways for the cell to possess all the hallmarks of cancer and that these mutations occur randomly 
due to stresses and ageing. Several observations contradict this model. Firstly, certain cancers have high 
incidence in early life and would unlikely have developed due to an accumulation of random mutations. 
Secondly, since differentiated cells have a finite lifespan, in order to accumulate mutations in the vital 
pathways a mutation causing unrestrained proliferation would need to occur very early to allow the 
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additional necessary mutations time to occur. The stochastic model also implies that each cell in a tumour 
is highly malignant and has equal tumour-initiating potential. However, in vivo studies have shown that 
implantation of at least 10,000 cancer cells are needed to reliably initiate tumours (in 
immunocompromised mice) which would indicate that relatively few have the appropriate tumour-
initiating capabilities. Hence the hierarchical hypothesis was proposed in which CSCs are responsible for 
tumour initiation, maintenance, and the development of more malignant clones that underlie metastatic 
spread (Wang et al., 2015). To support this, in numerous tumour types a specific subpopulation of cells 
have been isolated that have properties similar to stem cells, such as self-renewal, and that differentiate 
into tumour cells. These subpopulations have been confirmed as the drivers of metastatic spread in several 
tumour types (Schöning, Monteiro and Gu, 2017). However, currently the two models are not considered 
to be mutually exclusive, as it is unknown if the CSCs are indeed resident stem cells that have become 
transformed, or are somatic cells that have dedifferentiated during transformation.  
Hypoxia increases the stemness of cancer cells, most evidently through the activation of NOTCH signalling 
(Marignol et al., 2013). Furthermore, HIF-1α and HIF-2α regulate multiple stem cell marker genes and 
reduce proliferation. EMT is closely linked with acquisition of the CSC phenotype in several tumour types. 
Hypoxia also appears to play a vital role in CSC maintenance, and it is associated with CSC enrichment. This 
is because CSCs are known to prefer low oxygen environments since they are highly sensitive to ROS and 
may actively seek out a hypoxic niche. Two breast cancer studies showed that HIF-1α and HIF-2α regulated 
RNA demethylase ALKBH5, leading to increased Nanog expression and stability as well as significant 
enrichment of CSCs (C. Zhang et al., 2016), and HIF1/2α also induced serine synthesis which was associated 
with CSC function and metastasis to the lungs (Samanta et al., 2016). Intriguingly, hypoxia can also induce 
changes in CAFs that regulate CSCs; CAF-secreted TGF-β2 increased hedgehog signalling in CSCs and 
promoted chemoresistance in a colorectal cancer model (Tang et al., 2018). These results highlight the 
detrimental effect of a hypoxic microenvironment, considering its effect on CAFs and CSCs.  
1.2. V. e) Metastasis 
Increased expression of either HIF-1/2α was correlated with metastasis in patients with follicular thyroid 
cancer (Klaus et al., 2018), gastric carcinoma (Tong et al., 2015), gastrointestinal stromal tumour (Chen et 
al., 2005), osteosarcoma (El Naggar et al., 2012), cervical squamous cell carcinoma (Ishikawa et al., 2004). 
In vitro studies showed that hypoxia increased the metastatic potential of cancer cells and may also directly 
modulate stromal cells, although this area is poorly understood and requires further investigation (Araos, 
Sleeman and Garvalov, 2018b). 
Metastasis is a multi-step process based on dynamic interactions between cancer cells and their 
microenvironment, resulting in escape from the stroma and finally colonisation of a distant site. In order 
to disseminate, cells acquire motility and invasiveness, usually by reverting to a mesenchymal phenotype 
via EMT. HIF signalling directly increases the migratory and invasive potential of cancer cells by activation 
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of: receptor tyrosine kinases AXL and c-MET, the Rab11/αvβ3 integrin/focal adhesion kinase (FAK)/PI3K 
pathway, and miRNAs miR-210, miR-224 and miR-191 (Araos, Sleeman and Garvalov, 2018b). As mentioned 
in section XX, HIF signalling drives angiogenesis by upregulation of vascular endothelial growth factor 
(VEGF) and angiopoietin, which encourage the development of blood vessels that are typically weaker and 
more permeable than in healthy tissue, and are more susceptible to invasion by tumour cells. 
Overexpression of tissue remodellers such as MMPs by the cancer cells further promotes entry to the blood 
vessels (intravasation). However, of those cells, very few can survive the shear stress of the blood flow. A 
seminal in vivo study of neuroblastoma reported that hypoxic culture increased the ability of cells to 
intravade, colonise distant sites (extravasation), and proliferate there. This reveals that hypoxia is capable 
of profoundly reprogramming cancer cells, to confer increased ability to survive and drive metastasis and 
to the extent that they maintain their reprogrammed state even after colonisation (Herrmann et al., 2015). 
It is also important to note that the primary site of PCa metastasis is the bone (Hiraga, 2019), a naturally 
hypoxic region, and it could be that the PCa cells most prone to metastasis are also most resilient within 
hypoxic environments. Therefore, hypoxic signalling can promote all stages of metastasis and permanently 
reprogram cancer cells.  
 
1.2. VI. Cancer cell metabolism and hypoxia 
1.2. VI. a) The Warburg effect 
Hypoxia also has a role in regulating global metabolism and determining how the cell produces and stores 
energy, which has implications for cancer cell behaviour. The metabolic pathway glycolysis is an important 
energy provider for the cell. It consumes two molecules of ATP for the initial phosphorylation and yields 
four molecules of ATP. However, since the net gain of energy from the alternative pathway oxidative 
phosphorylation (OXPHOS) is between 30 and 36 ATPs, OXPHOS is normally the primary source of energy. 
However, since oxygen is required as cofactor for OXPHOS, glycolysis is an essential resource for the cell 
during anaerobic conditions. Furthermore, since the rate of ATP production by OXPHOS pathway saturates 
rapidly at high levels of substrate or limited oxygen supply, upregulating the glycolysis pathways can be 
used to steady the rate of ATP production (Potter, Newport and Morten, 2016). 
In the 1920s, biochemist Otto Warburg proposed that glycolysis was upregulated in cancer cells, even while 
oxygen levels were sufficient for OXPHOS, and he attributed this to impaired mitochondrial function. Later 
experiments by Weinhouse et al ran isotope-tracing experiments to show that glucose could be oxidised 
to CO2 by cancer cells at a rate comparable with normal cells. This indicated that cancer cells sustain a high 
rate of both glycolysis and OXPHOS, in contrast to normal cells (Otto, 2016). Indeed, one of the hallmarks 
of cancer is “Deregulating cellular energetics”. Cancer cells may upregulate glycolysis in order to boost the 
metabolic pathways that require glycolysis: the pentose phosphate pathway (for protein glycosylation); 
glycogenesis (for the storage of glucose); the serine biosynthesis pathway (which produces amino acids 
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and is followed by the one-carbon metabolism pathway that produces NADPH and is required for 
glutathione and purine biosynthesis), as well as for the methionine cycle (for methylation). Thus, 
upregulation of glycolysis allows cancer cells to increase the production of amino acids, nucleotides, and 
fatty acids and thus increase the production of proteins, nucleic acids, and membranes to support rapid 
growth. Cancer cells may exploit these regulatory pathways to fuel proliferation and to adapt to changing 
microenvironments. 
1.2. VI. b) Hypoxia and the Pasteur Effect 
The Pasteur Effect refers to the reflection of oxygen availability on metabolism, such that high levels of 
oxygen promote OXPHOS and inhibit glycolysis and vice versa. In fact, oxygen consumption can be used a 
measure of the rate of OXPHOS. This phenomenon has huge implications for cancer biology, in that hypoxic 
tumours would be expected to favour glycolysis. A review in 2004 by Zu and Guppy discussed how the 
perception that cancer cells invariably utilise aerobic glycolysis (a “Warburg effect”) may be a 
misconception, they report many instances in which this assumption confounded research, and influenced 
strategies for the diagnosis, monitoring, and treatment of tumours. For example, the diagnostic method 
fludeoxyglucose-positron emission tomography (F DG–PET) technique measures glucose uptake to 
differentiate cancerous from normal tissue. Zu and Guppy argued that although FDG–PET may be reliable, 
the glucose absorbed is likely converted into lipids rather than used for glycolysis. They also reported that 
at the time of publication, over half of the studies that they had reviewed had not accurately measured the 
energy budget of the cells (i.e. measured oxygen consumption as well as lactate production) to determine 
the contributions of OXPHOS and glycolysis. A hypoxic condition could bias this as lactate is being released 
although oxygen consumption not increased. Interestingly, those studies that had correctly measured the 
energy budget had actually reported lower proportions of ATP contributed by glycolysis than OXPHOS. 
Therefore, while some cancers may indeed display the Warburg effect, there is insufficient evidence to 
confirm that this is an inherent feature of cancer cells and it may have been vastly overestimated. In fact, 
in many cancers, OXPHOS is intact or even upregulated. Cancer cells may upregulate glycolysis not as an 
inherent feature but in response to hypoxia (Pasteur Effect), which would also explain the efficacy of the 
FDG–PET technique as hypoxic tumours tend to be most aggressive (Zu and Guppy, 2004). This highlights 
the prevalence of hypoxia in solid tumours and the importance of understanding its effects on cancer cells. 
1.2. IV g) Cancer cell dormancy 
Cancer patients often spontaneously develop metastatic disease after years or even decades in remission. 
This is due to cancer cell dormancy – a state of temporary quiescence followed by reactivation of growth 
signalling. There may also be subpopulations of “micrometastases”, cells that are cycling but dying at a 
similar rate due to CTL cytotoxicity (immunogenic dormancy) or insufficient blood supply (angiogenic 
dormancy) (Aguirre-Ghiso, 2007). Even very small tumours have been associated with metastases, 
suggesting that metastases can occur early but the cells can lie dormant and undetected for long periods. 
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Hypoxia may be pivotal in the process of dormancy, which is characterised by quiescence (G0-G1 arrest), 
low metabolism, and expression of stem cell markers (Manjili, 2017). In support of this, a study using breast 
cancer cells demonstrated that exposing cells to cycling hypoxia, conferred resistance to subsequent 
chronic hypoxia by entering a state of dormancy. Autophagy was upregulated in the dormant cells and may 
be important in the process (Carcereri de Prati et al., 2017). Suppression of Akt signalling was key in the 
establishment of dormancy following hypoxia in pancreatic cells (Endo et al., 2014). Dormancy is associated 
with resistance to chemotherapy, as traditional cytotoxic agents target mitotic cells. In colorectal cancer 
cells, hypoxia elicited dormancy as well as chemo-resistance (Endo et al., 2014).  
As mentioned previously, hypoxia is capable of extensive transcriptional reprogramming and this may 
include establishment of dormancy-like features, maintained throughout metastatic spread. Metastatic 
disseminations from hypoxic tumours showed propensity for dormancy and chemoresistance, via 
expression of HIF1α and dormancy factors NR2F1 and p27 (Fluegen et al., 2017). Therefore, a hypoxic 
primary tumour microenvironment is associated with dormant cancer cells that disseminate and evade 
therapy. However, hypoxia is also implemental in the reactivation of dormant disseminated tumour cells. 
In a study of breast cancer metastasis to bone, hypoxia in the bone was the trigger to suppress dormancy-
regulating signalling (the leukaemia inhibitory factor (LIFR)/STAT3/SOCS3 pathway) in the colonising breast 
cancer cells, and reawaken proliferation (Johnson et al., 2016). This study is critical in highlighting the 
multiple roles of hypoxia in promoting entry into dormancy and later exit. Moreover, it is likely that similar 
mechanisms occur in a PCa setting. 
 
1.2. VII. Hypoxia in Prostate Cancer 
Early studies of tumour oxygenation by probe measurements, showed that the majority of prostate 
tumours were hypoxic (Parker et al., 2004) and hypoxia is now considered a common feature of prostate 
tumours (Marignol et al., 2013). As noted in section 1.1. I, the prostate acts as a filter for toxins and age is 
associated with the accumulation of toxins, and the onset of PCa. Hypoxia also increases in the prostate 
with age, due to an ageing cardiovascular system causing reduced blood flow, or poorer vascular integrity 
in the transitional zone; there may also be age-related tissue remodelling which has a high consumption 
of oxygen. This hypoxia may promote the expression of pro-survival genes and indeed, transcriptional 
analyses have shown hypoxia-associated gene signatures in the ageing prostate (Watson et al>, 2009). 
This suggests that hypoxia may play a role in driving the initiation of PCa. Moreover, the expression of 
hypoxic markers correlate with PCa aggressiveness, resistance to therapy, and relapse (Vergis et al., 
2008)(Deep and Panigrahi, 2015).  
As discussed in section 1.1. VIII, PCa invariably develops resistance to ADT (leading to relapse) because 
the cancer cells adaptively switch to an androgen-independent pathway. Hypoxia may play a critical role 
in mediating the development of androgen independence, although this is a largely unexplored area. 
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Early mechanistic studies investigating AR signaIling highlighted crosstalk between AR, HIF-1α and NOTCH 
pathways. First, two groups showed that hypoxia upregulates NOTCH ligands in PCa, and HIF-1α binds 
NOTCH response elements and induces expression of target genes (Belandia et al., 2005)(Gustafsson et 
al., 2005). Then, two studies using the PCa cell line LNCaP revealed that DHT could increase expression of 
HIF-1α target gene GLUT-1, and hypoxia increased expression of PSA (Horii et al., 2007), and hypoxic 
conditions increased AR transcriptional activity (Park et al., 2006).  
Since then, other reports have specifically associated ADT and the occurrence of CRPC with hypoxia. An 
epidemiological analysis of men who had received HIF-1α inhibitors for PCa, revealed a significant 
reduction in their risk of developing CRPC (Ranasinghe et al., 2014). Furthermore, a genetic 
polymorphism in the HIF-1a gene (HIF1A +1772 T-allele) was associated with an increased chance of 
developing resistance to ADT and metastasis (Fraga et al., 2014). Another group showed that hypoxia 
induced the transcription factor STAT5 expression and this was also a feature of both long-term ADT 
treated and CRPC xenografts (Røe et al., 2013). Important insights have come from an approach using 
dynamic contrast enhanced magnetic resonance imaging, which revealed that ADT-treated xenografts 
had increased vascularisation (increased number of vessels, vessel density, and vessel area fraction) and 
increased hypoxia (shown by hypoxia staining). After approximately 6 months, the xenografts had 
become androgen-independent (CRPC) and displayed further increases in tumour vascularisation (Røe et 
al., 2012). A recent study found that CRPC samples overexpressed the oncogene positive cofactor 4 (PC4) 
which promotes proliferation via c-myc/p21, and they showed that it also activates HIF-1α and b-catenin, 
corroborating the link between hypoxic signalling and androgen-independence (Luo et al., 2019). 
Research from our laboratory has demonstrated that treatment with bicalutamide in vivo (using an LNCaP 
xenograft model of PCa) significantly increased hypoxia and also triggered the upregulation of genes 
involved in EMT (Ming et al>, 2013)(Byrne et al., 2016). In line with this hypothesis, use of the hypoxia-
activated pro-drug OCT1002 in combination with bicalutamide inhibited hypoxia and metastatic spread, in 
a murine model of PCa (Nesbitt et al., 2016). These in vitro and in vivo studies at Ulster provided consistent 
evidence that hypoxia is an important factor in selecting for cells with increased capacity for cancerous 
growth, although the mechanisms underpinning this remain to be elucidated. 
A recent study corroborated further the link between ADT, hypoxia and CRPC. The group reported that 
chronic ADT during hypoxia produced androgen-independence in cell lines, which was dependent on the 
expression of glucose-6-phosphate isomerase (GPI). GPI expression was repressed by AR during hypoxia, 
but was increased by ADT. The researchers concluded that during hypoxia, GPI diverts glucose metabolism 
away from the AR-dependent pentose phosphate pathway (PPP) and into glycolysis. This could explain why 
their enzalutamide treatment was less effective during hypoxia, as GPI was de-repressed and facilitated 
the switch to glycolysis. They also showed that inhibiting GPI prevented resistance to enzalutamide during 
hypoxia in vitro and that it improved the efficacy of enzalutamide in vivo (Geng et al., 2018). 
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Taken together, these findings demonstrate that ADT is associated with increased hypoxia, and that in 
turn hypoxia can modulate AR signalling. This emphasises the need to understand the precise genetic 
changes that occur following ADT and hypoxia in PCa cells, and implicates hypoxia as a modifiable facet of 
the microenvironment that if inhibited during adjuvant therapy may prevent relapse.  
 
1.2. IX. Summary 
Hypoxia is a physiological condition in many tissues, but when dysregulated it has deleterious effects, such 
as the increased malignancy observed in hypoxic tumours. Hypoxic signalling has been extensively 
characterised although some aspects remain poorly understood, such as its links with AR signalling that 
may underlie its role in the promotion of CRPC. And as the next section demonstrates, there is still much 
to be discovered about the genetic pathways affected by hypoxia. 
 
1.3 MicroRNAs 
1.3. I. Non coding RNAs 
The bulk of genetics research has focused on analysing the expression patterns of coding genes (comprising 
1.5% of the human genome), and until relatively recently, it was thought that non protein-coding regions 
were non-functional “junk” DNA. However, in the last 30 years, it has become apparent that some non 
protein-coding regions are also critical in maintaining healthy physiology. These regions may be transcribed 
into non-coding RNAs (ncRNA) that mainly function to regulate the synthesis of protein from mRNAs. 
NcRNAs include microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), transcribed ultra-conserved regions 
(T-UCRs), small nucleolar RNAs (snoRNAs), large intergenic non-coding RNAs (lincRNAs) and long non-
coding RNAs (lncRNAs) (a heterogeneous group of long RNAs). Even transfer RNAs can be cleaved to 
produce bioactive RNAs (tiRNAs)(Esteller, 2011).  
MicroRNAs are short in length (18-25 nucleotides) and are the most widely studied form of ncRNA. In 1993, 
Viktor Ambros’ and Gary Ruvkun’s research groups together discovered that the lin-4 gene in C. elegans 
encoded a short RNA molecule that was not detectable as a protein sequence but was nevertheless 
essential for C. elegans’ development. Shortly afterwards they discovered that it had antisense 
complementarity to the lin-14 gene and thus discovered the phenomenon of RNA-induced interference 
(RNAi) (Bartel, 2004). Twenty-five years later, miRNAs are recognised as pivotal regulators of essential cell 
processes. Many are highly conserved across animals and plants. In mammals, there are around 300 
conserved miRNA genes and a further 1000 loci that encode miRNA-like transcripts, although these are less 
conserved (Mendell and Olson, 2012). Approximately one third of miRNA genes are located within the 
intronic regions of protein coding genes (“miRtrons”) and are co-expressed with them, often with related 
functions (Mendell and Olson, 2012). In terms of mRNA targets, David Bartel’s group have shown that in 
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humans, over 45,000 miRNA binding sites within 3′UTRs were conserved, and that over 60% of protein-
coding genes were regulated by miRNAs (Friedman et al., 2009). 
1.3. II. MicroRNA biogenesis, structure and regulation 
The mature miRNA is a short RNA sequence (18-25 nucleotides long, and on average 22 nucleotides), which 
is the finished product of a two-step cleavage from a longer primary transcript, by two class III nuclear 
ribonucleases: Drosha and Dicer (Figure 7). The primary transcript (pri-miRNA) is mainly transcribed by RNA 
polymerase II (although some Pol I derived transcripts have been identified) and has the classic features of 
an mRNA: a 5’ cap and poly(A)tail. A microprocessor complex, containing Drosha and the double-stranded 
RNA binding protein DGCR8 (homolog of D. melanogaster and C. elegans’ Pasha), binds the pri-miRNA. 
Then, Drosha cleaves the pri-miRNA to release one or more 60-90 nucleotide sequences that form stem-
loop structures (the pre-miRNA). Pre-miRNAs can also arise as splice products of pre-mRNAs. Next, the pre-
miRNA is exported from the nucleus to the cytoplasm by the Exportin 5-RAN-GTP complex, and cleaved a 
second time by Dicer into a short duplex. The mature miRNA is loaded to a member of the Argonaute (AGO) 
family by Dicer and the TAR RNA-binding protein 2 (TRBP), to form the miRNA-induced silencing complex 
(miRISC). Loading of the miRNA onto AGO requires ATP and the activity of the chaperones Hsc70 and 
Hsp90. MiRNA loading onto RISC is highly regulated, as is the activity of the proteins of the miRISC (Bartel, 
2009). 
 
Figure 7. MicroRNA biogenesis. Image from Wikipedia, usage rights: labelled for reuse. Pre-miRNAs can arise as 
products of a pri-miRNA or as a splice product of a pre-mRNA. The pre-mRNA is exported from the nucleus by the 
exportin-RAN-GTP complex and cleaved by Dicer into the short duplex, one strand is retained and loaded onto miRNA 
ribonucleoprotein (miRNP/miRISC) complex.  
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One strand of the duplex is preferentially loaded onto RISC, which is determined by the thermodynamic 
stability of each sequence. AGO favours the strand with a thermodynamically less stable 5’ end and it 
prefers U and A over G and C as the terminal 5’ nucleotide. For some miRNAs (or in some specific tissue 
contexts), one “arm” of the pre-miR is associated with a drastically higher abundance of miRNAs, indicating 
that it is more biologically active and the opposing strand is degraded, and in some cases the more 
abundant strand switches (miRNA arm-switching). Traditionally, the less active strand was known as the 
“star” strand with an asterisk used to denote it (miRBase, 2019). 
The sequence of the miRNA/siRNA guides AGO to mRNAs by base complementarity. In animals, miRNAs 
usually bind the 3′ UTR of mRNA targets by their seed region (positions 2–8 of the mature miRNA, Figure 
8) although recent reports have shown miRNAs capable of binding coding regions and the 5’UTR. Therefore, 
some miRNAs can target numerous mRNAs and act as master regulators of a process. On the other hand, 
an mRNA can be targeted by numerous miRNAs, and miRNAs can regulate their targets cooperatively. This 
produces highly complex networks of miRNA regulation and can orchestrate multiple cellular processes. 
Individual miRNAs have been shown to be essential for cellular functions such as differentiation, 
metabolism, apoptosis, and tissue development. MicroRNAs with important biological functions may be 
highly conserved; some miRNAs have an almost identical sequence across invertebrates and vertebrates 
(Esteller, 2011). 
At the genomic level, over 40% of miRNAs are organised in clusters (within 10kb from one other, and on 
the same strand) which allows them to be regulated spatially and temporally and to act cooperatively 
(Altuvia et al., 2005). For instance, the miR-17-92a cluster is a polycistronic transcription unit (C13orf25) 
giving rise to six miRNAs: miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a. MiRNAs may also 
have “family” members, which share a common ancestor and arose from duplication and mutational 
events. MiRNA families are often clustered, may have sequence similarity (particularly of the seed region) 
or similar secondary structure, and often target the same mRNAs providing redundancy. For example, the 
let-7 gene encodes a conserved miRNA family, including let-7b, let-7c and let-7d, which have various cell-
specific influences but are all involved broadly in pathways associated with differentiation (Roush and 
Slack, 2008).  
MicroRNA activity is regulated both transcriptionally and post-transcriptionally. The expression of pri-
miRNA transcripts are controlled, as is the activity of splicing factors that may give rise to a pre-miRNA from 
an mRNA, and the activity of Drosha, Dicer, AGO and other enzymes involved in miRNA biogenesis and 
function. MicroRNAs may be actively degraded post-transcriptionally, and some have greater stability in 





























Figure 8. MicroRNA-messengerRNA interaction. MicroRNA bound to AGO-containing miRISC binds the 3’UTR of an 




1.3. III. Mechanisms of microRNA-mediated gene silencing 
The involvement of Dicer and the RISC complex is common to all forms of RNA-interference (RNAi), which 
includes siRNA gene knock down and is mechanistically similar to gene knock out by the CRISPR-Cas9 
system. MicroRISC contains a mature miRNA and the RISC cofactors, including AGO that binds the mature 
miRNA and GW182 which is crucial for effective gene silencing. AGO has four variants, and is bilobal with 
four conserved domains: N-terminal, Piwi Argonaute Zwilli (PAZ), MID, and PIWI. AGO2 is unique in that it 
has slicer activity and can cleave perfectly matched targets, however, the other three variants can equally 
load miRNAs and guide the RISC complex. Interestingly, a Dicer independent miRNA biogenesis pathway 
was identified, using the slicer activity of AGO2 (Cifuentes et al., 2010). The PAZ domain binds the 3’ end 
of the miRNA, the PIWI domain is responsible for catalytic activity that allows the mRNA to be cleaved, and 
a hydrophilic pocket in the MID domain binds the 5' phosphate of the miRNA, and a rigid loop binds the 5’ 
base (the nucleotide specificity loop). The 3’ end is bound by the PAZ domain, although there is little or no 
specificity to the 3’ base identity. Therefore, all the domains of AGO (including the linker domains) are in 
contact with the guide RNA, while specific pockets of the PAZ and MID domains bind its termini. The seed 
region (nucleotides 2-7) is held in an A-form helical loop by AGO by a series of salt bridges and hydrogen 
bonds with the phosphate backbone. Nucleotides 2-6 are exposed to the solvent, and form Watson-Crick 
base-pairing with target mRNAs. The remainder of the miRNA is wound through a hydrophobic channel 
between the two lobes (Schirle and MacRae, 2012).  
MicroRISC binding causes translational repression, usually accompanied with mRNA decay. Messenger-
RNA decay occurs by either whittling down of the poly(A) tail (de-association with the poly(A) binding 
protein removes its protection from degradation) or by immediate cleavage. Work from the Bartel group 
has recently shown that the initial length of the poly(A) tail determines the rate of mRNA degradation upon 
RNAi, with short-tailed mRNAs being more rapidly degraded. This staggers the rate at which mRNA targets 
are degraded upon miRNA overexpression. Mechanistically, translation repression is achieved in several 
ways: pre-initiation by interfering with eIF4E recognition of the cap (indeed, the MID domain of AGO has a 
structure similar to the cap-binding motif found in eIF4E), or by preventing recruitment of the 40S or 60S 
ribosomal subunit. Translation may be inhibited post-initiation by preventing ribosomal elongation. 
Alternatively, the miRISC causes mRNA decay through GW182 interacting with deadenylase complexes 
(CCR4–NOT and PAN2–PAN3), which deadenylate the poly(A) tail. Next, the 5’ cap is removed by the DCP1–
DCP2 complex. In the absence of the cap and poly(A) tail, an Xrn1 5′–3′ exonuclease digests the mRNA. 
GW182 also binds poly(A) binding protein (PABP), which is known as a translation initiation factor by 
promoting mRNA circularisation. This indicates that GW182 may prevent translation initiation by 
competitively binding PABP and inhibiting the PABP-eIF4G association and mRNA circularisation, or by 
recruiting the deadenylation complexes to the cap. Therefore, the miRNA sequence determines which 
mRNAs are targeted, and the associated proteins determine the effect on the mRNA (Esteller, 2011). 
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1.3. IV. Functions of miRNAs in cell signalling pathways 
MicroRNAs modulate cell signalling pathways through multiple mechanisms. The simplest is when a 
protein-coding gene regulates the expression of a miRNA, which then plays an integral part in the pathway. 
Secondly, a miRNA may be expressed constitutively and function to titrate the activity of an mRNA target 
that becomes induced. Here, the miRNA may play an important dampening or heightening effect on the 
target. Thirdly, miRNAs can facilitate both negative and positive feedback loops, by promoting or inhibiting 
the pathway through new targets, or by targeting their own transcriptional activators or repressors. Finally, 
miRNAs may simultaneously up- and down-regulate a pathway, producing a buffer effect and stabilising 
the signal. This is evident when the deletion and overexpression of a miRNA produces the same phenotype 
(Mendell and Olson, 2012). As well as intracellularly, miRNAs are essential mediators of paracrine 
signalling; they are detected in exosomes and may have important local and systemic effects. However, 
the levels of miRNAs found in circulating exosomes may be too low to exert significant biological effects on 
distant tissues, although this remains to be investigated (Mendell and Olson, 2012). 
1.3. V. MicroRNAs and human disease 
A single miRNA can play an enormous role in regulating the activity of a specific pathway and often 
functions to coordinate numerous pathways. Given their involvement in basic cell processes, the aberrant 
expression if miRNAs can result in developmental defects and disease. The abnormal expression of 
individual miRNAs is involved in the development of cancer, neurodegenerative and metabolic disorders, 
and viral infection (Eulalio, Huntzinger and Izaurralde, 2008). Here, dysregulation in miRNA expression can 
arise from mutational or epigenetic events at the pri-miRNA gene or promoter region, genomic relocations 
leading to amplifications or deletions, or in the expression (or activity) of transcription factors or enzymes 
involved in miRNA processing, such as the splicing factors (Eulalio, Huntzinger and Izaurralde, 2008).  
1.3. VI. MicroRNAs in cancer 
The link between miRNA dysregulation and cancer first arose as miRNAs were shown to be essential in key 
cancer-related pathways such as cell proliferation and apoptosis. Genome-wide association studies (GWAS) 
also indicated that specific miRNAs were lost in cancers. The first evidence of miRNA involvement in cancer 
was a study of chronic lymphocytic leukaemia (CLL), in which the authors reported frequent deletion of the 
miR-15a/16-1 and confirmed them as driver mutations of the disease (Calin et al., 2002). Since then, the 
results of hundreds of sequencing-based studies have confirmed that tumours have highly abnormal 
miRNA expression patterns, and in vitro functional studies showed that miRNAs have oncogenic roles (e.g. 
miR-21, miR-155) and tumour-suppressive roles (e.g. miR-15∼16), while some are context-dependent (e.g. 
miR-29 and miR-146) (Kasinski and Slack, 2011). The miR-200 family have been extensively studied and are 
known to be involved in many tumour types, since they are key regulators of the ZEB family of transcription 
factors that induce EMT in numerous tumours including PCa (Chen et al., 2014) (Abisoye-Ogunniyan et al., 
2018). Preclinical models have confirmed this: in vivo transgenic expression of the miR-17-92a cluster in 
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hematopoietic progenitor cells caused Myc-activated B-cell lymphomagenesis to progress rapidly in vivo 
(He et al., 2005), while its deletion resulted in apoptosis in Myc-induced lymphoma cells in vitro (Mu et al., 
2009). Furthermore, delivery of certain tumour-suppressive miRNAs inhibited tumour growth, such as let-
7, miR-34a, miR-26a, and miR-143/145 (Kota et al., 2009; Pramanik et al., 2011; Trang et al., 2011).  
1.3. VII. MicroRNAs and stress responses 
Since GWAS studies showed that miRNAs were deleted in certain cancers, early studies focused on miRNA 
knock-out models to identify their function. However, most failed to identify precise roles as the mice 
appeared to develop normally. Moreover, miRNAs rarely played a vital role in the development of model 
organisms such as C. elegans and D. melanogaster. However, it was later observed that while deleting 
certain miRNAs often did not impact the development of a mammalian organ, it incapacitated its ability to 
respond to stress. For instance, mice with miR-208a-/- have normal cardiovascular development and 
function, but have impairments in cardiac remodelling and do not develop cardiac fibrosis following 
stresses (van Rooij et al., 2007). Similarly, mice with homozygous knock-out of miR-375 develop normal 
pancreases but cannot induce pancreatic β-cell expansion after obesity-induced insulin resistance, leading 
to severe diabetes (Poy et al., 2009). Intriguingly, miRNAs appear to be crucial in mediating the hypoxic 
response. One group knocked out Dicer in non-small cell lung carcinoma (NSCLC) cells and used them to 
establish a xenograft model; the resulting tumours were highly hypoxic but poorly vascularised, suggesting 
that miRNAs mediate angiogenesis (Chen et al., 2014). Additionally, hypoxia is associated with a specific 
miRNA profile in many cancer types. In breast and lung cancer tumours, the miRNA miR-210 is highly 
upregulated by HIF-1α as one of the earliest effects of hypoxia. MiR-210 was also implicated in 
mitochondrial dysfunction following hypoxia (Chen et al., 2014). MiRNAs are pivotal in inflammatory 
signalling, in particular, miR-155 and miR-342-5p. These miRNAs regulate intra- and intercellular 
inflammatory responses, and are thus involved in cancer progression (Chen et al., 2014). 
In support of their prominent role in stress responses and cancer cell maintenance, in vitro and in vivo 
studies have shown promising results in that miRNA-based therapies can damage cancer cells while healthy 
cells remain unaffected. This suggests that transformation renders the cell more sensitive to (or reliant) on 
changes in miRNA signalling. This may be because cancer essentially represents a state of chronic stress, 
with persistent DNA damage and sustained DNA-damage response, an accumulation of misfolded proteins 
and aggregates due to abnormal protein complexes, aneuploidy, and metabolic reprogramming that fuels 
increased growth but results in high levels of toxic intermediates such as ROS (Luo, Solimini and Elledge, 
2009). Therefore, modulation of miRNAs may selectively affect diseased cells with minimal impact on 
healthy cells. 
Alternatively, it has been suggested that miRNAs serve mainly to maintain cells in a differentiated state. 
This would also explain the abnormal miRNA expression patterns observed in cancer, and their importance 
in fully developed tissues rather than early development (Reid et al., 2016).  
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1.3. VIII. MicroRNAs in prostate cancer 
Individual miRNAs have been attributed oncogenic effects within the context of PCa. For example, miR-21 
is a marker of cancer in many tumour types and increases with Gleason grade in a linear manner in PCa 
(Cannistraci et al., 2014). Similarly, miR-221 and miR-222 are increased in PCa tissue and increase 
clonogenicity in vitro. Mechanistically, they may exert oncogenic effects by downregulating CDK inhibitor 
p27Kip1 and promoting cell cycle progression (le Sage et al. 2007; Galardi et al. 2007; Mercatelli et al. 2008). 
MiR-141 is overexpressed following castration and may play a role in androgen-independence (Zhang et 
al., 2013); it was also increased in PCa patients’ serum (Mitchell et al., 2008). MiR-18a is highly upregulated 
in PCa and in advanced PCa as well as upregulation in the serum (Al-Kafaji, Al-Naieb and Bakhiet, 2016). 
Other miRNAs which are upregulated in PCa, and may have oncogenic effects, are miR-32 (regulator of 
PI3K) (Jalava et al., 2012), the miR-106b/miR-25 cluster (regulator of CASP7) (Walter et al., 2013), and miR-
125b (Amir et al., 2013).  
Conversely, a number of miRNAs have been reported as downregulated in PCa, have been shown to 
regulate pathways involved in cancer progression, and thus may be tumour suppressors. For instance, miR-
34 was reduced in PCa tissues and was confirmed to influence the cell cycle by targeting the cyclin-
dependent kinases p16 and p27 (Lynch, McKenna, et al., 2016). MiR-34 inhibits stemness by regulating the 
adhesion molecule CD44 (Liu et al., 2011) and it is also downregulated by hypoxia, and derepresses 
NOTCH1 and JAG1 to facilitate EMT (Chen et al., 2014). The miR-17-92a cluster appears to have tumour-
suppressive effects in PCa, by inhibiting the cell cycle, EMT, and migration as well as improving sensitivity 
to bicalutamide (Ottman et al., 2016). miR-30a was also proposed to be a tumour suppressor in CRPC, 
potentially by targeting cyclin E2 (L. Zhang et al., 2016).  
Interestingly, the role of epigenetics in regulating miRNA expression in PCa is emerging. For example, miR-
4534 becomes expressed due to loss of hypermethylation of its promoter region and inhibits PTEN (Rea et 
al., 2016), and the shared promoter region of miR-200c and miR-141 was methylated in inverse correlation 
with their expression level in PCa cell lines (Lynch, O’Neill, et al., 2016). 
 
1.3. IV. MicroRNAs as biomarkers and therapeutic targets  
MicroRNAs are ideal candidates for biomarkers since their short size and association with the miRISC 
complex and/or exosomes renders them relatively stable compared to mRNAs and very suitable for testing 
in patient samples. They are abundant in tissues and bodily fluids (e.g. serum, urine, saliva) and readily 
quantified by polymerase chain reaction (PCR) experiments. Many miRNAs are detectable in systemic 
circulation and may be useful as biomarkers of a disease state or a response to treatment, and miRNAs 
profiling was capable of predicting cancer incidence or outcome in bladder cancer, gastro-oesophageal 
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cancer, pancreatic cancer, and lung cancer (Blick et al. 2015; Winther et al. 2016; Wu et al. 2016; Mace et 
al. 2013).   
MicroRNAs are also attractive as therapeutic targets, as they can be mimicked or inhibited by synthetic 
oligonucleotides (Kreth, Hübner and Hinske, 2018). Firstly, this is useful because the oligo can regulate 
numerous signalling pathways at once, as opposed to the traditional “one target, one drug” approach. 
Targeting multiple pathways simultaneously improves the scope of the agent over different clones and 
reduces the chances of drug resistance developing (Reid et al., 2016). Moreover, synthesising an oligo that 
is complementary to a miRNA is easy and cost-effective from a drug development perspective, compared 
with designing small molecules that fit a protein domain and have acceptable bioavailability, metabolic 
half-life, and minimal side effects. This means RNAi-based therapies may allow the targeting of previously 
“un-druggable” proteins.  
The first miRNA-based therapy to enter clinical trials was MRX34, double-stranded synthetic version of 
miR-34a (23 nucleotides long) encapsulated in a ~110 nm liposomal nanoparticle, for the treatment of 
advanced solid tumours in the liver. MiR-23a is a master tumour-suppressor that regulates over 30 
oncogenes. MRX34 was administered intravenously and permeated many organs including the spleen and 
bone marrow. It demonstrated significant anti-tumour activity and acceptable safety at Phase I although 
failed ta Phase II (Kreth, Hübner and Hinske, 2018). MiRNA “antagomiRs” and “sponges” exert the opposite 
effect to mimics. Unlike mimics they are single stranded, and can also be administered intravenously. 
AntagomiRs contain an antisense sequence and sponges are longer with multiple antisense seed sequences 
to “mop up” an excess of a miRNA. Recruitment is underway for Phase I trial for MRG-106, a miR-155 
antagomiR to treat cutaneous T cell lymphoma. Currently the only miRNA-based therapy to have passed 
Phase II is an anti-miR-122 that treats hepatitis C virus infection, although many more are in development 
(Kreth, Hübner and Hinske, 2018). The main issues in RNAi based therapies are preventing off-target 
sequence binding, and facilitating the delivery and preservation of small RNA molecules (that eukaryotic 
cells have evolved to recognise as foreign genetic material). However, new delivery means are being 
developed, such as the GalNAc ligand which can be conjugated to siRNA and facilitates delivery in liver cells 
(Springer and Dowdy, 2018).  
 
1.3. V. Summary 
MicroRNAs are a species of non-coding RNA that were discovered 26 years ago and have since been shown 
to regulate literally all cellular pathways, and they are essential for rapid cellular adaptation to stress 
conditions. As a disease, cancer essentially comprises a state of chronic cellular stress and miRNAs are 
therefore of interest as novel cancer therapy targets. Indeed, the abnormal expression of individual or 
groups of miRNAs is observed in many cancers and modulating miRNA expression can reduce cancer 
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progression in preclinical models. Moreover, miRNAs make attractive candidates as biomarkers or 
treatment targets due to their physical stability in tissues and fluids, and they are simple to mimic or inhibit 
pharmaceutically, and a new generation of RNAi-based cancer therapies are entering the clinic. A role for 
miRNAs in the hypoxic response has been demonstrated in many tissues during both physiological and 






















1.4. Overall summary and aims of the Project 
1.4. I. Overall summary 
Hypoxia following ADT may play a key role in facilitating cell survival and dormancy, and contribute to the 
observed relapse with CRPC. A clearer understanding of the effects of ADT and tumour hypoxia on 
biochemical progression is needed to reveal why AR inhibition ultimately fails. In particular, the role of 
miRNAs in the hypoxic response in PCa is understudied.  
The overarching aim of this PhD project is to investigate the role of miRNAs in the hypoxic response in PCa, 
to explore how they may contribute to the development of CRPC in this context.   








                            
 
Figure 9. Outline of the PhD: identification of miRNAs involved in the hypoxic response in PCa. In vitro and in vivo 
models of PCa hypoxia were set up and used to identify hypoxia-regulated miRNAs. The clinical relevance of the 
hypoxia-associated miRNAs to human PCa was explored by measuring their expression in human prostate tumour 
samples (use of an in-house cohort and publically available datasets). To confirm oncogenic effects of the miRNAs, 
phenotypic assays were used and the regulation of the miRNAs’ expression by epigenetics were explored in PCa cell 
lines.  
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1.4. II Project objectives 
1. Produce a list of candidate miRNAs that are regulated by hypoxia or cancer in a variety of tissue 
contexts. 
2. Develop models of tumour hypoxia in the laboratory and analyse expression of candidate miRNAs 
during hypoxia by RT-qPCR. 
I. PCa cell lines cultured in hypoxic gas chamber (2D cell layer). 
II. PCa cell lines cultured as spheroid “prostataspheres” (3D culture). Internal cells become 
hypoxic once a critical size is reached. 
III. Establish in vivo xenograft tumour model of prostate cancer. We expect that tumours 
become hypoxic with size increase, and hypoxia is accelerated by bicalutamide treatment. 
3. Exploration of the clinical relevance of the hypoxia-associated miRNAs by measuring their 
expression in human PCa tissue relative to non-tumour tissue. 
I. Analysis of in-house cohort of prostate biopsy samples.  
II. Data mining of online repositories – to investigate expression of the miRNAs in sequenced 
prostate tumour samples, and for identification of key signalling pathways. 
4. Analyse the functional role of the miRNAs in cancer progression by using phenotypic screening to 
examine the effect of miRNA inhibition/overexpression on markers of apoptosis, senescence or 
proliferation. 
5. Investigate the regulation of miRNA expression by DNA methylation to explore how its expression 
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2.1. In vitro experiments 
2. 1. I. Tissue culture 
2. 1. I. a) Monolayer cell culture. LNCaP, 22RV1, DU145, PC3 and RWPE1 were obtained from American 
Type Culture Collection (ATCC) and were cultured as a monolayer on sterile culture dishes. All were grown 
in Roswell park memorial institute (RPMI) 1640 medium supplemented with 20% foetal bovine serum (FBS) 
(GIBCO, Thermo Scientific) except RWPE1, which were cultured in Keratinocyte Serum-Free medium 
supplemented with 25mg Bovine Pituitary Extract and 2.5μg extracellular growth factor per 500mL (GIBCO, 
Thermo Scientific). Media was aliquotted in 20mL volumes in universals and the required amount was 
warmed in a water bath at 37°C prior to use. Cells were incubated in a humidified incubator at 37°C with 
5% CO2. Cells were grown to a maximum of 90% confluency before passaging and used in experiments 
within 10 passages after breaking out. To passage, cells were rinsed with sterile phosphate buffer saline 
(PBS, pH 7.4) and detached by incubation in 0.05% trypsin in PBS for 3-10 mins before centrifugation at 
1200rpm for 3-5mins and resuspension in fresh media. Cells were frozen at low passage in 60% complete 
media with 20% foetal bovine serum (GIBCO, Invitrogen) and 20% sterile dimethyl sulfoxide (DMSO) and 
stored in liquid nitrogen. Cells were broken out by warming 1 or 2 cryovials until semi-thawed and dropping 
the ice cube into a small flask containing 10mL pre-warmed complete media and gently swirling, and the 
media was carefully changed after 6h, and again after 24h including a PBS rinse. For counting, cells were 
trypisined and re-suspended in fresh media, 1µL was counting using the average of the four quadrants of 
a haemocytometer after staining for viability with trypan blue dye (1:10 dilution of trypan : cell suspension). 
To determine the number of cells per mL from the number (#) per µL, the following formula was used: 
#/mL = #/µL * (1/0.1) * 0.9 * 1000. To determine the volume required to obtain a specified number of cells 












Table 1. Epithelial prostate cell lines used for experimental work including transformed status, site of origin, AR 
status, and AR variant status.  
 
Cell line Transformation 
status 











None (Bello et al., 
1997) 
LNCaP Tumorigenic Metastatic human 
prostate cancer, 




with mutation at 
position T877A in 
the ligand-binding 
domain. Receptor is 







et al., 2013) 
22Rv1 Tumorigenic Human prostate 
carcinoma epithelial 
cell line. Derived 
from a xenograft 
that was serially 
propagated in mice 
after castration-
induced regression 




AR detectable and 
DHT weakly 
stimulates growth, 
















PC3 Tumorigenic Metastatic human 
prostate cancer, 
derived from the 
bone 
AR detectable, cells 
AR-independent 
ARV7 (Kaighn et al., 
1979)(Alimirah 
et al., 2006)(Xu 
and Qiu, 2016) 
DU145 Tumorigenic Metastatic human 
prostate cancer, 
derived from the 
brain 
AR detectable but 
cell line is AR-
independent 
ARV7 (Stone et al., 
1978)(Alimirah 
et al., 2006)(Xu 








2.1.I.b. Hypoxia Incubator Chamber. For paired hypoxic and normoxic samples, cells were split into two 
flasks, allowed to reseed overnight and incubated within a hypoxia incubator chamber (Stemcell 
technologies) and  standard incubator for timepoints of 24h, 48h and 72h. The hypoxic incubator was 
supplied with HEPA-filtered air at 0.1% oxygen. Cells to be cultured in hypoxia were seeded at 70% 
confluence to account for the slower growth and cells for normoxic culture were seeded at 30% confluence.  
2.1.I.c. Aza-dc treatment. Fresh media containing 5µM 5-aza-2’-deoxycytidine (aza-dc) that had been 
solubilised in DMSO was applied to the cells following a PBS rinse. Cells were treated for 3 consecutive 
days, then if necessary grown for 24h and harvested for RNA and DNA extractions. To confirm the aza-dc 
treatment had worked, mRNA levels of SYPC3 and DAZL were measured.  
2.1.I.d. Prostatosphere cell culture. 6-well plates were double-coated with a polyhema acrylamide layer 
(1.2% poly(2-hydroxyethyl methacrylate) solubilised at 50°C overnight in 95% ethanol) which inhibited cell 
adhesion to the base of the plate. 10,000 cells were seeded and grew in clusters, the growth of which was 
measured by microscopy. To obtain sufficient cells for protein extraction, prostatospheres were cultured 
in a 10cm petri dish seeded with 30,000 cells. Media was replaced every 3 days, with half the volume of 
media being carefully aspirated and replaced without disturbing the prostatospheres.  
2.1.I.e. Transient transfection of precursor miRNA molecules. Transfections were performed at a final 
concentration of 25nM. Cells were transfected when 30% confluent and typically seeded 16h before 
transfection into wells of a 6-well plate (at 80,000 cells per well for RWPE1, PC3, and 22RV1, and 100,000 
cells per well for LNCaP). To transfect, OptiMem serum-reduced media was used for transfection (GIBCO, 
Invitrogen). Lipofectamine 2000 reagent (Thermo-Scientific) was complexed to RNA of interest (pre-miRs, 
Ambion, Thermo Fisher) by incubation at room temperature for 20 minutes. The pre-miR was solubilised 
in 50µL NF-H2O to provide a stock of 100µM (stored at -20°C). For transfection of the pre-miR, 1µL of the 
100µM stock was complexed with 3µL Lipofectamine (1µL RNA : 199µL OptiMem, mixed with 3µL 
Lipofectamine : 197µL OptiMem) mixed by pipetting and incubated at room temperature for 20 minutes. 
The seeded cells were rinsed with PBS and 1.6mL OptiMem was added. The Lipofectamine/RNA solution 
was gently added (400µL total) and mixed by swirling. Cells were incubated with the Lipofectamine-RNA 
solution for 4-6 hours, before it was replaced with the normal complete media. The effects of pre-miRs 
were gauged relative to the control scrambled sequence pre-miR, which does not target known human 
mRNAs (pre-miR-neg). Cells were harvested at 48-72h depending on confluency.  
2.1.II. Luciferase reporter assay. Cells were co-transfected with the precursor pre-miR molecules as 
described (non-targeting negative control pre-miR-neg, and pre-miR of interest), with plasmids containing 
luciferase gene cloned downstream of a wild-type or mutated promoter sequence of the gene of interest 
such that if the miRNA binds the promoter sequence then the expression of luciferase will be silenced. The 
plasmids were a kind gift from by Dr Fabio Martelli upon request (I.R.C.C.S. Policlinico San Donato, Milan, 
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Italy). Cells were co-transfected with 100ng of vector/mutant plasmid plus the miRNA precursor at 25nM. 
30ng Renilla luciferase vector was included in each well to control for transfection efficiency. The two 
nucleic acids were independently complexed to Lipofectamine before the solutions were mixed and 
applied to the cells. After 48 hours, cells were lysed in lysis buffer (Promega) and luciferase activity 
measured using the Dual-Glo® Luciferase Assay Kit (Promega) on a FluoStar Omega plate reader (BMG 
LabTech). Transfections were carried out in triplicate, measurements within experiments were performed 
in duplicate, and firefly luciferase readings were normalised against renilla luciferase readings before 
analysis.    
2. 1. III. Phenotypic assays 
2.1.III.a. Scratch wound assay. Once 80-90% confluent, the cell monolayer was “scratched” using a 20μL 
pipette tip in a cross (used to orient when imaging), and rinsed with PBS to remove detached cells. Cells 
were rinsed before imaging at the same points (around the cross) for 24h, 48h, 72h, and 96h (Nikon Eclipse 
TS100).  
 2.1.III.b. XTT cell proliferation assay. Cells seeded into a 96-well plate at 500-1,000 cells per well in eight 
technical replicates. Cells were counted and the cell number per mL was adjusted and added to a basin 
(cleaned with 70% IMS) and a multichannel pipette used to add 100µL of the suspension to each well using 
a multichannel pipette. For each time point, a different 96-well plate was used. 50µL XTT reagent (2,3-Bis-
(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) (Roche) was added to wells and 
allowed to incubate at 37°C for 4-6 hours. The XTT reagent was made up of XTT labelling reagent and XTT 
electron coupling reagent (5mL : 100μL, respectively). After 16h, absorbance (optical density, O.D.) was 
measured using the FLUOstar Omega Spectrophotometer (BMG LabTech) at 495nm, normalised to the 
reading at 650nm. 
2.1.III.c. Flow cytometry. Cells were harvested by trypsinisation and pelleting, the pellet was flicked to 
gently re-suspend and 1mL ice-cold PBS was added to rinse (this ice-cold PBS rinse was repeated twice). To 
fix the cells, the cell pellet was re-suspended by flicking it in 100μL PBS then the cells were vortexed on the 
lowest speed while 900μL 100% ethanol was slowly dripped in. Cells were rinsed again twice in ice-cold 
PBS, and then re-suspended in the staining solution. Cell cycle analysis. Staining solution contained: 
0.1mg/mL RNAse A, 0.01mg/ml propidium iodide (PI), 0.1% Triton X, and 5mg/mL tri-sodium citrate. After 
5 minutes at room temperature in the dark, the solutions were analysed on a two laser eight colour 
GalliosTM flow cytometer (Beckman Coulter). Apoptosis analysis: The Alexa Fluor® 488 Annexin V/Dead Cell 
Apoptosis Kit (Thermo Fisher Scientific) was used. Cells were harvested and rinsed twice in ice-cold PBS, 
and a master mix was prepared containing 1X Annexin Binding Buffer, Alexa Flour stain, and PI at 100µg/µL 
(according to the manufacturer’s instructions). 600µL of master mix was added to the cells and left to 
incubate in the dark at room temperature for 15 minutes before being analysed.  
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2.1.III.d. Colony forming assay. Cells were seeded as 500 cells per well of a 6-well plate, and left for 7 days 
without changing the media. The cells were rinsed with ice-cold PBS and an ice-cold fixing solution was 
gently added (7 parts methanol : 1 part acetic acid) for 5 minutes. Cells were stained with 0.5% crystal 
violet solution (Sigma) in 25% methanol for 5 mins and rinsed with water. To quantify the crystal violet, 
cells were lysed in 1% SDS solution for 30mins at room temperature with rapid rocking. 100μL of the SDS 
solution was added in triplicate to wells of a 96 well plate and the O.D. was measured at 595nm.  
2.1.III.e. Migration and invasion assay by Boyden chamber. For migration analysis, the cells’ ability to cross 
a porous membrane was assessed. For invasion analysis, the cells’ ability to invade and cross a matrigel-
coated porous membrane was assessed. xCELLigence® CIM-16 plates were used and analysed using the 
RTCA DP Instrument (both ACEA Bio). The upper chambers were filled with 20μL media lacking FBS/growth 
factors and the lower chamber with complete media to act as chemoattractant. The lower chambers were 
slightly overfilled with 160μL media to produce a meniscus and ensure contact with the upper chamber. 
The upper and lower parts were fitted together and were left in the incubator for 1 hour for a growth factor 
gradient to form, and a background reading was taken on the instrument. Next, 100μL of cell solution 
(adjusted to contain 20,000 cells) was added to the upper chamber and cells were left to seed for 30 mins 
at room temperature (in the hood) before adding to the instrument and monitoring growth. For invasion 
analysis, matrigel (growth-factor reduced, Corning) was thawed overnight in a small ice bucket in the fridge, 
and diluted at 1.2mg/mL, 0.6mg/mL, and 0.3mg/mL, in media lacking growth factors or FBS. The porous 
membranes of the upper chamber was coated in Matrigel (20μL of Matrigel was used per well, 50μL was 
initially added to cover base, and 30μL removed by pipette) and allowed to polymerise in a 37°C incubator 
for 4 hours without touching the underside side of the membranes. Then cells were seeded as for the 
migration assay.  
2. 1. IV. Gene expression analysis  
2. 1. IV. a). RNA extraction. RNA was extracted from cell lines, tumours and spheroids using Tripure® 
reagent (Life Technologies), using approximately 500μL Tripure® per 5x105 cells (500µL per well-of a 6-well 
plate, 1mL per small flask and 1.5mL per medium flask). The media was removed as much as possible and 
the dish was placed on ice, cold Tripure was added directly to the plate and swirled to cover the cells. The 
dish was then incubated at 4°C for 15 mins to lyse the cells. The Tripure was then transferred to a chilled 
Eppendorf after pipetting gently over the plate to collect all cells. It was kept on ice for the duration of the 
RNA extraction and mixed only by gentle inversion or pipetting, never vortexing. Tumour samples were 
homogenised by pipetting or very gentle mashing, using a very small amount of tissue (approximately 
2mm2 per 1mL Tripure). Chloroform (100μL per 1mL Tripure) was added, the solution was mixed by gently 
inverting the tubes for 15 seconds and left on ice for 5mins, before centrifugation at 13,200rpm for 10mins 
in a centrifuge pre-cooled to 4°C. The colourless upper fraction (aqueous) was transferred to a clean chilled 
1.5mL Eppendorf and ice-cold isopropanol was added (200μL per 1mL Tripure), the solution was mixed by 
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inverting the tube gently 5 times and incubated on ice for 10mins before centrifugation at 13,200rpm at 
4°C for 12mins to pellet the precipitated RNA. The supernatant was removed without touching the pellet. 
The pellet rinsed with 75% ethanol to reduce the salt content, by carefully adding 1mL and inverting the 
tube before removing as much as possible, a short centrifuge was sometimes needed to re-fix the pellet to 
the tube. As much as possible, any residual ethanol was removed by pipetting (without touching it) and air 
drying for less than 3mins at room temperature by lying the tube sideways on a clean bench. The RNA 
pellet was solubilised using high-grade nuclease-free water (NF-H2O), the water was dripped down the side 
of the Eppendorf onto the pellet and incubated on ice to dissolve the pellet (30-50µL water used depending 
on the size of the pellet). Serum miRNA was extracted using a column-based RNA isolation kit miRCURY™ 
RNA Isolation Kit - Biofluids according to the instructions (Exiqon), with the small RNA fraction isolated by 
two sequential elutions with NF-H2O at the final stage. All RNA was stored at -80°C. RNA integrity was 
always confirmed by agarose gel electrophoresis and examination of the ribosomal RNA fragments. 
2.1.IV.b. Quantification. A NanoDrop 1000 spectrophotometer (Thermo Scientific) was used to estimate 
nucleic acid concentration and purity, absorbance at 260nm indicated nucleic acid concentration. Pure 
preparation of RNA indicated by OD260:OD280 ratio of 2.00, absorbance at 230nm indicated organic 
compound contamination, absorbance at 280nm indicated protein contamination. Serum miRNA was not 
quantified by spectrophotometry; 50μL serum was used for the RNA extraction kit (and 5μL of the eluted 
water was used in for production of micro-cDNA in total volume of 10μL as described below. 
2.1.IV.c. cDNA and micro cDNA production. First strand Complementary DNA (cDNA) synthesis was 
performed by 2-step reverse transcription kit (Roche) using 1μg total RNA, first annealing oligo dTs to the 
polyA tails of mRNAs with a 5 min 65°C step. Next, a mastermix containing the DNA polymerase, dNTPs and 
buffer was added and a PCR cycle was completed according to the manufacturer’s instructions. 
Complementary DNA to miRNAs (micro-cDNA) was amplified using 50ng total RNA, with the miRCURY 
LNATM microRNA 1-step PCR system of buffer and reverse transcriptase (Exiqon). Serum RNA was not 
quantified, 5μL RNA was used for the micro-cDNA synthesis and the final micro-cDNA diluted 1:10 with NF-
H2O for RT-qPCR. 
2.1.IV.d. Primer design. Primers specific to regions flanking genes of interest were designed using NCBI 
Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) using the accession code provided by a 
search for the gene of interest using PubMed Gene database and selecting human mRNA. Alternatively 
primers were designed using Primer3Plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) based on the UCSC hg.38 mRNA sequence and purchased from 
Invitrogen (primer sequences in Table 2).  
2.1.IV.e. Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Gene expression was 
quantified by real-time quantitative PCR (RT–qPCR) using a SYBR™ Green fluorometric-based detection 
68 
 
system (Roche). cDNA was diluted 1:5 with NF-H2O with 4μL used in each reaction. Primers were re-
suspended in NF-H2O to produce a 100µM stock and further diluted to produce 20µM working solutions, 
and used at a final concentration of 0.2µM. A master mix for each gene of interest was prepared containing 
200nM forward and reverse primers, 5μL SYBR green reagent 2X (Roche) and 0.75μL NF-H2O. 6μL master 
mix was added to each well of a 96-well qPCR plate. Each reaction was prepared in triplicate. Genes of 
interest were normalised to the expression of a reference “housekeeping” gene (hypoxanthine 
phosphoribosyltransferase 1 (HPRT) or actin-β). qPCR was performed on a LC480 Lightcycler (Roche). Wells 
containing only master mix and water for each primer set (no cDNA) were used to confirm the absence of 
contamination.  
2.1.IV.f. miRNA-qPCR. 5ng micro-cDNA was used per reaction, with the small non-coding nucleolar genes 
SNORD48 or U6 as a housekeeping gene for human tissue samples or miR-191 for serum samples. Micro 
cDNA was diluted 1:50 and 4μL used per reaction. miRCURY LNA SYBR® Green PCR Kits were used with 5μL 
SYBR reagent, 0.5μL primer (both Exiqon), and 0.5μL NF-H2O. Primers were purchased from Exiqon 
(sequences patented).  
2.1.IV.g. qPCR analysis. A melting point dissociation curve (Tm curve) was automatically calculated by the 
Lightcycler after every assay, and was examined to confirm the presence of a single PCR product (a single 
peak), indicating primer specificity to the region of interest and absence of contaminating DNA (evident as 
multiple peaks spaced apart far enough so as not to indicate a splice variant), and the lack of primer-dimer 
formation (evident as a second peak at half the temperature and height). Relative expression of the genes 
of interest were calculated, normalised to the expression level of the endogenous reference gene and 
relative to the expression level of the same gene in the control sample. The “Cycle Threshold” (CT) value 
stands for the fractional PCR cycle, at which the quantity of the amplified PCR product reaches a 
predetermined threshold. Relative expression was calculated using the comparative CT equation: 
ΔCT = CT(gene of interest) − CT(reference gene) 
ΔΔCT = ΔCT(test condition) − ΔCT(control condition) 
2−ΔΔCT  = expression level of the gene of interest   
 
The qPCR graphs present the combined results from three independent biological replicates (different 
culture day), with 3 technical replicates on each plate (additions of cDNA and master mix). Primers were 
confirmed to be efficient by amplification of decreasing concentrations of cDNA in triplicate (at least 5 10-
fold dilutions) and by plotting the log dilution factor against the mean CT obtained, calculating the slope 
and the percentage efficiency as: E=(10^(-1/The Slope Value)-1)*100.  
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2. 1. V. Epigenetics – DNA methylation quantification 
2. 1. V. a). DNA extraction and bisufite conversion. Pelleted cells were lysed in 500μL lysis buffer ( 50mM 
Tris pH8, 0.1M EDTA, 0.5% SDS) and proteinase K (0.2mg/mL) and incubated at 55OC for 24h with rotation. 
500μL of a phenol chloroform buffer (phenyl: chloroform: isoamyl, ratio 25:24:1) was added, the solution 
was vortexed and centrifuged at 13200rpm for 10mins at room temperature. The aqueous layer was 
collected and the phenol chloroform separation was repeated twice more. 1mL DNA precipitation solution 
(1M ammonium acetate in 90% ethanol) and 2μL carrier glycogen were added and left to precipitate 
overnight at -20 Oc. Samples were centrifuged at 13200rpm for 10mins, the pellet was washed with 80% 
ethanol (residual ethanol was evaporated off the pellet at 65Oc) and re-suspended in 100μL NF-H2O. 500ng 
DNA was used in the bisulfite conversion reaction using the Epitect Bisulfite Kit (QIAGEN), including DNA 
clean up, according to manufacturer’s instructions and eluted in 40μL NF-H2O.   
2. 1. V. b). PCR and Pyrosequencing. The PCR reaction has the dual purpose of amplifying the region of 
interest for sequencing, and converting unmethylated cytosines to thymine (since the DNA polymerase 
base-pairs uracil with adenine and subsequently thymine). Since the key to a successful pyrosequencing 
reaction is an ample PCR product, the PCR reaction involves a high performance DNA polymerase and an 
increased number of cycles (45 rather than the standard 30) to amplify as much as possible. Therefore, 
DNA contamination is a prominent risk and all PCR reactions included negative controls containing all 
reagents except input DNA. Gel electrophoresis was used to confirm the PCR amplicons expected sizes and 
the absence of a product in the negative controls. The PCR product was then extracted by sepharose beads 
(via a biotin tag on one of the PCR primers) and sequenced, in a sequencing-by-synthesis method that 
involves light emission due to a chain reaction in which pyrophosphate is released (hence the name 
“pyrosequencing”). The output is a type of electropherogram called a “pyrogram” that includes the 
percentage methylation at each methylated CpG. This refers to the percentage of sequenced fragments 
with T instead of C and thus approximates the frequency of its methylated state (Delaney, Garg and Yung, 
2015).  
The region of interest was amplified by Pyro PCR kit (PyroMark, QIAGEN) using 2μL bisulfite converted DNA, 
12.5μL master mix, 2.5μL coral, 1.5μL of each primer (at 10μM) and 5.5μL NF-H2O. 5-10μL PCR product was 
used in the pyrosequencing reaction. A master mix was prepared allowing for each reaction: 2μL 
streptavidin sepharose beads and 40μL binding buffer (PyroMark, QIAGEN) adjusted to 23μL reaction total 
with NF-H2O. The PCR products were annealed to the beads by their biotin tag by shaking at 1400rpm for 
10 mins. The beads were bound to suction and filter based probes on the pyrosequencing apparatus tool 
and rinsed in 70% ethanol (5 secs), denaturation buffer (0.2M NaOH, 5 secs) and 1X wash buffer (10X 
QIAGEN, 10 secs) and released onto wells of a PyroMark Q24 plate (QIAGEN) containing 0.3μM sequencing 
primer in 25μL annealing buffer. The plate was heated to 80Oc for 2mins on a heatblock and cooled at room 
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temperature for 5 mins. Samples were run on a PyroMark Q24 Pyrosequencer (Qiagen) using assays specific 
to the region (designed on PyroMark software v2.0.6).  
2. 1. V. c). Primer design. The genomic sequence was obtained from UCSC Hg.38 and its bisulfite-converted 
form was generated by MethPrimer (assuming all cytosines converted to uracil). The PCR and sequencing 
primers and pyrosequencing assay were designed with PyroMark Q24 software (QIAGEN). Primers were 
obtained from Metabion, one of the PCR primers was biotinylated and HPLC grade, and the primer for 
sequencing binds complementary to the biotinylated strand.  
 
Table 2. Primer sequences for mRNAs and genes analysed.  
Gene name Forward sequence Reverse sequence Amplicon length 
Actin ACAGAGCCTCGCCTTTGCC GATATCATCATCCATGGTGAGCTGG 70 
HPRT CCTGGCGTCGTGATTAGTGA CGAGCAAGACGTTCAGTCCT 137 
PTEN ACCCACCACAGCTAGAACTT GGGAATAGTTACTCCCTTTTTGTC 221 
POUF5 GTCATGCTGGATGTCAGGGC AGCTTGCTTTGAGGGTCCCA 262 





























Spry2 GAGTGTTCATCAGCGGGGAA CACATCTGAACTCCGTGATCG 198 




2. 1. V. Protein analysis 
2. 1. V. a). Protein extraction. Protein was extracted using 40-100μL of urea-containing lysis buffer (8M 
urea, pH 7.5 with 1% β-mercaptoethanol (Sigma) and Complete Mini® protease inhibitor (Roche)), 
depending on the size of the cell pellet. The solution was gently and briefly vortexed and incubated at room 
temperature for 30mins. After this point, proteins were always kept on ice. The solution was centrifuged 
at 13200rpm for 8min at 4°C to pellet debris, which if large may be further broken down by additional lysis 
buffer to release transmembrane proteins. The supernatant was transferred to a clean tube and stored at 
-80°C. Protein samples were aliquoted if repeated use was required to avoid repeated freeze/thaw cycles. 
2. 1. V. b). Protein quantification. A standard curve was produced using bovine serum albumin (BSA) with 
distilled water. Bradford assay was used for quantification (DC™ Protein Assay, Bio-Rad Life Science 
Research). In an Eppendorf, 2μL of the protein lysate was mixed with 8μL water, and 50μL solution A’ was 
added (1μL reagent S + 50μL reagent A) and then 400μL solution B. The tube was vortexed lightly and 
incubated at room temperature in the dark for 10mins. 150µL was added to clear 96-well plates in triplicate 
and the absorbance was read on a FLUOstar Omega Spectrophotometer (BMG LabTech) at 650nm.  
2. 1. V. c). Sample preparation and migration. Westerns were performed using the Invitrogen NuPage® 
Novex® Gel System and reagents. For each sample, 20-80μg protein was mixed with 3.5μL SDS-containing 
sample buffer and 2.5μL reducing agent, with distilled water to a total volume of 20-25μL, and kept on ice. 
8-12% NuPAGE precast gels were used with 1X Running buffer. Samples were heated to 70°C for 15 mins 
to denature proteins for accurate sizing. The samples were pipetted into the wells while still hot, run at 
100V for 5 mins or until the protein cleared the stacking gel and then 120V for 90mins. Prestained protein 
ladder (Invitrogen) was used as size marker.  
2. 1. V. d). Transfer, antibody binding, and detection. The gels were removed from the casing and 
sandwiched against a 0.2μm or 0.45μm pore PVDF membrane, with 2 sheets of filter paper and a sponge 
on either side. The sandwich was positioned with the membrane between the gel and the anode, in the 
transfer tank with 1X transfer buffer (NuPage®, Invitrogen) with 10% methanol (increased to 20% if 
transferring 2 gels) and an ice block at 30V for 2 hours. After transfer, the membrane was stained with 
Ponceau solution (Sigma) and distilled water to confirm equal loading and then rinsed again in water for 
5mins to remove the Ponceau. The membrane was blocked in 5% milk solution (TBS (6.05 g Tris and 8.76 g 
NaCl adjusted to 7.6 with 1 M HCl) with 1% Tween-20 (TBST) and 5% milk powder) for 1 hour at room 
temperature with gentle rocking. The primary antibody (also in TBST with 5% milk) was incubated with the 
membrane overnight at 4Oc with gentle rocking. The membrane was rinsed three times for 5 mins in TBST 
and then the membrane was incubated with the secondary antibody for 1 hour at room temperature with 
gentle rocking and rinsed again as before. Chemiluminescent detection (Thermo Scientific) was performed 
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by adding equal parts of reagents A and B to the membrane and incubating in the dark for 1 min before 
exposure on a high resolution G-BOX imager for fluorescence and chemiluminescence (Syngene).  
 
 
Table 3. Primary antibodies used for Western blot analysis with supplier and dilution.  
 
Protein name Supplier and identifier Dilution factor Animal 
A-actin Sigma ABT1487 1 : 10,000 Mouse 
GAPDH Santa Cruz Biosciences, sc-
47724 
1 : 200 Mouse 
HIF-1α Sigma 1 : 500 Rabbit 
NCAM Santa Cruz Biosciences, sc-
7326 
1 : 200 Mouse 
RhoB Santa Cruz Biosciences, sc-
8048 
1 : 200 Mouse 
Spry2 Santa Cruz Biosciences, sc-
100862 
1 : 200 Mouse 
TGFβRIII Santa Cruz Biosciences, sc-
74511 
1 : 200 Mouse 
FKHR (FOXO1) Santa Cruz Biosciences, sc-
374427 












2. 2. In vivo experiments 
In vivo experiments were conducted as established by previous research in the group (Nesbitt et al., 2016, 
2017). 
2. 2. I. Animal maintenance. Experiments were performed in accordance with the Animal (Scientific 
Procedures) Act 1986 and the UKCCCR guidelines for the welfare of animals in experimental Neoplasia 
(Workman et al., 1988). Male nude mice weighing 25-30g (Envigo, Cambridgeshire, UK) were housed under 
standard laboratory conditions in a temperature controlled (22OC; 50-55% humidity) specific pathogen-
free environment with a 12-hour light/dark cycle. Food and water were supplied ad libitum. Procedures 
were performed under aseptic conditions. The work was approved by the ethical review committee of 
Ulster University and covered by establishment licence and project licence.  
2. 2. II. Animal care. Mice were sacrificed if the tumour reached (1,500mm3), the mouse lost >20% of its 
body weight within one week or showed other signs of pain or suffering, otherwise 28 days after treatment 
had commenced.  
2. 2. III. Xenograft establishment. LNCaP-luc xenografts were established on 24 nude mice at 8-10 weeks 
old. Mice were briefly anaesthetised by inhalation of isofluorane, and the cells were implanted. 100μl of 
ice-cold matrigel containing 5 x 106 LNCaP cells was slowly injected under the skin of the dorsum with an 
ice-cold 21 gauge needle (Becton Dickinson, Oxford, UK) and allowed to harden as a lump. After 
approximately 1 week the matrigel had been degraded and after approximately 2 weeks small tumours 
became palpable, and dimensions were then measured using Vernier calipers, using the formula (height x 
height x width)/2.  
2. 2. IV. Drug administration. When tumour volume reached between 150mm3, mice were randomly 
assigned to treatment groups and dosing initiated. Bicalutamide (Sigma) was solubilised in DMSO and 
diluted in corn oil (Sigma) to be administered orally via gavage at 6mg/kg as a daily dose. Mice receiving 
no treatment were given the vehicle alone (0.1% DMSO in corn oil).  
2. 2. V. Oxygen electrode measurement. Mice were anaesthetised (1 hypnorm : 1 hypnovel : 2 sterile 
PBS) via intraperitoneal injection. A fibre optic probe (OxyLite®) was inserted into the tumour through a 
21-gauge needle. 30 readings were taken at two sites, allowing the probe to adjust (readings becoming 
consistent) before readings were recorded. The median reading of each site was used, then the mean of 




2. 3. Patient samples 
2. 3. I. Ex vivo prostate biopsy cohort. A previous collaboration was established with Altnagelvin 
hospital, Derry and a cohort of 25 prostatectomy samples had been obtained as previously published 
(Lynch et al., 2016). The study design was a paired comparison of tumour with non-tumour tissue from the 
same patient. These were excised whole tumours following radical prostatectomy from men aged 41-66 
(Table 3). All tumours were localised at the time of surgery and between Gleason grades 6-8. The tumours 
were paraformaldehyde-fixed, paraffin embedded (FFPE) and sectioned by a pathologist who confirmed 
that tumour sections were >60% tumour cells. Use of patient material and information was approved by 
ORECNNI (ref 10/NIR0213). Paraffin was removed by two stages of immersion in xylene and heating (65OC, 
3 mins), two rinsing stages using 500µL 100% ethanol and centrifugation (13,200rpm, 2mins), air drying 
(ambient, 15mins). RNA was extracted by RecoverAll Total Nucleic Acid Isolation Kit (Ambion) according to 
manufacturer’s instructions.  
Table 3. Anonymised patient and tumour characteristics for the 22 prostatectomy samples. TNM: Tumour Node 
Metastasis. PIN: Prostatic Intraepithelial Neoplasia. 













1 65 10 3 + 3 = 6 pT2 Yes Yes No Yes 
2 57 4.5 3 + 3 = 6 pT2 Yes No No No 
3 66 9.2 3 + 3 = 6 pT2 Uncertain No No No 
4 61 7 4 +  3 = 7 pT2 Yes Yes No No 
5 52 Not Stated 3 + 3 = 6 pT2 Yes Yes No Yes 
6 60 7.34 3 + 4 = 7 pT2 Yes No No No 
7 62 10.9 3 + 4 = 7 pT2 Yes No No Yes 
8 50 13 3 + 5 = 8 pT3 Yes No No Yes 
9 67 5.7 4 + 4 = 8 pT2 Yes No No No 
10 60 Not Stated 3 + 3 = 6 pT2 No No No No 
11 53 8 2 + 3 = 5 pT2 Yes Yes No No 
12 57 6.4 3 + 3 = 6 pT2 Yes No Yes Yes 
13 41 3.9 3 + 3 = 6 pT2 Yes Yes Yes No 
14 64 9.2 3 + 3 = 6 pT2 Yes Yes Yes Yes 
15 62 8.3 3 + 3 = 6 pT2+ Yes Yes Yes Yes 
16 58 10 3 + 4 = 7 pT2 Yes Yes No No 
17 47 8 3 + 3 = 6 pT2 Yes Yes Yes Yes 
18 65 6 3 + 3 = 6 pT2 No No No No 
19 59 5.7 3 + 5 = 8 pT3a Yes Yes No No 
20 62 17.7 3 + 5 = 8 pT2 Yes Yes No No 
21 58 4.5 3 + 3 = 6 pT2 Yes No No No 
22 62 7.2 3 + 3 = 6 pT2 Uncertain Yes Yes Yes 
23 60 Not stated 3 + 4 = 7 pT2 Yes No No No 
24 65 6 3 + 3 = 6 pT2 No No No No 
25 51 8 2 + 3 = 5 pT2 Yes Yes No No 
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2. 4. Statistical Analysis and Bioinformatics   
2. 4. I. Statistical analyses. Graphs and statistics were generated Graphpad PRISM v5. Data normality 
was assessed by Shapiro-Wilk test. Group means were compared to the baseline value (100) by one-way t-
test (or non-parametric Mann Whitney test) and multiple groups’ means were compared by two-way t-test 
or in the case of three or more groups by ANOVA when at least five replicates were used (or non-parametric 
Kruskal Wallis test). For multiple hypothesis correction, the adjusted p-value was calculated (Q value / False 
Discovery Rate (FDR)) which is defined as the minimum FDR at which the test can be called significant 
(Benjamini and Hochberg 1995). The mean + SEM is shown. P-values considered significant when *p<0.05, 
**p<0.01, ***p<0.001. When differences were non-significant, no asterisks are shown.  
2. 4. II. Databases. To identify mRNA targets of the miRNAs, databases miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw)  (Chou et al., 2016), miRWalk 2.0 (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/index.html)  (Dweep and Gretz, 2015) were searched to find 
consistently predicted targets. MEDLINE/PubMed was searched using search strategies containing (miRNA) 
or (gene of interest) AND (prostate cancer) OR (hypoxia) to identify relevant literature 
(https://www.ncbi.nlm.nih.gov/pubmed/).   
Analysis of The Cancer Genome Atlas (TCGA) repository data was performed using the Regulome Explorer 
(http://explorer.cancerregulome.org/) and Firebrowse (http://firebrowse.org/) analysis tools. Regulome 
Explorer analysis was based on a single primary prostate cancer dataset (TCGA Research Network, 2015). 
Firebrowse analysis was based on larger cohort of prostate adenocarcinoma (PRAD) samples (Broad 
Institute TCGA Centre, 2016). To identify significant correlation between miRNA expression and predicted 
target expression, the All Pairs Statistical Associations function was used. All Pairs parameters as follows: 
Feature 1: micro RNA expression, Label: [miRNA of interest] with Feature 2: All Gene Expression, using the 
parameters p value (-log10) ≥ 2, Correlation Abs ≤ 0, # of samples ≥ 0, Max Results = 2000, Filter by = 
Association. Significant correlations between the miRNA, or target at Gene Expression/ Protein level, with 
a Clinical Feature were identified using the same parameters. CSV data was downloaded. To identify 
significant correlations between clinical features with miRNA expression, the supplementary table 1 of all 
results was screened. To access boxplots of miRNA expression levels in features of prostate cancer, the file 
‘Analysis Results (MD5 checksum)’ was downloaded and the graphs screened for the miRNAs of interest.  
Survival analysis was performed using KM Express (http://ec2-52-201-246-161.compute-
1.amazonaws.com/kmexpress/index.php) (Chen et al, 2018),  Human Protein Atlas 
(https://www.proteinatlas.org/) (Uhlen et al, 2015), and Kaplan Meier Plotter (KM Plotter) 
(http://kmplot.com/analysis/) (Nagy et al., 2018) analysis tools. 
76 
 
2. 4. III. RnBeads workflow for analysis of methylation array data.  RnBeads package version 0.99.19 
was used for exploratory and differential analysis, according to the 2015 vignette (http://rnbeads.mpi-
inf.mpg.de/data/RnBeads.pdf)(Müller, Assenov and Lutsik, 2015). Ghostscript v9.27 for Windows (32 bit) 
(Artifex Software) was installed from (http://ghostscript.com/download/gsdnld.html).  
2. 4. IV. RNA-seq analysis for the prostatectomy cohort. Needle core biopsies were sent to BioSpyder 
Technologies (Carlsbad, CA) who performed the following procedures for RNA extraction and sequencing 
by miRNAseq and mRNAseq. RNA extraction. 1mm3 of tissue per sample was added to 50µL of 1x lysis 
buffer, for eventual (ideal) concentration of 0.02 mm3 per µL. 20µL of mineral oil was overlaid over the 
mixture, and the tube was heated to 95°C for ten seconds to remove the paraffin, and the process was 
repeated with 20 µL of fresh oil to completely remove paraffin. 5µL of proteinase K solution (100µg) was 
added to each sample. Samples were incubated at 37°C for 30 minutes, and the proteinase was inactivated 
at 95°C for 15 minutes. Hybridisation. The binding mix for hybridization was as follows: 0.4 µL 5X Annealing 
Buffer, 0.6 µL water, 1 µL DOs (human surrogate 1.0), 2 µL digested sample. The temperature settings were: 
80°C for 10 seconds, cooled down until 70°C at 0.1°C per second. The samples were left at 70°C for 10 min, 
and decreased by.5°C per 1 min until a final temperature of 45°C and then left at final temperature 
overnight. Exonuclease reaction. Per reaction the following was added: 2.4μL 10x Exo Buffer, 0.25µL 
Exonuclease I (at 200U/µL), 21.4µL water, then incubated for 1.5 hours at 37°C. Ligation Mix. Per reaction 
the following was added 2.4µL 10X Ligation Buffer, 1 µL5 U/µL T4 DNA Ligase, 20.6µL Water, Incubate at 
37°C for 1 hour. The exonuclease was inactivated by incubating at 80°C for 30 minutes. Amplification Mix. 
10µL of the ligation product was added to 10µL PCR mix for a total of 20µL final,  Per reaction: 1µL 20 µM 
forward primer, 1µL 20 µM reverse primer, 8µL BioSpyder PCR pre-mix. 10µL sample was added and the 
cycles were as follows: 37°C, 2 min, 95°C, 2 min, 6 cycles of 95°C, 30sec; 54°C 30sec; 72°C 120 sec, 21 cycles 
of 95°C, 30sec; 72°C 120 sec, 72°C 60 sec, before cooling to 40°C. Analysis. Differential expression analysis 
was calculated using the DESeq2 method and verified by MA plot. Volcano plots were made using R version 
3.4.4 and RStudio (RStudio, Inc., Boston, 2015) (for code see Appendix 1). Log2foldchange <0 was 
considered downregulated, >0 upregulated, and statistically significantly when the adjusted p value <0.1. 
2. 4. V. Network and Pathway Analysis. Functional enrichment analysis and gene set analysis were 
performed using KEGG and DAVID Bioinformatics Resources 6.8 (Huang et al, 2009a; 2009b) 
(https://david.ncifcrf.gov/) . Pathway analysis was performed by DAVID Bioinformatics Resources 6.8 and 
QIAGEN Bioinformatics Ingenuity Pathway Analysis (IPA) software 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/). For IPA core analyses 
the Ingenuity knowledge base (genes only) was accessed, including all node types, and all data sources. 
The confidence level accepted was: experimentally observed or predicted with high confidence. Species: 
all mammals (human, rat, mouse). All tissues and cell lines. All Mutations. Log2FoldChange cutoffs 
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(<0=downreg, >0=upreg), p value <0.05, adj p value <0.1. For miRNAseq data these parameter allowed 12 
analysis ready molecules (10 up, 2 down). For pathway analysis of differentially methylated sites, the 
cutoffs were <-0.1 and >0.1, p value <0.05, and adj p value <0.1. 
2. 4. VI. RNA-sequencing of AR variant expressing LNCaP. Log2(fold change) results were the mean 
ratio of three biological replicates. Library preparation and high-throughput sequencing had been 
performed on the Illumina Hiseq 4000 as Single-Read 50 base reads, by the GenomEast genomic platform 
(IGBMC, Illkirch, France). Reads were mapped onto hg38 assembly of human genome using Tophat v2.0.14 
(Kim et al., 2013) and bowtie2 v2.1.0 aligner (Langmead and Salzberg, 2012). Quantification of gene 
expression was performed using HTSeq v0.6.1 (Anders, Pyl and Huber, 2015) and gene annotations from 
Ensembl release 84. Read counts were normalized across libraries with the method proposed by Anders 
and Huber (Anders and Huber, 2010) and then normalized according to the gene length. Comparisons of 
interest were performed using the method proposed by Love et al (Love, Huber and Anders, 2014) 
implemented in the DESeq2 Bioconductor library (DESeq2 1.6.3) in order to obtain log2(fold change) and 
corresponding p-values. P-values were adjusted for multiple testing using Benjamini and Hochberg method 
(BENJAMINI et al., 1995) (p-value / number of hypotheses). Genes were considered significantly 
differentially expressed when the FDR adjusted p-value <0.05 and log2(Fold Change) >1 or <-1.  
2. 4. VII. Python for data analysis. Data analysis and graphs for the ARV collaboration were written in 
python (Oliphant, 2007) using the Jupyter Notebook 5.4.0 from the Anaconda Navigator, using the panda, 
numpy, matplotlib and bokeh packages. Results with adjusted p-value <0.05 were considered significant.  
2. 4. VIII. Analysis of ChIP-seq data. Two chip-seq datasets were analysed via the Cistrome Data Base 
webpage (http://cistrome.org/db/#/), by searching for datsets in LNCaP using an AR antibody. The 
Cistrome Database datasets used were numbers 44330 (Ramos-Montoya et al., 2014) and 71170 (McNair 
et al., 2017). Datasets were visualised in UCSC (https://genome.ucsc.edu) using human Hg.19 with the track 
‘GH Reg Elems (DE), Enhancers and promoters from GeneHancer (Double Elite)’ on pack visibility. No ChIP-
seq datasets including AR variant analyses were available on Cistrome DB, therefore a study was chosen 
that had used ChIP-seq to compare AR-WT with AR variants (He et al., 2018). Files were downloaded from 
NCBI Gene Expression Omnibus (GEO) at accession number GSE80743. In this study, 22RV1 cells had been 
transfected with non-target siRNA (designated as ARFL+/ARVs+), siRNA targeting ARV1/3/4/7 (designated 
as ARFL+/ARVs-), or siRNA targeting AR exon7 (designated as ARFL-/ARVs+) therefore 
GSM2734940_AR_siARV_rep1.bw was assumed to represent AR-FL binding and 
GSM2734942_AR_siARFL_rep1.bw to represent AR-V7 binding. The files were visualised using Integrative 
Genome Viewer (https://igv.org/app/) with the RefSeq genes track, gene regions were searched by 
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3. 1. Introduction 
One miRNA that has been consistently implicated in the hypoxic response is hsa-miR-210-3p (miR-210). 
MiR-210 expression is consistently associated with hypoxia in many tissues under both physiological and 
pathological conditions (Bavelloni et al., 2017). Perhaps best characterised is its role in maintaining cellular 
integrity following hypoxia in the cardiovascular system; diseases such as acute myocardial infarction, heart 
failure, atherosclerosis, and aortic stenosis are accompanied by acute ischaemia and are associated with 
overexpression of miR-210. Here, miR-210 may exert a protective effect on the cells by promoting survival 
and angiogenesis, and inhibiting apoptosis via the regulation of proapoptotic proteins E2F3, PDK1, and 
BNIP3 (Guan et al., 2019). Furthermore, miR-210 was secreted by the exosomes of stem cells and exerted 
protective effects on cardiomyocytes and attenuated fibrosis (Moghaddam et al., 2019). It was also 
reported to be a marker of pre-eclampsia, a disorder of the placenta that occurs during pregnancy due to 
poor trophoblast invasion and results in hypoxia, oxidative stress and inflammation (Gan et al., 2017). 
These studies suggest that the expression of miR-210 has protective effects that buffer against the effects 
of acute hypoxia, and that it may have diagnostic value as a marker of hypoxia in different tissues. As well 
as promoting cell survival, miR-210 plays a key role in regulating mitochondrial metabolism. MiR-210 has a 
HIF-binding site in its promoter region and is a direct transcriptional target of HIF, making it one of the 
earliest responders to hypoxia (Bavelloni et al., 2017). Early experiments using pulmonary arterial 
endothelial cells showed that miR-210 targets iron-sulfur cluster assembly proteins (ISCU1/2) and inhibits 
the activity of prototypical iron-sulfur proteins such as acontiase Complex I. More metabolic targets have 
since been identified including GPD1L, SDHD, COX10, and NDUFA4 and sequencing experiments have 
linked miR-210 overexpression to mitochondrial dysfunction (Qin, Furong and Baosheng, 2014). These 
studies highlight the influence of miR-210 over the balance between glycolysis and oxidative 
phosphorylation.  
However, since miR-210 has cytoprotective and metabolic regulatory effects, prolonged expression could 
facilitate carcinogenesis or facilitate tumour progression. Indeed, miR-210 is commonly overexpressed in 
cancers, including breast, pancreatic, head and neck, renal, lung, oesophageal and ovarian cancers, 
although occasionally it is downregulated or deleted (Qin, Furong and Baosheng, 2014). In colorectal cancer 
(CRC), miR-210 expression correlates with advanced clinical stage, tumour size, lymph node metastasis, 
resistance to radiotherapy, and poor outcome (Bavelloni et al., 2017). Furthermore, miR-210 containing 
exosomes from CRC cell line HCT-8 were mediators of cross talk between primary tumour cells and 
disseminated metastatic cells (Yang et al>, 2017). Similarly in gastric cancer, miR-210 may promote 
migration, invasion, and chemo-resistance (Yang et al>, 2017). In breast cancer, miR-210 was induced by 
hypoxia and was associated with increased cell proliferation, epithelial-mesenchymal-transition (EMT), 
migration and invasion, and self-renewal (Tang et al., 2018) and has been used as a prognostic factor 
(Camps et al., 2008; Madhavan et al., 2012; Li et al., 2013). In non-small cell lung cancer (NSCLC), it was a 
82 
 
diagnostic factor (Jiang et al., 2018) and was further overexpressed in the late stages (Puisségur et al., 
2011). Furthermore, miR-210 was upregulated in both the tumour and urine of patients with clear cell renal 
carcinoma (Petrozza et al>, 2017). In neuroblastoma cells, miR-210 targeted BCL2 meaning that it could 
regulate both apoptosis and autophagy (Chio et al., 2013). Therefore, miR-210 likely plays a key role in the 
hypoxic response in many tissues and was overexpressed in many cancers, which could indicate either 
hypoxia or oncogenic effects. For example, it may confer a survival advantage by regulating proliferation 
and motility, and by inhibiting oxidative phosphorylation and contributing to a glycolytic phenotype.  
However, although prostate tumours are particularly hypoxic, relatively few studies have investigated miR-
210 in PCa. Numerous studies have demonstrated that the overexpression of miR-210 in primary tumours 
correlated with lymphogenic metastatic and bone metastatic PCa (Eminaga et al>, 2018)(Dai et al., 
2017)(Ren et al., 2017). Likewise, the sera from patients with PCa contained higher levels of miR-210 (Qu 
and Huang, 2018)(Cheng et al>, 2013). However, these studies did not confirm the hypoxic status of these 
tissues, meaning that it is unclear whether miR-210 was acting as a result of hypoxia in vivo. In vitro work 
has shown that miR-210 targets key players in the NF-κB (Ren et al., 2017) and TGF-β (Dai et al., 2017) 
signalling pathways in PCa, while others have suggested miR-210 expression in stromal fibroblasts can 
contribute to prostate tumour progression through promotion of EMT (Taddei et al., 2014)(Andersen et 
al., 2016)(Taddei et al., 2014). However, the link between hypoxia and miR-210 in PCa has not been 
confirmed in vitro or in vivo. The hypothesis of this chapter was that miR-210 would be induced by hypoxia 


















3. 2. Results 
3. 2. I. Hypoxia upregulates miR-210 in prostate cancer cells. 
To explore the regulation of miR-210 by hypoxia, three models of PCa hypoxia were designed. The first 
model involved culturing LNCaP prostate cancer cells in hypoxic (0.1% O2) conditions using a hypoxic 
chamber and measuring miR-210 expression by RT-qPCR relative to the normoxic condition (Methods 
section 2.1.I.b. and 2.1.IV). Hypoxia resulted in significant miR-210 upregulation compared to 20% O2 by 
24h (Figure 1A). The induction of hypoxia in these cells was confirmed by upregulation of hypoxic marker 
genes PTEN and POU5F1 (Figure 1B) and HIF-1α protein (Figure 1C). MiR-210 was further increased by 48h, 
although a reduction in cell viability was observed after 72h at 0.1% oxygen, indicated by abnormal cell 
morphology and trypan blue staining, and therefore 24h was considered the optimal duration for hypoxic 
experiments. The induction of miR-210 in response to 24h hypoxic culture was also noted in 22Rv1 and 
PC3 prostate cancer cells, as well as non-transformed RWPE-1 epithelial prostate cells (Supplementary 
Figure 1).  
As a second model of PCa hypoxia, LNCaP cells were cultured as spheroids by double-coating the base of 
the culture dish in poly(2-hydroxyethyl methacrylate) to prevent seeding (Figure 1D-E)(Methods section 
2.1.I.d.). Cell spheroids are globular clusters of cells and the centres were predicted to become hypoxic 
once it reached a certain size. This was designed to produce a more representative model of tumour 
hypoxia since the proportion of cells that become hypoxic are lower and a gradient of diffused oxygen and 
hypoxic cells develops from the core to the surface. The spheroids became hypoxic at approximately 50µm 
(Figure 1F) which correlated with a significant upregulation in miR-210 expression (Figure 1G). LNCaP 
proved a perfect cell line model for establishing spheroids since they aggregate naturally in culture. 
Preliminary experimentation with LNCaP, 22Rv1, PC3 and RWPE-1 to generate suitable spheroid cultures 
was conducted. Of these, LNCaP spheroids proved the most reproducible and was used in subsequent 




Figure 1. Two in vitro models of hypoxia demonstrate miR-210 upregulation in LNCaP cells. A) RT-qPCR result 
showing increased mean expression of miR-210 in three biological replicates following culture at 0.1% 02 (hypoxia) for 
24h and 48h, relative to mean expression in paired flasks cultured at 20% 02 (normoxia). Mean + SEM of three biological 
replicates. B) Hypoxia successfully induced as indicated by RT-qPCR measurement of hypoxic response genes PTEN 
and POUF51 after 24h hypoxia relative to normoxia (mean + SEM of three biological replicates), and C) Western blot 
analysis of HIF-1α following hypoxic culture for 0-48h. Representative image of two biological replicates. D) Spheroid 
size increase between day 3 and day 16 as measured by light microscope, mean + SEM of 10 spheroids at each time 
point shown. E) Light microscope images of the spheroids at mean 10µm and 50µm in size. F) Western blot analysis 
showing HIF-1α stabilisation in spheroids at 50µm. Representative image of two biological replicates. G) RT-qPCR 
analysis of miR-210 expression in spheroids showing significant upregulation at 50µm. Mean + SEM of three biological 






3. 2. II. In an in vivo model of prostate cancer, bicalutamide increases hypoxia and miR-210 
Next, a murine LNCaP xenograft model was set up, which has previously been employed by the McKenna 
laboratory to study tumour hypoxia in response to bicalutamide treatment and is described in Methods 
section 2.2 (Nesbitt et al., 2016)(Byrne et al., 2016) (Figure 2A-C). Nude mice were chosen for the study, 
which have a mutation in the FOXN1 gene resulting in an impaired thymus gland and greatly reduced 
number of T cells, and are thus incapable of mounting a rejection response (Szadvari, Krizanova and Babula, 
2016). LNCaP cells were selected since they are AR-dependent and thus susceptible to AR inhibition. Briefly, 
ectopic implantation was performed, using 5X105 LNCaP cells solubilised in 100µL ice-cold matrigel, under 
the skin of the dorsum. Once under the skin, the matrigel warms and polymerises, and acts as a solid matrix 
that remains for approximately 1 week, during which time the cancer cells may proliferate and form a 
tumour. At least four animals were used for each group at each time point. Once the tumour reached 
150mm3, dosing was initiated; mice received either the AR-inhibitor bicalutamide or vehicle for 7 or 28 
days. Tumour size was measured every 3 days (Figure 2D), and tumour oxygenation measured at day 7, 
day 14, and day 28 (Figure 2B and 2E) as well as tail vein bleeds for serum extraction, before culling and 
tumour excision at day 7 or day 28 (Figure 2C).  
As expected, tumour growth was inhibited by bicalutamide treatment after 28 days, in comparison with 
vehicle treated tumours (Figure 2D). In accordance with previous research (Nesbitt et al., 2016)(Byrne et 
al., 2016), bicalutamide treatment induced tumour hypoxia after 7 days (Figure 2B), resulting in HIF-1α 
stabilisation (Figure 2E). In correlation, miR-210 expression was upregulated by day 7 and significantly so 
by day 28 (Figure 2C). There was also an induction of miR-210 expression in the sera of some bicalutamide-







Figure 2. In vivo model of hypoxia demonstrates miR-210 upregulation in LNCaP xenograft. A) Photograph of LNCaP 
xenograft tumour on the dorsum of nude mouse at 150mm3. B) Photograph of oxygen electrode measurement of 
partial oxygen tension (PO2, in mmHg). C) Photograph of an excised tumour at day 7. D) Tumour growth curves in 
bicalutamide and vehicle treated mice at days 0, 7, 14, 21, and 28 showing reduced tumour size in bicalutamide-
treated mice. Mean + SEM shown, data points represent measurements from at least four animals. E) Oxygen 
electrode readings showing significantly reduced PO2 in tumours of bicalutamide-treated mice relative to vehicle 
treated mice at day 7. F) RT-qPCR analysis showing increased expression of miR-210 in bicalutamide-treated tumours 
at day 7 and day 28. G) RT-qPCR analysis of serum samples showing non-significantly increased levels of miR-210 in 
the serum of bicalutamide treated mice. H) Representative western blot image demonstrating stabilisation of HIF-1α 
in bicalutamide-treated tumours at day 7 and day 28 compared with vehicle-treated mice. One-way t-tests were used 
to compare condition means to the control (hypothetical value 100), two-way t-tests were used to compare two 
means, and p-values considered significant when *p<0.05, **p<0.01, ***p<0.001. 
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3. 2. III. MicroRNA-210 is associated with markers of prostate cancer progression. 
Next, the clinical relevance of miR-210 expression was explored. A cohort of 19 prostatectomy samples 
were analysed, which had been acquired through a collaboration with Alnagelvin hospital in Derry, 
Northern Ireland. As described in Methods section 2.3. these were whole tumours that had been excised 
from patients during surgery, and sectioned. A previous member of the lab (Dr Seodhna M. Lynch) had 
organised the collaboration and extracted RNA from the sections, the RNA from a tumour section was 
normalised to non-tumour section from the same prostate. These samples were analysed and miR-210 was 
successfully quantified in 17 of the paired samples (Figure 3A). The tumours did not uniformly have 
upregulated miR-210, which was not unexpected as previous work in our laboratory had noted a similar 
variation in expression of miR-24, miR-200c, and miR-141 in a related set of samples (Lynch et al., 2016a; 
Lynch et al., 2016b). This variation could be indicative of the relative hypoxic status across the tumours, 
which in turn may provide useful diagnostic or prognostic information, although protein levels of HIF-1α 
would need to be confirmed and unfortunately the sections were too small to obtain a protein sample. 
Due to the small size of the cohort, the tumours were grouped based on their Gleason grade group rather 
than Gleason score and interestingly, there was a mild trend of increasing miR-210 expression across the 
groups (Figure 3B). However, it was clear that a larger clinical dataset was needed to gain statistically 
significant results.  
To explore a larger dataset, The Cancer Genome Atlas database was accessed. RNA-sequencing data from 
the Prostate Adenocarcinoma (PRAD) samples was downloaded, using the tools Regulome Explorer 
(http://explorer.cancerregulome.org/) and Firebrowse (http://firebrowse.org/). Regulome Explorer 
accesses a single primary prostate cancer dataset of 330 samples (hereafter referred to as Regulome 
Explorer dataset) ) (TCGA Research Network, 2015). Firebrowse accesses a larger cohort of prostate 
adenocarcinoma (PRAD) samples, which is continually updated and currently has over 400 samples 
(hereafter referred to as PRAD dataset)(Broad Institute TCGA Centre (2016). The data consists of 
sequenced localised prostate tumour samples normalised against non-tumour tissue from the same 
patient. Analysis of this data using the Firebrowse tool revealed that miR-210 levels were significantly 
increased in correlation with Gleason score, lymph node metastasis, but not with TNM stage or PSA level 
(Figure 3C-D). Furthermore, analysis of the same data using the KM-Express informatics tool 
(https://omictools.com/km-express-tool) revealed that PCa patients with high miR-210 expression had 
significantly shorter time of disease-free progression than those with low expression (Figure 3E).  
To further evidence that the increased expression of miR-210 is associated with hypoxia in clinical samples, 
expression of various hypoxia-related genes was examined using the Regulome Explorer tool. This showed 
that EZH2, another marker of prostate tumour hypoxia (Zhou et al., 2018), has a strong positive correlation 
with miR-210 expression in these samples (Figure 3F). Finally, KEGG analysis and Gene Ontology mapping 
of validated miR-210 targets demonstrated that miR-210 is significantly associated with both PCa and 
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hypoxia-related cell processes, through its various target genes (Tables 1A-B). This in silico analysis 
corroborated the laboratory results in demonstrating that miR-210 is likely to be a key mediator of the 












Figure 3. MiR-210 correlates with prostate cancer aggressiveness in human prostate tumour samples. A) Cohort of 
19 prostatectomy biopsies. RT-qPCR analysis shows miR-210 expression is can be both up-regulated and down-
regulated in tumour tissue, which may reflect the relative hypoxic nature of the specimen. B) Grouping the prostate 
samples by Gleason grade group (≥6, 3+4=7, 4+3=7, 8) indicates that the mean relative expression of miR-210 is 
increased in tumours of higher grade group. Groups contained at least 2 samples. C) Analysis of data downloaded from 
The Cancer Genome Atlas prostate adenocarcinoma (PRAD) cohort using the Firebrowse tool. Mean relative miR-210 
expression significantly correlated with tumours of higher Gleason score score (p=6.917E-08, adjusted p-value 
(Q)=1.35E-06) and with lymph node metastasis (p=0.0009338, adjusted p-value (Q)=0.0168), and correlated but not 
significantly with pathological T stage and PSA level. Analyses utilised Spearman’s rank correlation, with p-values 
adjusted for multiple hypothesis testing. A p-value of < 0.05 and Q-value < 0.3 was deemed significant. D) Boxplot 
illustrating significantly increased mean relative miR-210 expression in tumours of Gleason score ≥8 compared with 
Gleason score ≤7 from Regulome Explorer data. E) Survival analysis of PRAD data using KM Express tool reveals miR-
210 expression significantly increased in men with shorter progression-free survival (y-axis: miR-210 expression, x-
axis: time (months), hazard ratio, 0.52, p=0.0375). F) In the Regulome Explorer data, relative miR-210 expression 




Table 1. Analysis of the functions of predicted miR-210 target genes. A) KEGG pathway analysis shows highly 
significant association of miR-210 with cancer-related disease terms. B) Gene Ontology Mapping showing highly 
significant association of miR-210 with selected GO classifications related to hypoxia and oxidative stress. P-values 
generated by modified Fisher Exact test. Benjamini values represent corrected p-value for multiple hypothesis testing 
using the Benjamini-Hochberg method to minimise false discovery rate. 
A 
Disease Term Gene Count P-value Benjamini 
CANCER 38 0.0026 0.046 
tobacco use disorder 33 0.023 0.91 
breast cancer 11 0.0057 0.83 
ovarian cancer 9 0.0069 0.76 
prostate cancer 9 0.039 0.91 
lung cancer 9 0.041 0.9 
bladder Cancer 9 0.047 0.88 
 
B 




cellular response to oxygen levels  8 0.000092 0.047 
cellular response to oxidative stress  9 0.00022 0.048 
cellular response to hypoxia  7 0.00035 0.049 
cellular response to decreased oxygen levels  7 0.00047 0.054 
response to oxidative stress  11 0.00049 0.05 
response to oxygen levels  9 0.0018 0.11 
response to hypoxia  8 0.0043 0.17 
response to decreased oxygen levels  8 0.0051 0.19 
regulation of oxidative stress-induced cell death  4 0.0063 0.21 
 
3. 2. IV. Identification of a novel mRNA target of miR-210 in PCa 
The previous figure illustrates how the function of miR-210 can be gauged by exploring the effects of the 
mRNAs that it binds and suppresses. Next, to probe the oncogenic effects of miR-210, a list of putative 
mRNA targets was compiled using the miRTarBase software tool 
(http://mirtarbase.mbc.nctu.edu.tw/php/index.php).  Among these, neural cell adhesion molecule 
(NCAM1) was of particular interest as an adhesion molecule that could be a potential tumour-suppressor. 
The prostate cell lines in our laboratory were screened for expression of NCAM and interestingly it was 
only detected in the non-transformed cell line RWPE-1 (Figure 4B). Transient transfection was used to 
overexpress miR-210 in this cell line (Figure 4C) and levels of NCAM1 were decreased as measured by RT-
qPCR, although this was not significant, perhaps because the mRNA is incompletely degraded due to 
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imperfect binding of the seed region (Figure 4D). However, at the protein level there was a reduction in 
NCAM levels, suggesting miR-210 can indeed regulate levels of functional NCAM (Figure 4E).  
Next, NCAM1 was confirmed as a direct target of miR-210 by luciferase reporter assay, as outlined in 
Methods section 2.1.II. (Figure 4F). Briefly, the luciferase activity of a reporter construct containing the 
wild-type NCAM1 3’UTR region (WT-3’UTR) was reduced when miR-210 was co-expressed in the same cells. 
However, when miR-210 was co-expressed with a reporter construct which had deleted residues in the 
miR-210 binding site of NCAM1 3’UTR (DEL-3’UTR), luciferase activity was intact, therefore indicating that 
NCAM1 is a direct target of miR-210 in these cells. Hence, through this mechanism, the hypoxia-induced 
expression of miR-210 has the potential to impact upon cell adhesion processes and potentially with 










Figure 4. Neural cell adhesion molecule (NCAM) is a novel target of miR-210 in PCa. A) The seed region of miR-210 
has three potential binding sites on the 3’UTR of NCAM, data from miRTarBase. B) Western blot analysis of NCAM in 
prostate cell lines reveals it is detectable in non-transformed RWPE-1 but not in the cancer cell lines LNCaP, 22RV1, or 
DU145, with small amount detected in PC3. C) Using RWPE-1, miR-210 was overexpressed artificially by transient 
transfection of precursor molecule (pre-miR-210) or the non-targeting negative control (pre-miR-neg). RT-qPCR 
analysis reveals successful transfection and overexpression of miR-210 in three biological replicates in RWPE-1. D) RT-
qPCR analysis showing reduced NCAM levels in pre-miR-210 transfected cells relative to pre-miR-neg, in three 
biological replicates. E) Western blot showing reduced NCAM protein in pre-miR-210 transfected cells relative to pre-
miR-neg, image representative of three biological replicates. F) Luciferase reporter assay showing that co-transfection 
of pre-miR-210, but not pre-miR-neg, silences expression of luciferase which has been cloned downstream of the 
intact but not deleted miR-210 binding region (top panel of A), mean of three biological replicates. One-way t-tests 
were used to compare condition means to the control (hypothetical value 100), two-way t-tests were used to compare 




3. 2. V. MicroRNA-210 and NCAM expression is inversely correlated in prostate tissue 
These experiments indicated that increased hypoxia in tumours induces miR-210 which in turn could 
decrease the levels of NCAM1. The Regulome Explorer and PRAD datasets were explored to investigate this 
relationship. Interestingly, there was a significant inverse correlation between miR-210 and NCAM1 gene 
expression in the Regulome Explorer dataset (R=-0.34; -log10(p-value)=9.8; samples n = 330)(Figure 5A). 
Expression of NCAM1 also showed a significant negative correlation with clinicopathological markers of 
prostate cancer progression in the Firebrowse dataset: Gleason score (R=-0.1282, adjusted p value 
(Q)=0.004215, samples n=497), and number of lymph nodes (R=-0.1282, adjusted p value (Q)=0.009714, 




Figure 5. Evidence to support the regulation of NCAM by miR-210. A) Significant inverse association between gene 
expression levels of miR-210 and NCAM in sequencing data downloaded from Regulome Explorer. B) Significant 
correlation between NCAM1 expression level and clinicopathological features of PCa as reported in Firebrowse data. 
C) Boxplot representation of the difference in mean NCAM1 levels between patients with Gleason score ≤7 and ≥8 






3. 2. VI. Phenotypic assays explore the effect of miR-210 overexpression on cell proliferation 
and migration 
To assess the effect of miR-210 overexpression on cell behaviour in vitro, LNCaP, 22Rv1, PC3 and RWPE-1 
cells were transfected pre-miR-210 or pre-miR-neg and phenotypic assays were used to examine the effect 
on cell behaviour. First, flow cytometry was employed to quantify the number of mitotic cells by propidium 
iodide staining, post-transfection with pre-miR-210, in the cell lines RWPE-1 and LNCaP (as described in 
Methods section 2.1.III.c.). However, in both cell lines the cell cycle of pre-miR-210 transfected cells were 
equivalent to the control (Figure 6A-B). 
Next, the transfected cells’ ability to re-cover a scratch “wound” in the cell monolayer was monitored 
(Methods section 2.1.III.a.). RWPE-1 cells were transfected and allowed to near confluence before a scratch 
in the cell layer was made using the tip of a pipette. The ability of the cells to cover the scratch was 
monitored for up to 96h. LNCaP were found to be unsuitable for this assay since they do not form a 
confluent monolayer but rather clusters across the plate and the scratches were inappropriate for 
measuring. There was no evident effect of miR-210 overexpression on the ability of RWPE-1 to cover over 
the scratch, and the speed at which pre-miR-210-transfected cells covered the scratch area was not 
significantly different from the negative control (Figure 6C-D). However, there was a striking difference in 
the morphology of the pre-miR-210 transfected cells. Numerous apoptotic cells can be observed, and the 
cells appeared slightly more fibroblastic, which was clear in all three technical replicates (1 representative 
image shown). The cells also did not become as confluent as the pre-miR-neg cells by the time of the 
scratch, indicating a slower growth rate in the first 24h post-transfection. Therefore, it may be that miR-








           
 
 
Figure 6. Analysis of the cell cycle and scratch wound migration. A) Flow cytometry analysis of PI-stained RWPE-1, 
and B) LNCaP, showing no difference in the number of cells undergoing mitosis (G2/M) or growth arrest (G0) between 
pre-miR-210 and pre-miR-21 transfected cells, mean of two biological replicates shown. C) Scratch wound assay in 
RWPE-1 showing no evident difference in the rate of coverage between pre-miR-210 and pre-miR-neg transfected 
cells, although striking difference in cell morphology, representative image of 3 technical replicates. D) Two-way t-test 





3. 2. Discussion 
3. 2. I. Summary of findings 
While extensive evidence has linked miR-210 expression with the hypoxic response in cancers such as 
breast cancer, there is little data available exploring its role in PCa, despite this being a tumour type with a 
high occurrence of hypoxia. This chapter presents novel data using three laboratory models of hypoxia, 
showing that hypoxia was consistently associated with miR-210 upregulation in a dose-dependent manner. 
That bicalutamide treatment was associated with increased hypoxia is in accordance with previous findings 
from our group, and this is the first study to show that miR-210 expression is expressed in correlation. 
Overall these experiments advocate miR-210 as a key mediator of the hypoxic response in PCa.  
The analysis of 17 prostate tumour samples from a private in-house prostatectomy cohort as well as the 
independent TCGA datasets revealed that overexpression of miR-210 predicted Gleason grade and lymph 
node metastasis with strong statistical significance. This additionally associates miR-210 expression with 
tumour progression, and corroborates the deleterious effect of hypoxia in PCa. However, miR-210 
expression was not consistently correlated with the incidence of cancer in our private cohort nor the TCGA 
repository, indicating that miR-210 could be a useful marker of hypoxia but not cancer incidence. This 
highlights the importance of measuring the hypoxic status of tumours when investigating miR-210 
expression in cancers; numerous research groups have reported that miR-210 is overexpressed during 
cancer but it is unclear whether this reflects a driver mutation or is a result of hypoxia.  
To understand better the functional role of miR-210, we explored the effect of miR-210 overexpression in 
several PCa cells lines and I show for the first time that miR-210 was capable of regulating neural cell 
adhesion molecule (NCAM) in PCa. I confirmed a binding site for miR-210 in its 3’UTR by luciferase reporter 
assay and NCAM1 and miR-210 significantly inversely correlated in the TCGA cohort, which corroborates a 
regulatory relationship. NCAM is a large cell surface receptor from the immunoglobin superfamily. NCAM 
was chosen as a candidate target because it is involved in adhesion, cell: cell interactions and migration, 
and thus may be a tumour-suppressor. As the name suggests, the functions of NCAM have been mainly 
characterised in the context of neuroscience, it was highly expressed in neurons and glia, and during 
development it stimulated neurite outgrowth and dendritic branching and complexity (Sergaki and Ibáñez, 
2017).  
NCAM also has functions outside the CNS, although these have not been explored as extensively. It was 
detected on the surface of many haematopoieic cells (natural killer (NK) cells, gamma delta (γδ) T cells, 
activated CD8+ T cells, and plasmacytoid dendritic cells), where it is more frequently referred to as CD56. 
High levels of CD56 tend to indicate immune cell activation and cytotoxic capabilities, and NCAM was 
involved in immune surveillance and T cell expansion (Van Acker et al>, 2017). NK-derived exosomes 
contain NCAM, suggesting that it may be necessary for binding and to induce cell death in target cells (Van 
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Acker et al., 2017). NCAM was detected in mesenchymal stromal cells of the bone marrow where it 
contributed to a favourable environment for haematopoietic stem cells (Prag et al., 2002), and in some 
peripheral tissues such as skeletal myocytes where it facilitated the growth of neurons in muscles. The 
NCAM1 gene was expressed by neuroendocrine cells (cells that respond to neurotransmitters and regulate 
endocrine secretions).  
Three splice variants exist, giving rise to proteins of approximately 180 kDa, 140 kDa or 120 kDa and the 
downstream effects of its activation depend on the isoform present. Isoforms NCAM-180 and NCAM-140 
are transmembrane proteins with long and short intracellular domains, respectively, whereas NCAM-120 
lacks an intracellular domain and anchors extracellularly to the plasma membrane by a 
glycosylphosphatidylinositol. Interestingly, the NCAM isoforms have tissue- and temporal-specific 
differences in expression; typically, NCAM-140 and NCAM-180 predominate in embryonic tissues and 
NCAM-120 (which was detected in RWPE-1) predominates in adult tissues. Many neoplasms had 
detectable NCAM, including those of neuroendocrine origin (such as small cell lung carcinoma and 
pheochromocytoma), haematopoeic origin (myeloma, myeloid leukaemia, NK/T cell lymphomas), ovarian 
stromal tumours, tumours of brain (such as neuroblastoma and paraganglioma) pancreatic acinar cell 
carcinoma, nephroblastoma (Wilm’s tumour), and Ewing’s sarcomas of the bone (Van Acker et al>, 
2017)(Prag et al., 2002). Furthermore, NCAM staining could identify the origin of certain tumours, 
distinguishing between small cell and non-small cell lung carcinomas (Kontogianni et al., 2005), and could 
differentiate subtypes of thyroid tumour (Golu et al., 2017).  
In some cancers NCAM-120 was replaced by NCAM-140 or NCAM-180 (Perl et al, 1999), which suggested 
that the cytoplasmic domain may have tumour-suppressive effects. The extracellular domain participates 
in both homophillic and heterophillic interactions (either on the same cell (cis) or an opposing cell (trans)). 
Notably, NCAM was a ligand for the fibroblast growth factor receptor (FGFR), such as on T cells (Kos and 
Chin, 2002)(Doherty and Walsh, 1996) and heterophillic cis-binding with FGFR was essential for FGF 
signalling in tumour-associated macrophages in oesophageal cancer (Takase et al., 2016). The cytoplasmic 
domain of NCAM-140 activated the non-receptor tyrosine kinase p59fyn leading to sustained MAPK 
signalling in neurons (Beggs et al., 1997)(Schmid et al., 1999). However, NCAM-120 also activated 
intracellular signalling by interacting with other transmembrane proteins and creating functional 
membrane domains, and only NCAM-120 was able to cis-dimerise (Kulahin et al., 2011). NCAM was 
considered a mesenchymal marker and in breast cancer cells, NCAM was upregulated by loss of E-cadherin 
during epithelial-mesenchymal-transition (Golu et al., 2017) although this suggested an oncogenic 
association. Similarly, in melanoma NCAM-140 stimulated invasion by activating CAMP-dependent protein 
kinase and phosphatidylinositol 3-kinase pathways (Shi et al., 2011). However, experiments using rat 
glioma cell lines showed that NCAM reduced motility via both the extracellular and cytoplasmic domains, 
activating p59fyn (intracellularly) and by binding a heparan sulfate proteoglycan (extracellularly) which 
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affected the cells’ binding to the ECM (Prag et al., 2002) and therefore may have tumour-suppressive 
associations in other cancer types. Moreover, in pancreatic and colorectal cancer, low levels of NCAM 
correlated with increased malignancy (Fogar et al., 1997)(Roesler et al., 1997) and in pancreatic β-cells, 
reduction of NCAM-120 was a rate-limiting step in metastatic dissemination (Perl et al., 1999). In HuH28 
cells (a liver carcinoma cell line), CD56 homophillic binding between CD56+ NK cells and the HuH28 cells 
inhibited NK-mediated cytosis, suggesting it was necessary for target recognition (Takasaki et al., 2000).  
Surprisingly, in PCa the role of NCAM has barely been investigated. The Protein Atlas Database reports that 
prostate tissue has low but detectable expression of NCAM1 (Fagerberg et al., 2014), in accordance with 
my results. One subtype of prostate cancer (of neuroectoderm differentiation) stained positive for NCAM 
(Yamazaki et al., 2012) but other than this study NCAM levels in PCa have not been studied. Here, I report 
for the first time that the cancer cell lines PC3, LNCaP and 22Rv1 do not express NCAM although it was 
detected in RWPE-1, suggesting that it may be present in the prostatic epithelium but is lost during 
carcinogenesis. Since miR-210 is expressed by many cell types and mediates cell: cell interactions, it could 
potentially downregulate targets such as NCAM in neighbouring cells producing a microenvironment 
conducive to tumour initiation and progression. This may allow PCa cells to evade CD56+ NK cells, FGFR+ T 
cells, or macrophages, to modulate immune subversion which is a critical step in tumorigenesis. Another 
hypothesis could be that the loss of homophillic NCAM binding between PCa cells increases their motility 
or de-differentiation, or affects their interaction with stromal cells. Therefore, by targeting NCAM it is likely 
that miR-210 can participate in the regulation of migration or cell : cell interactions in PCa. However, 
although there was an inverse association between miR-210 and NCAM1 levels in the TCGA sequence data, 
this should be interpreted with caution as the sequencing was performed on whole tumour lysates, and 
we cannot rule out the possibility that this reflects a reduced number of infiltrating CD56+ immune cells, 
which was reported to occur during hypoxia (Jayaprakash et al., 2018).  
However, in these preliminary experiments, artificial overexpression of miR-210 in RWPE-1 did not increase 
the coverage of RWPE-1 cells over a scratch. This contrasts with the findings of another study which 
reported that miR-210 was capable of promoting migration, invasion and EMT in VCaP and C4-2B cells, 
although these authors utilised a boyden chamber assay method (Ren et al, 2017) which may be more 
sensitive, and perhaps these effects of miR-210 only occur in PCa cells. In hindsight I speculate that the 
scratch wound assay is generally insensitive to cell migration. Mainly, this is because the cells covering the 
scratch could simply be proliferating (aka, daughter cells of the cells from the leading edge). It seems 
unlikely that they would be migrating across the plate since there is no chemotaxic gradient as is used by 
the boyden chamber method. Furthermore, the creation of the scratch surely damages the cells at the 
leading edge, affecting their potential for migration/proliferation. Finally, in order to observe cells covering 
the scratch the cells must be almost confluent at the time of scratching. However, since they are 
transfected at approximately 30% confluency in order to grow and assume the effects of the transfection, 
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and this means that one must wait at least 4 days after transfection to create the scratch and another 4 
days to monitor the scratch. This creates two issues: Firstly, the precursor molecules may be reduced in 
concentration by this point. Secondly, at the time of scratch the remainder of the plate is confluent 
meaning growth arrest and cell death are imminent (indeed many floating cells must be rinsed away before 
imaging) and apoptotic factors being released into the media may affect the behaviour of the cells at the 
leading edge.  
Nevertheless, it was clear from the scratch wound images that cells with miR-210 overexpressed had 
striking changes in morphology, so it would be interesting to look for changes in the levels of 
epithelial/mesenchymal markers such as E-cadherin or N-cadherin, or apoptosis mediators in future 
studies. The flow cytometry experiments indicated no change in the cell cycle in pre-miR-210 transfected 
RWPE-1 nor LNCaP, however, I had observed during the hypoxic chamber experiments that hypoxic culture 
profoundly reduced LNCaP proliferation so perhaps a combination of HIF-1α induced factors are required 
to induce growth arrest and overexpression of miR-210 alone, while contributory, may be insufficient.  
3. 2. II. Future directions 
3. 2. II. a) Short-term 
Since miRNAs are highly stable, it seems likely that high levels of miR-210 following hypoxia would persist 
long after re-oxygenation and degradation of HIF-1α (unless an active turnover process occurs as negative 
feedback). To explore this we could culture the cells at hypoxia for 24h and then return them to normoxic 
conditions and monitor the levels of miR-210 in the following hours or days and compare this with the 
stability of HIF-1α. This would have implications for the subsequent effect of acute hypoxia. Similarly, 
chronic hypoxia could be mimicked by culturing the cells at 0.5% oxygen for several days or weeks, to 
determine if miR-210 is involved in the chronic hypoxia response.  
It is important to consider what exactly constitutes physiological oxygen levels (McKeown, 2014). Twenty 
percent is often used as the normoxic condition although in fact normoxic human tissues are between 3-
5% O2. It would be interesting to culture cells at 5% and use this as the normoxic conditions, to obtain a 
more realistic impression of miR-210 induction during tumour hypoxia. However, this would mean the cells 
were not paired samples from the same parental flask. It would also be interesting to investigate how 
rapidly miR-210 is upregulated, in hours rather than periods of 24h. However, the phenotypic assays that 
we use to investigate functionality commence 24h post-transfection so it seems logical to use a 24h time-
point after commencing hypoxic culture. Similarly, future experiments could explore culturing cells at 
higher oxygen (e.g. 1% O2) for longer time points to mimic chronic hypoxia. 
Since miR-210 was induced by hypoxia and NCAM was reduced by miR-210 overexpression, it would be 
interesting to measure NCAM protein levels in RWPE-1 following hypoxia, to explore if it was reduced by 
hypoxia. However, the caveat of this experiment would be that 72h of culture is the standard length of 
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time between transfection with pre-miR-210 and cell harvesting, which is needed for protein turnover to 
observe clear differences between the conditions. My initial hypoxic experiments showed that cells were 
not viable after 72h at this oxygen level, and moreover they were inhibited from proliferating by hypoxia 
almost immediately. This means it is unlikely that NCAM levels would be noticeably reduced, however, we 
could experiment using chronic hypoxia (such as 1% O2 for 72h) which may induce miR-210 and yet allow 
the cells to proliferate and survive longer periods.  
As previously mentioned, we could quantify apoptosis signalling in RWPE-1 and LNCaP following 210 
transfection by flow cytometry (quantifying Annexin V staining), by Tunel assay, or using Western blot to 
probe for cleaved caspase-3, as has been performed by other researchers (Bucur et al., 2012). A suppressive 
effect of miR-210 on apoptosis would be interesting as it could indicate a mechanism through which 
hypoxia prevents ADT-induced apoptosis and facilitates survival.  
3. 2. II. b) Medium-term 
NCAM was detected at the protein level in non-transformed RWPE-1 but not in the cancer cell lines, which 
are cells harvested from metastatic sites and thus at the end stage of cancer development. It would be 
interesting to use immunohistochemistry to explore NCAM protein levels in human tumours compared 
with healthy prostate tissue of varying stages of progression, to determine if indeed it is lost during 
carcinogenesis. This would also allow us to see which cells NCAM is expressed in – epithelial cells or 
infiltrating immune cells. If there was an antibody available to detect NCAM by flow cytometry, we could 
use FACS to sort the cells expressing NCAM from fresh tumour lysate, and determine if they are epithelial 
cells or immune cells. We could also co-stain for NCAM plus in situ hybridisation of miR-210 on tissue 
sections to explore a potential inverse correlation, this would also confirm that miR-210 levels are stable 
in the cells and not being rapidly turned over which has been observed for some miRNAs (Guo et al., 2015).  
I consider the scratch wound assay insensitive to migration however it would be interesting to use a Boyden 
chamber method to explore migration and invasion potential of cells following overexpression of miR-210 
(Falasca, Raimondi and Maffucci, 2011). Since the growth curves did not demonstrate an effect on 
proliferation, ki-67 staining could be used as a second indication (Scholzen and Gerdes, 2000). 
I used an oxygen electrode probe to measure tumour hypoxia in the in vivo model, which was limited in 
that it only measures PO2 at the region the probe enters and may not be representative of the total hypoxia 
of the tumour. There are numerous other ways to quantify hypoxia, such as staining with pimonidazole or 
PET imaging. Oxygen electrodes have long been considered the gold standard (Walsh et al>, 2014) but 
recent advances in technology mean that tumour hypoxia can be measured more accurately across the 
tumour by new devices based on PET imaging (Lopci et al., 2014).  
Interestingly, there is some evidence that miR-210 expression is regulated by DNA methylation of its 
promoter region. A study of schwannoma (tumour of the myelin sheath) found that the miR-210 promoter 
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region was hypermethylated in normoxia, and demethylated in hypoxia, and this demethylation was 
associated with enhanced proliferation, autophagy, and invasion (Wang et al., 2017). Moreover, during 
helicobacter pylori infection increases DNA methylation of the miR-210 promoter which silences its 
expression and contributes to gastric disease (Kiga et al., 2014). In neural progenitor cells, miR-210 
expression was regulated by DNA methylation during both hypoxia and normoxia (Xiong et al., 2012). 
Further methylation assays showed miR-210 expression correlated with DNA methylation during steroid-
associated osteonecrosis of the femoral head (Yuan et al., 2016). However, the regulation of miR-210 
expression by DNA methylation has not been studied extensively and scarcely in the context of hypoxia.  
3. 2. II. c) Long-term 
Mass spectrometry could be used to quantify NCAM after transfection with pre-miR-210, since Western 
blot is not quantitative, and the mRNA level is not always an accurate representation of the efficacy of 
miRNA targeting. Alternatively, we could use immunohistochemistry (IHC) to probe for NCAM using a 
fluorescently labelled antibody, since it is a surface protein we may see a loss of extracellular NCAM after 
transfection or hypoxia without permeating the cells. If it was confirmed by IHC that NCAM is lost during 
prostate carcinogenesis, we could investigate if it has tumour suppressive function. To explore this, 
immunoprecipitation experiments could be used to pull it down and determine which proteins it is binding 
to in the basal state. Using fresh tissue samples may mean that we could determine if it was binding to 
receptors from other cell types such as immune or stromal cells. Mass spectrometry could be used to 
identify or quantify its binding partners. If there were potential binding partners in mind, Western blot 
could be used to detect them, or a yeast-two-hybrid assay (Maccarrone et al., 2017)(Paiano et al., 2019).  
However, there is always the possibility that NCAM has no intrinsic tumour-suppressive effects and its loss 
during carcinogenesis is simple a result of the changing expression pattern of an upstream regulator or 
perhaps it is simply not required due to the changing behaviour of the cell. To test this, we could disrupt 
the function of NCAM and explore the effect in RWPE-1. NCAM-120 has no intracellular domain, and exerts 
its signalling effects by dimerising with other receptors; therefore siRNA could be used to silence expression 
or use point mutations by CRISPR-Cas9 to disrupt parts of the extracellular domain (Koch et al., 2018).  
If the previously mentioned FACS analysis showed that NCAM was expressed on tumour cells, we could 
purify the NCAM expressing cells from tumour lysates and sequence them, and compare them with cells 
not expressing NCAM and perform pathway analysis or functional enrichment to identify differential 
signalling. Similarly, transcriptomic effects of miR-210 could be explored by overexpression and RNA-seq.  
Bicalutamide increased hypoxia and miR-210 expression, but the reason for this remains obscure. It would 
be interesting to use enzalutamide to determine if it similarly increases hypoxia. If so, it would be 
interesting to explore how AR inhibition increases hypoxia. Perhaps the loss of AR signalling, which is 
essentially a starvation of growth factors, induces a state of stress in the cell that somehow activates HIF-
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1α as a means of slowing down cellular processes. Chromatin-immunoprecipitation (ChIP-seq) experiments 
(Chen, Bhadauria and Ma, 2018) could be useful to explore transcriptional targets of AR, perhaps focusing 
on HIF-1α regulators such as FIH or PHD. 
Interrogation of publically available survival data using the KM plotter tool (http://kmplot.com/analysis/)  
revealed that when expression of miR-210 was dichotomised into “high” and “low”, high expression was 
associated with reduced survival in several other cancer types:  cervical squamous carcinoma, liver 
hepatocellular carcinoma, thyroid carcinoma, lung squamous cell carcinoma, pancreatic ductal 
adenocarcinoma, and sarcoma (Supplementary Figure 2)(data for PCa not provided)(Nagy et al., 2018). The 
role of miR-210 and/or hypoxia in these cancer types could be a worthwhile avenue for further research.  
3. 2. III. Summary 
This is the first study to link miR-210 expression with hypoxia and bicalutamide treatment in PCa. We also 
suggest for the first time that NCAM, an important sensor and signal transducer, may be lost during PCa 
development and may be regulated by miR-210. Therefore, this study highlights a central role for miR-210 


























Supplementary Figure 1. MiR-210 expression in hypoxic 22Rv1, PC3 and RWPE1 cells. qRT-PCR analysis showed 
increased expression of miR-210 in 22Rv1, PC3 and RWPE1 cells exposed to hypoxia. A) 22Rv1 after 48h hypoxia, B) 
PC3 after 24h hypoxia, C) RWPE-1 after 48h hypoxia. Mean + SEM of three biological replicates shown (Student t-test 





Supplementary Figure 2. High expression of miR-210 is associated with reduced survival. In A) Cervical squamous 
carcinoma, B) Liver hepatocellular carcinoma, C) Thyroid carcinoma, D) Lung squamous  cell carcinoma, E) Pancreatic 
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Chapter 4. The Oncogenic MicroRNA-21 is Induced by Hypoxia in 
































4. 1. Introduction 
Chapter 3 evaluated the relevance of hypoxia-associated miR-210 in PCa. Conversely, this chapter 
investigates hsa-miR-21-5p (miR-21), which has been attributed oncogenic effects in many cancer settings 
but scarcely investigated in PCa hypoxia.  
MiR-21 expression correlates with cancer incidence in numerous tissue types including in the lung, colon, 
breast, pancreas and the stomach (Sha et al, 2015; Tao et al, 2015; Chen et al, 2016; Gao et al, 2016; He et 
al, 2016; Wu et al, 2016; Yan et al, 2016; Zheng et al, 2018). Furthermore, screenings of cancer patients 
consistently implicate miR-21 as a marker advanced forms of the tumour, in prostate, breast, pancreatic, 
and colon cancer (Anwar et al, 2019; Bahreyni et al, 2019a; Kurul et al, 2019; Vila-Navarro et al, 2019). 
Many in vitro studies have explored the phenotypic effects of miR-21 expression that may explain these 
associations, to the extent that reviews assessing its role in colorectal cancer, cervical cancer, and lung 
cancer have concluded that it has an oncogenic effect when overexpressed in cancer (Bahreyni et al., 
2019b)(Wang et al., 2019)(Bica-Pop et al., 2018). This places miR-21 as one of the most prominent 
“oncomiRs” in cancer research, and many studies have investigated it in the context of PCa. However, the 
majority of these studies were investigations into differentially expressed miRNAs in the tissue, blood, or 
urine of PCa patients compared to controls (or high-grade PCa compared with low-grade), concluding that 
miR-21 was a robust biomarker of  disease status (Zhou and Zhu, 2019). The majority of PCa based studies 
did not investigate the functionality of miR-21, aside from validating its mRNA target interactions. These 
showed that many tumour suppressors were regulated by miR-21 either using qPCR or western blot 
approaches and in some instances by reporter assay. MiR-21 regulated Myristoylated Alanine-Rich protein 
Kinase C Substrate (MARCKS) which facilitates apoptosis and invasion (Li et al., 2009a); Bone 
Morphogenetic Protein Receptor II (BMPRII) which may indicate a regulation of bone metastasis (Qin et al., 
2009); metalloproteinase (MMP) inhibitor RECK (Reis et al., 2012)(Leite et al., 2015); TGFβR2 the immune 
signalling mediator (S Mishra et al., 2014); p57Kip2 which regulates the cell cycle (Sweta Mishra et al., 
2014); and RNA Binding Protein with Multiple Splicing (RBPMS), Regulator of Chromosome Condensation 
and POZ Domain Containing Protein 1 (RCBTB1), and Zinc Finger protein 608 (ZNF608) which were 
mediators of cisplatin resistance (Báez-Vega et al., 2016), and programmed cell death 4 (PDCD4) and PTEN 
which are important tumour suppressors in PCa (Lu et al., 2008)(Feng and Tsao, 2016). 
A few studies have performed phenotypic assays to assess the effect of miR-21 overexpression or inhibition 
on cell functionality. One group transfected PC3 cells with inhibitors of miR-21-3p and miR-21-5p and 
observed reduction in colony formation in agar (Báez-Vega et al, 2016), another group similarly reported 
that the miR-21-5p inhibitor reduced the motility and increased sensitivity to apoptosis of DU145 and PC3, 
although proliferation was not affected (Li et al., 2009b). In another small study, miR-21 transfection was 
associated with increased cell viability (Yang, Guo and Shao, 2017). Furthermore, in PCa cell lines miR-21 
was upregulated by the androgen receptor and contributed to androgen-independence (Ribas et al., 
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2009)(Guan et al., 2019), it upregulated AKT, ERK and HIF-1a signalling (L.-Z. Liu et al., 2011), and it was 
upregulated in docetaxel-resistance PCa cells (Shi et al., 2010). However, another group treated PC3 and 
DU145 with miR-21 inhibitors and observed no effect on cell proliferation, radioresistance, nor an effect 
on PTEN and PDCD4; they concluded that miR-21 is not prominent in the carcinogensis of PCa (Folini et al., 
2010).  Therefore, reports on its role in PCa have been mixed.  
Interestingly, there is evidence from other tissue types that miR-21 is involved in the hypoxic response. The 
pri-miR-21 promoter has a HIF-binding site (Kulshreshtha et al., 2007) and early research demonstrated 
that its expression was deregulated in pulmonary arterial hypertension (caused by abnormal vasculature) 
following ischaemia and reperfusion injury (Xu et al., 2014; Bienertova-Vasku, Novak and Vasku, 2015). This 
indicated that miR-21 responds to cellular oxygen levels and that it exerts control over vascularisation as 
well as inflammation. It was upregulated early in both the inflammatory and hypoxic responses and 
regulated a wide range of pathways to protect cell integrity and restore homeostasis during such 
fluctuations. For instance, it was upregulated by the drug gastrodin, thus revealing a mechanism through 
which gastrodin protects pulmonary tissue from hypoxic injury following myocardial infarction (Xing and 
Li, 2019). MiR-21 expression prevented hypoxia- and glucose deprivation-induced apoptosis in human 
neural stem cells by inhibiting JNK and p38 MAPK signalling (Chen et al., 2019). Similarly, it mediated the 
protective effect of loperamide, a µ-opioid receptor agonist that protects against myocardial 
ischemia/reperfusion injury in cardiomyocytes (Shen et al., 2019). Based on this it was proposed that miR-
21 expression by cancer cells upon chemotherapy could promote survival and mediate chemoresistance 
and indeed, miR-21 expression has been associated with resistance to radiation therapy and cisplatin (Jiang 
et al., 2016; Dong et al., 2019).  
However, in PCa an involvement of miR-21 in the hypoxic response has not been confirmed. One study 
investigated the effect of a curcumin-derived synthetic analogue called CDF on PCa cells, and measured 
the effect of CDF on attenuating the expression of hypoxia-associated genes. One of their initial assays 
included measuring the expression of miR-21 after culture at 1% oxygen although the duration of culture 
was not stated (Bao et al., 2012). Therefore, the regulation of miR-21 by hypoxia in PCa warrants further 
investigation.  
In summary, miR-21 has been studied in several cancers, and is generally accepted to have an oncogenic 
role, and it has been strongly promoted as a diagnostic marker in PCa although its effects in PCa cells are 
unclear. Furthermore, a link with PCa hypoxia remains understudied. Several mRNA targets of miR-21 have 
been identified in PCa although there is scope to discover further novel targets and/or mechanisms of 
action, particularly in relation to those that might be involved in the hypoxic response. 
The hypothesis of this chapter was that miR-21 would be induced by hypoxia in PCa and would produce 
oncogenic effects when overexpressed in PCa cells. 
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4. 2. Results 
4. 2. I MicroRNA-21 is regulated by hypoxia in vitro and in vivo  
The three models of hypoxia were used: hypoxic chamber culture at 0.1% O2 relative to 20% O2, LNCaP 
spheroid culture, and bicalutamide-induced hypoxia in vivo (as described in chapter 3). MiR-21 was 
upregulated by hypoxia in a dose-dependent fashion in all three models, albeit not always significantly 
due to variation between replicates (Figure 1). As with miR-210, the in vivo analysis suggested miR-21 
was most strongly upregulated by day 28 in the tumours of bicalutamide-treated mice relative to vehicle-
treated mice. This suggested that hypoxia was further established by day 28 and that hypoxia-associated 
miRNAs accumulated by this time-point. Interestingly, we were able to detect miR-21 in the serum 
samples of the mice, even using such low volumes that none of the other miRNAs that were investigated 
could be detected including the housekeeping miR-191. This indicated that miR-21 is highly abundant in 
serum which lends further weight to the suggestions that is could be a useful diagnostic marker. Unlike 
miR-210, miR-21 was further upregulated between day 7 and day 28 in the serum suggesting it may be 
actively exported in correlation with hypoxia.  
 
 
Figure 1. miR-21 is increased by hypoxia in vitro and in vivo. A) RT-qPCR analysis showing miR-21 expression increases 
in a dose-dependent fashion with hypoxia following hypoxic chamber culture of LNCaP. Mean + SEM of three biological 
replicates.  B) RT-qPCR analysis showing miR-21 expression in LNCaP spheroids increased at 30µm and 50µm relative 
to 10µm. Mean + SEM of three biological replicates shown. C) RT-qPCR demonstrates increased expression of miR-21 
in the tumours, and D) serum, of bicalutamide-treated mice relative to vehicle-treated mice at day 7 and day 28 of 
treatment. The mean + SEM is shown, groups contained at least 4 mice. One-way t-tests were used to compare 




4. 2. II MicroRNA-21 expression in 19 prostatectomy samples  
Next, the clinical relevance of miR-21 expression was investigated by measuring its expression in our in-
house bank of human prostatectomy samples, as described in Chapter 3. Since miR-210 is an established 
indicator of hypoxia, including in PCa as demonstrated in Chapter 3, we wanted to confirm that miR-21 
expression correlated positively with miR-210 in both the in-house prostatectomy cohort and the TCGA 
prostate samples. MiR-21 expression significantly correlated with miR-210 expression which corroborated 
the regulation of miR-21 expression by hypoxia (Figure 2A). As was the case with miR-210, the 
prostatectomy samples did not display uniform upregulation of miR-21 relative to the paired non-tumour 
tissue, which would indicate upregulation in the cancer state (Figure 2B), however there was a mild trend 






Figure 2. Expression of miR-21 correlates with hypoxic marker miR-210 and Gleason grade group in human 
prostatectomy samples (n=19). A) RT-qPCR analysis demonstrating significant correlation between miR-21 and miR-
210 in prostatectomy samples (Pearson correlation, R=0.9006, p<0.001). B) RT-qPCR measurement of miR-21 levels 
across prostatectomy samples. C) RT-qPCR analysis revealed slight correlation (ns) between miR-21 expression level 





4. 2. III. MicroRNA-21 expression in the TCGA datasets 
The Cancer Genome Atlas database was then analysed (n=330), using the Regulome Explorer tool (TCGA 
Research Network, 2015). In this data there was significant positive correlation between expression of miR-
21 and miR-210 (Figure 3A). Furthermore, miR-21 expression was significantly increased in the highest 
Gleason grade tumours, it significantly correlated with an increased number of lymph nodes positive for 
PCa, and was significantly increased in the tumours that did not go into complete remission (suggesting an 
inherently more aggressive tumour or less susceptibility to treatment).  
Analysis of the Firebrowse dataset Prostate Adenocarcinoma (PRAD) similarly revealed miR-21 expression 
significantly associated with Gleason score, number of positive lymph nodes, and pathological T stage 
(Figure 3C-F)(Broad Institute TCGA Centre, 2016). Since miR-21 was readily detected from extremely small 
amounts of tissues during the initial in vitro experiments, the expression levels of miR-21 and miR-210 in 
TCGA cohort were compared and indeed miR-21 was expressed at much higher levels, highlighting its 





Figure 3. Expression of miR-21 correlated significantly with miR-210 and parameters of tumour aggressiveness in 
human prostate biopsy samples. Data from the from The Cancer Genome Atlas project was accessed using the 
Regulome Explorer tool (n=330) and the Firebrowse PRAD dataset (n=>400). Regulome Expolorer analysis reveals A) 
Significant correlation between expression of hypoxic miR-210 and miR-21 (Pearson correlation, p<0.001). B) MiR-21 
levels significantly more abundant than miR-210 levels (Mann Whitney test p<0.0001). Significantly higher miR-21 
expression positively associated with C) Gleason score (one way ANOVA, p<0.001), D) number of lymph nodes positive 
for PCa (one way ANOVA, p<0.001), E) pT3b tumours compared with pT2c, and F) in patients with partial remission 
compared with complete remission response (Mann Whitney test, p<0.001). G) In the Firebrowse PRAD dataset, miR-
21 expression correlated with Gleason score, number of positive lymph nodes, and pathological T stage. P-values 
considered significant when *p<0.05, **p<0.01, ***p<0.001. 
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4. 2. V. Investigating the functionality of miR-21  
These findings suggested that miR-21 appears to be a hypoxia-regulated miRNA that is overexpressed in 
aggressive PCa. To examine its oncogenic effects, transient transfection was used to overexpress miR-21 in 
cell lines and phenotypic assays were used to evaluate the resultant changes in cell behaviour. First, the 
basal expression of miR-21 in the prostate cell lines was compared to determine which cell lines would be 
suitable for overexpression. Interestingly, miR-21 was expressed at a lower level in the cancer cell lines 
relative to the non-cancer transformed RWPE-1 (Figure 4A), with the exception of DU145 in which 
expression was hugely upregulated (Figure 4B). This could suggest that in these cell lines miR-21 is not a 
constitutively overexpressed driver of the disease. Potentially however, its induction by hypoxia could 
promote cancer advancement. It was concluded that either LNCaP, PC3 or 22Rv1 could make suitable 












Figure 4. Establishing expression level of miR-21 in the prostate cell lines. Mean + SEM of three biological replicates 
shown. A) miR-21 levels are reduced in PCa cell lines compared with RWPE-1. B) Vastly increased expression level of 
miR-21 in DU145 compared with RWPE-1. One-way t-tests were used to compare condition means to the control 
(hypothetical value 100) and p-values considered significant when *p<0.05, **p<0.01, ***p<0.001. 
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4.2.V.a. The effect of miR-21 overexpression on proliferation 
Since there were conflicting reports in the literature regarding the effect of miR-21 on PCa proliferation, 
XTT cell proliferation/viability assays were performed following transfection with pre-miR-21. The assay 
utilises the tetrazolium salt XTT, which is broken down to formazan indirectly due to the activity of 
mitochondrial enzymes. Formazan has a higher absorbance of light at wavelengths of around 495nm, and 
thus cell viability can be determined by comparing the absorbance across the transfection conditions. As 
described in Methods section 2.1.III.b., cells were transfected with either pre-miR-21 (two transfection 
replicates) or controls (untreated, lipofectamine alone “mock”, or non-targeting pre-miR-neg). After 24h 
the transfected cells were trypsinised, counted and re-seeded at 500 cells per well of a 96-well plate, with 
a plate for each timepoint and 8 technical replicates per sample per plate. The results indicated that there 
was no consistent effect of miR-21 overexpression on the growth curves (Figure 5A-C). 
A flow cytometry based analysis was then employed, which involved staining the transfected cells with 
propidium iodide (a nucleic acid stain) that allows quantification of genetic material and so estimation of 
cell cycle stage (see Methods section 2.1.III.c.). Similarly, no difference was observed in the pre-miR-21 
transfected cells compared to the controls (Figure 5D). This assay suggested that miR-21 overexpression 
did not influence cell proliferation.  
 
 
Figure 5. Investigation of the effect of miR-21 on cell proliferation. XTT assays of one biological replicate, two 
technical replicates of pre-miR-21 in A) RWPE-1, B) 22Rv1, and C) PC3, all showing no consistent influence of the 
transfection of pre-miR-21 on cell proliferation. Negative controls: untreated, lipofectamine alone (Mock), non-
targeting and pre-miR-neg. D) Flow cytometry quantification of RWPE-1 cells showing no difference in the proportion 
of cells in each stage of the cell cycle following transfection with pre-miR-21 or controls. One biological replicate. 
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4.2.V.b. The effect of miR-21 overexpression on colony forming ability 
As mentioned in the introduction (section 4.1) previous research had suggested that miR-21 inhibitors 
reduced colony formation on agar (Báez-Vega et al., 2016). To complement this, the effect of miR-21 
expression on the colony forming ability of RWPE-1, 22Rv1 and PC3 was assessed (described in Methods 
section 2.1.III.d.). Briefly, the cells were transfected and 24h following transfection were counted and re-
seeded at very low densities (optimised to be 750 or 1,000 cell per well of a 6-well plate). After 7 days, the 
cells were stained with crystal violet to evaluate cells’ ability to survive at such low confluence. 
Interestingly, in all cell lines and at multiple seeding densities, transfection with pre-miR-21 increased the 
number of cell colonies that were present 1 week after seeding. The effect was most evident in RWPE-1 
(Figure 6), to some extent in 22Rv1 (Figure 7) and least so in PC3 (Figure 8). The appearance of the colonies 
also differed, some colonies were larger following miR-21 overexpression indicating faster growth. The 
crystal violet was extracted using 1% SDS and quantified by measuring the absorbance at 595nm on a 
spectrophotometer; the rate of change in crystal violet concentration was determined in pre-miR-21 
treated cells relative to pre-miR-neg treated cells in order to combine the results from all replicates (which 
had involved various seeding densities during optimisation). The crystal violet concentrations reflected the 
appearance of the plates.  
Therefore, while an effect of miR-21 on proliferation was not isolated, it appeared to promote survival in 


















Figure 6. Colony forming assay in RWPE-1. Two biological replicates. A) 1,000 cells seeded. B) 750 cells seeded. 
 
Figure 7. Colony forming assay in 22Rv1. One biological replicate. A) 1,000 cells seeded. B) 750 cells seeded.  
 
 
Figure 8. Colony forming assay in PC3. One biological replicate. A) 1,000 cells seeded. B) 750 cells seeded.  
 
 
Figure 9. Rate of increase in the concentration of crystal violet in pre-miR-21 treated cells compared with pre-miR-
neg treated cells. Crystal violet quantified using 1% SDS and absorbance at 595nm recorded using spectrophotometer. 



















































4.2.V.c. The effect of miR-21 overexpression on migration 
Another feature of cancer cells is increased motility and migration. To explore the effect of miR-21 on this 
process an electrode-monitored Boyden chamber assay was utilised (xCELLigence CIM16 system, ACEA 
bio). Since the greatest effect on colony forming assay was apparent in RWPE-1, this cell line was used. As 
described in Methods section 2.1.III.e.,The cells were transfected, and after 24h were re-counted and 
seeded at 30,000 cells per well into the upper chamber in serum-free media, with complete media in the 
lower media. Three technical replicates were seeded per biological replicate, with serum-free lower 
chambers used to assess background migration in the absence of chemoattractant. Cell migration towards 
the serum-containing media was monitored (by electrical impedance as cells crossed the copper pore 
membrane dividing the chambers) for 120h post-transfection. Interestingly, the miR-21 overexpressing 
cells had increased ability to migrate across the membrane, the difference between cell migration of pre-
miR-21 transfected cells and untreated cells was statistically significant although the difference between 







Figure 9. Boyden chamber based cell migration assay in RWPE-1. 30,000 cells untreated or transfected with pre-miR-
neg or pre-miR-210 were seeded into the upper chamber, and the cell index that migrated across electrode monitored 
porous membrane towards serum-containing media was recorded.  Significant difference between the migration 
curves of pre-miR-21 and untreated but not pre-miR-neg (one-way ANOVA, p<0.001). Mean + SEM of three biological 






































































4. 2. VI. Identification of a novel target of miR-21 in prostate cancer 
Next, a novel target of miR-21 in PCa was sought. Using miRTarBase, a list of potential miR-21 targets was 
collected. The candidate genes TGFBR3, NTF3, SPRY2, and RHOB were selected based on a literature 
review which found them all to have tumour-suppressive effects in PCa or another cancer, or evidence 
for involvement in the hypoxia response pathway.  
RWPE-1 cells were transfected with pre-miR-21 or pre-miR-neg (in three biological replicates) and the 
mRNA levels of the candidate targets was measured. PTEN was selected as a positive control, as it is a 
known target of miR-21 in PCa (Feng and Tsao, 2016). The expression of several of the targets was 
unaffected by pre-miR-21 transfection, perhaps indicating that the mRNA was incompletely degraded 
following miR-21 binding, or that the interaction was not functional in this cell-line or perhaps that other 
interactions override this one such as transcriptional upregulation of the target in response to miR-21 due 
to an independent signalling axis. Intriguingly, levels of TGFBR3 and RHOB were equivalent to PTEN in the 
miR-21 overexpressing cells (Figure 11A). As a second cell line, LNCaP cells were transfected and in this 
second cell line RHOB was also reduced (Figure 11B). The hypoxic murine tumour samples were then 
analysed, and in the bicalutamide-treated tumours RHOB expression was reduced slightly by day 7 and 
extensively by day 28, in inverse correlation with the expression of miR-21 (Figure 1E). To detect the protein 
level of RhoB by western blot following miR-21 overexpression, an antibody was ordered but it was not 
effective and the protein could not be visualised, even after the quantity was increased to 80µg and a non-
denaturing lysis buffer was used, to determine if the antibody would bind better to the undenatured 
structure. Another antibody could be ordered from a different supplier to complete this experiment. 
Corroborating a potential regulation of RHOB by miR-21, analysis of the TCGA data by Regulome Explorer 
revealed that the expression levels of RHOB and miR-21 were significantly inversely correlated, and RHOB 
levels were significantly reduced in tumours of Gleason score ≥8 compared with score ≤7, and with 
pathological T stage pT3b compared with pT2b. Of note, while miR-21 levels were significantly different 
between pT2c and pT3b, RHOB expression levels differed between pT3b and pT2b. This suggests that RHOB 
levels are independently associated with cancer progression independently of its inverse correlation with 





















Figure 11. Identification of RHOB as a target of miR-21 in PCa. A) Mean + SEM relative expression of candidate targets 
of miR-21 following miR-21 overexpression in RWPE-1 cells, PTEN as positive control as a known target of miR-21. 
Mean + SEM of three biological replicates shown. B) RhoB is similarly reduced by miR-21 overexpression in LNCaP 
cells. C) RHOB is reduced in the tumours of bicalutamide-treated mice at day 7 and day 28. D) The predicted binding 
between miR-21 and RHOB based on data from miRTarBase. The mean expression level in each bicalutamide-treated 
group was normalised to the mean expression level of the vehicle-treated group, groups contained at least 4 mice. 
One-way t-tests were used to compare condition means to the control (hypothetical value 100) and p-values 












Figure 12. RHOB expression in TCGA datasets. In the PRAD dataset, A) miR-21 and RHOB expression correlate 
inversely, B) RHOB expression is reduced in Gleason score ≥8 compared with score ≤7, and C) in pathological T stage 
pT3b compared with pT2b. D) In the Firebrowse dataset, RHOB expression significantly inversely correlated with 
Gleason score and number of PCa-positive lymph nodes.  
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4. 2. VII. Stratification of TCGA samples based on miR-21 and miR-210 expression improves the 
ability of Gleason score to predict PCa remission 
Taken together, the above data indicates that like miR-210, miR-21 is probably a hypoxia-regulated miRNA 
with oncogenic properties. Therefore, levels of these miRNAs could have clinical value as markers of 
hypoxia and/or cancer progression. To determine if the levels of these “hypoxamiRs” together in 
combination with Gleason score for each individual patient, might predict their response to therapy, we 
performed a decision tree and random forest analysis (using code designed by colleague Christopher 
McNally). The TCGA data was mined using Regulome Explorer to collect the expression level of miR-21 and 
miR-210, as well as the Gleason score, and remission response (re-grouped as complete or incomplete) for 
each patient (n=330). Alone, neither miRNA was able to predict the patient’s response, however, the 
combination of both miRNAs improved the ability of Gleason score to predict complete remission. An 
individual decision tree is illustrated in Figure 13A. The random forest model, which is based on 500 
decision trees, was capable of predicting complete remission with over 90% accuracy, 100% specificity, and 
50% sensitivity (p<0.001) (Figure 13B).  
This model indicates that including quantification of miR-21 and miR-210 with Gleason grading at biopsy 
would be superior to Gleason score alone and therefore this model could have clinical value. Since my data 
suggest both of the miRNAs are hypoxamiRs in PCa, their levels may reflect tumour hypoxia and could be 
used to help distinguish a subset of tumours that are intrinsically more aggressive and/or more difficult to 








Figure 13. Combining miR-21 and miR-210 levels with recorded Gleason Score increases accurate prediction of 
complete remission response to therapy. A) Decision tree visualisation of the combination of miR-21 and miR-210 
levels to Gleason Score and prediction of complete (1) or non-complete (0) remission response after therapy, with 
number of patients / total in this group and as the % of the total cohort. B) Random forest based on 500 decision trees 











4. 3. I. Summary of findings  
The literature is replete with studies attributing miR-21 diagnostic or prognostic potential in various cancer 
settings. A link between miR-21 and hypoxia is emerging although it has not been confirmed in PCa. The 
work in this chapter present novel data to show that miR-21 expression is upregulated by hypoxia in PCa. 
Furthermore, the biological effects of this up-regulation were assessed, to show how it could contribute to 
tumour progression by regulating cell migration and clonogenicity. Moreover, a simple statistical model, 
based on miR-210, miR-21 and Gleason score for each patient, was able to predict response to treatment 
with over 90% accuracy in the PRAD dataset. Increasingly, clinicians are making use of personalised 
medicine and bioinformatics-based approaches such as these in order to best diagnose, prognose, and 
treat each patient, and the efficacy of this model highlights the importance of in vitro identification of 
miRNAs involved in disease and the integration of in vitro findings with bioinformatics.  
Intriguingly, miR-21 was upregulated in the sera of bicalutamide-treated mice, which suggests that it could 
additionally prove useful as a circulating marker of hypoxia. Circulating biomarkers are particularly valuable 
since they are less invasive, and can be used for longitudinal measurement during routine blood sampling 
and could be used to monitor disease progression or response to treatment, whereas biopsies provide only 
a snapshot at diagnosis. In fact, studies of other tissue types have reported that miR-21 was detected in 
exosomes, in correlation with the degree of stress including hypoxia (Eismann et al., 2017)(Li et al., 2019). 
Furthermore, transfer of the secreted fluid or exosomes to other cells (including immune cells) induced 
behaviours associated with cancer progression, such as proliferation and migration (Ren et al., 
2019)(Tejchman et al., 2017). Similarly, hypoxic culture of glioblastoma cells stimulated the release of 
exosomes with a distinct miRNA expression profile (including increased levels of miR-21), which could 
modulate immune cell function when applied to them. Myeloid-derived suppressor cells, a regulatory 
immune cell type with a dampening effect on T cell activity, became enhanced and multiplied upon 
application of these exosomes that had been derived from hypoxic glioblastoma cells (Guo et al., 2018). 
Taken together these findings indicate that miR-21 could be an important mediator of paracrine signalling 
during the hypoxic response in PCa as well as other cell types. However, the promiscuity of miR-21’s activity 
in numerous signalling pathways bodes caution for its use as a marker of hypoxia. MiR-21 was involved in 
the pathogenesis of inflammatory diseases and autoimmune diseases including multiple sclerosis, systemic 
lupus erythematosus, and type 1 diabetes (Husakova, 2016; Sanders et al., 2016; Sekar et al., 2016; Zhao 
and Shao, 2016). It was also overexpressed during asthma, chronic obstructive pulmonary disease (COPD), 
fibrosis, and regulates infection by viruses such as herpesvirus and retrovirus (Kim et al., 2017; Bernier and 
Sagan, 2018; Zeng et al., 2018)(Wang et al., 2018). Therefore, it may be useful as part of a hypoxic-signature 
panel but not specific enough for use alone.  
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The effect of miR-21 expression on PCa cell functionality has been disputed.  Some studies reported that it 
exerted growth-promoting effects while others found it to have no effect. My experiments suggested that 
miR-21 increased migration and clonogenicity in RWPE-1 but did not affect cell proliferation, at least, not 
when overexpressed alone, in a cell line, and at these time points, although it cannot be ruled out that it 
could exert longer-term effects through the regulation of its targets. Furthermore, screening of potential 
mRNA targets identified Rho GTPase B (RhoB, also known as Ras homolog family member B), as 
downregulated by miR-21 overexpression. RhoB was one of a candidate list of targets that were chosen 
due to their reported tumour-suppressive functions in PCa and an involvement in the hypoxic response.  
RHOB expression inversely correlated with tumour aggressiveness in the TCGA data, indicating that it has 
tumour-suppressive effects in PCa. As will now be discussed, RhoB has been attributed both oncogenic and 
tumour suppressive effects in different tumour types, although it has scarcely been explored in PCa. One 
study reported that RhoB increased migration and MMP1 expression in DU145 (Yoneda et al., 2010), but 
otherwise it has not been investigated.  
RhoB is a Rho GTPase, which are a family of signalling proteins. They are small guanine nucleotide binding 
proteins, which are inactive while bound to GDP and become active when bound to GTP. They have intrinsic 
(although inefficient) GTPase activity meaning that they are active until they have catalysed GTP hydrolysis 
to GDP. GTPases are activated by guanine exchange factors (GEFs) that convert the bound GDP to GTP, and 
inactivated by GTPase-activating proteins (GAPs) that stimulate their GTPase activity. Rho GTPases are 
mainly localised to the plasma membrane and participate in G protein receptor signalling. Activated Rho 
GTPases bind to a variety of downstream effectors and regulate cell migration, invasion, cell division, 
wound healing, and actin reorganisation, among other pathways and therefore they are important 
mediators of diverse processes. There are many forms of RhoGTPase although three are closely related: 
RhoA, RhoB, and RhoC. RhoB is a small protein (22KDa) encoded by a single exon; it is thought to have 
arisen by reverse copy integration of RhoA (Vega and Ridley, 2018). Interestingly, although they share over 
87% sequence identity, the function of RhoB is distinct and in many ways elusive (Ju and Gilkes, 2018). All 
three proteins are regulated by posttranslational modifications (PTMs), mostly by the addition of a lipid 
group to the C-terminal domain such as a farnesyl and geranylgeranyl (RhoB can also be palmitolated) or 
phosphorylation, and the PRK family of kinases have higher affinity for RhoB than RhoA and RhoC. The 
PTMs regulate their cellular localisation and their interactions with the plasma membrane and with 
downstream effectors; the differences in PTMs likely underlies the distinct activities of RhoB. While RhoA 
and RhoC were only detected at the plasma membrane, RhoB was also found in endosomes, multivesicular 
bodies, and in the nucleus. Due to the differences in cell localisation, RhoB could be exposed to different 
downstream effectors as well as different GAPs and GEFs, and this could allow it to participate in different 
pathways (Ridley, 2013)(Vega and Ridley, 2018).  
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Due to their role in growth factor signalling, the Rho GTPases have been investigated as a potential cancer 
treatment targets. RHOB knockout is not embryonic lethal, indicating that its function is not essential for 
development (although its knockout was associated with neurological impairments); nevertheless it is 
considered important for healthy cell integrity and development, as indicated by the defects that are 
observed in RhoB expression levels in various cancers. Initial experiments reported that RhoB was an 
oncogene because it was upregulated in response to growth factors and cytokines. However, it has since 
been confirmed to have tumour-suppressive effects. In fact, oncogenes such as Ras, Akt, and EGFR all 
downregulate RHOB at both the transcriptional and mRNA level, and immunohistochemistry experiments 
demonstrated that RhoB protein levels are reduced in solid tumours. Furthermore, its knockout is 
associated with increased propensity for carcinogenesis (Huang and Prendergast, 2006; Vega and Ridley, 
2018). Early research showed that RhoB was involved in mediating apoptosis and was important for stress 
responses (Prendergast, 2001). This is particularly important during the response to UV or DNA damage; 
for example, RhoB-deficient cells cannot perform homologous recombination following DNA damage, 
which was linked to an impaired de-phosphorylation of histone γH2AX by phosphatase PP2A. DNA damage 
also drives Akt and Chk1 signalling that downregulates RhoB expression (Wang et al., 2014a). It has long 
been known that farnesyltransferase inhibitors, a widely used chemotherapeutic agent, act by causing an 
accumulation of geranylgeranylated RhoB which inhibits proliferation (Mazières et al., 2005). RHOB 
expression is epigenetically upregulated by histone acetylation and histone deacetylase-1 (HDAC1) 
suppresses RHOB expression to the extent that HDAC inhibitors effectively reduce tumours when used in 
combination with paclitaxel, by inducing RHOB expression (Marlow et al., 2015). It is also important to note 
that the specific localisation of RhoB to endosomes permits it to regulate the trafficking and recycling of 
numerous proteins, such as the oncogenic intracellular kinases Src and Akt, and the oncogenic receptors 
EGFR and CXCR2, which have been co-localised with RhoB in endosomes of varying stages (Vega and Ridley, 
2018). Therefore, insufficient levels of RhoB could result in the accumulation of these oncogenes. Since the 
continued proliferation and suppression of apoptosis in the presence of DNA damage is a hallmark of 
cancer cells, the downregulation of RHOB could be one means of facilitating cancer cell survival in this 
context.  
Another reason that RhoB is interesting as a target of miR-21, is its involvement in hypoxia, inflammation 
and vasculogenesis. One study used in vitro and in vivo models to show that it regulated TNFα and nitric 
oxide secretion in macrophages, in response to lipopolysaccharide (Wang et al., 2014b). RhoB may be 
important for macrophage morphology, function, and migration; it was reported to be involved in hypoxia-
activated inflammation (Wang et al., 2013). As previously mentioned, miR-21 is a key player in 
inflammatory signalling and therefore its regulation of RhoB could also be relevant in this context. Perhaps, 
miR-21 secreted by hypoxic tumour cells helps to dampen macrophage activation by targeting RHOB. This 
suggests that the regulation of RhoB by miR-21 could have implications for both PCa cell function and the 
regulation of the tumour microenvironment as a whole. 
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4. 3. II. Future experiments 
4. 3. II. a)  Short term 
To confirm RhoB as a target of miR-21 a Western blot analysis of its reduction at the protein level following 
miR-21 overexpression should be performed, followed by a luciferase reporter assay in a manner similar 
to that shown in Chapter 3 for miR-210 and NCAM1. This has been performed for miR-21 and RHOB in 
colorectal cancer cells (M. Liu et al., 2011) although never in PCa. Alternatively, the cells could be 
transfected with oligonucleotides that bind the miR-21 binding site on RHOB which may prevent the miR-
21 associated reduction in RHOB mRNA levels (miRNA zippers)(Meng et al., 2017). 
The effect of miR-21 on cell invasion could be investigated by coating the Boyden chamber dividing 
membrane with matrigel, which cells must break down in order to reach the serum-containing media. This 
would mimic the ECM and confirm that miR-21 upregulates the expression of enzymes that would allow it 
to extravasate, and has been used in lung cancer models (Kadera et al., 2013). 
It has been reported that in some tissue types, RHOB was induced by hypoxia, such as glioblastoma (Skuli 
et al., 2009)(Skuli et al., 2006), clear cell renal carcinoma (Turcotte, Desrosiers and Béliveau, 2003) and lung 
cancer (Huang et al., 2016). In macrophages, RhoB was essential for their activation (Huang et al., 2017). 
RHOB expression should be measured following hypoxia in PCa to explore whether it is similarly induced, 
in which case its regulation by miR-21 could provide an essential means of negative feedback.  
As an alternative to transient transfection of the miRNA, lenti/retroviral methods of genomic transduction 
could be used. This have been suggested as a more realistic model of miRNA overexpression since the 
expressed levels will be lower and more physiological, and the classic miRNA biogenesis pathway will be 
used to produce them in the cell. This could be useful as there have been concerns that transient 
transfection of precursors induces too high levels of the molecule which a) is not physiological and b) can 
cause large RNA aggregates as observed by Northern blot experiments although this was most associated 
with a 100nM concentration whereas we use 25nM (Jin et al., 2015). However, these genes are already in 
the genome but subject to regulation, and so I do not see a clear benefit of transduction methods. Use of 
a concentration lower than 25nM could be another option, although this concentration has been optimised 
previously by our laboratory for the purpose of exaggerating its effect in order to clearly observe the 
phenotype. Perhaps it would be useful to perform a titration of the miRNA precursor levels, and then 
perform the phenotypic assays again, to pinpoint a level that produces the effect. This could be useful to 
determine the optimal miRNA concentration to transfect while minimises off target effects. It could also 
highlight the effect of increasing miRNA expression as hypoxia would increase.  
4. 3. II. b) Medium term 
To complement the migration assay, some groups used antagomiRs (inhibitors) to show that the inhibition 
of miR-21 prevented cancer-associated behaviours such as colony formation or migration. However, miR-
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21 expression was already reduced in the cancer cell lines compared to RWPE-1 and in the absence of a 
stimulus such as hypoxia, an inhibitor would be unlikely to exert an effect (Báez-Vega et al., 2016)(Li et al., 
2009b). However, use of inhibitors could complement the precursor studies, and would be expected to 
exert the opposite effects, such as increase in RHOB levels, although as previously mentioned in basal 
conditions they may exert no effect, comparable to the control pre-miR-neg. It could be informative to 
compare cell transfected with pre-miR-neg and miR-21 inhibitors following a stress condition such as 
hypoxia or lack of growth factors. If the inhibitor transfected cells were more sensitive to cell death 
following the stress condition, it would highlight a role for miR-21 in suppressing cell death. It is also worth 
noting that future therapies could involve using miR-21 inhibitors to reduce the deleterious effects of 
tumour hypoxia, and although no miRNA inhibitors have yet entered the clinic such use is imminent (Bardin 
et al., 2018). 
My cell proliferation assay could not isolate an effect of miR-21, although it may yet contribute to the 
regulation of proliferation but require the context of other miRNAs or genes. It would be interesting to 
perform co-transfection of miR-21 and miR-210 to examine if the two miRNAs could work together to 
regulate proliferation or suppress apoptosis.   
In order to confirm that RhoB has tumour suppressive effects in PCa, it could be knocked down using an 
siRNA or shRNA based approach, and the phenotypic assays performed to isolate its function. This has 
successfully been used to study RhoB’s function in the endothelial cell barrier (Marcos-Ramiro et al., 2016).  
Additionally, tissue sections from PCa specimens could be stained for RhoB which would indicate its 
abundant or localisation, and could potentially be correlated with Gleason grade or resistance to therapy. 
This has been used to correlate the protein NUP98 with response to treatment in breast cancer (Mullan et 
al., 2019). However, unless extremely different the staining could be difficult to quantify accurately and so 
potentially quantification by mass spectrometry could be more effective.  
Similarly, the exosomes of hypoxic PCa cells could be extracted by centrifugation and analysed for miR-21 
levels, which would confirm that miR-21 is exported during hypoxia as a paracrine mediator. These could 
be applied normoxic macrophages or prostatic epithelial cells and levels of RHOB be measured, to indicate 
if secreted miR-21 could modulate immune cell activation. Numerous studies have screened for exosomal 
miRNAs and performed similar studies, as reviewed in (Zhang et al., 2015).  
Some groups have investigated the regulation of miR-21 expression by DNA methylation in other diseases; 
one group found miR-21 was hypomethylated in papillary thyroid cancer (Ortiz et al., 2018) and it was 
upregulated by hypomethylating agent therapies for myelodysplastic syndromes (Kim et al., 2014). 
Therefore, the regulation of miR-21 expression by DNA methylation of its promoter region could be 
relevant in PCa. This theme is explored in chapter 5.  
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Interestingly, putting the list of miR-21 targets that from the miRTarBase database into DAVID reveals 
functional enrichment of apoptosis associated pathways (Supplementary Table 1). The involvement of miR-
21 in the regulation of apoptosis could be explored using flow cytometry (by dual staining with propidium 
iodide and Annexin V) or caspase 3/9 activity, as has been used by other researchers (Dong et al, 2018). 
Apoptosis could be measured following miR-21 overexpression or inhibition in healthy cells, and cells 
subjected to a stress such as hypoxia or chemotherapy, to determine if miR-21 can inhibit stress-induced 
apoptosis. 
Supplementary Table 1. DAVID Gene Ontology Enrichment of the list of predicted targets of miR-21.  
Functional annotation No. of genes  p-value Benjamini 
Cellular protein modification process 247 5.90E-25 3.90E-21 
Regulation of molecular function 193 1.90E-20 6.50E-17 
Apoptosis process 128 1.70E-15 1.60E-12 
Programmed cell death 133 1.90E-15 1.60E-12 
Regulation of apoptosis process 110 1.90E-15 1.60E-12 
Cell death  136 1.10E-14 5.80E-12 
 
 
4. 3. II. c) Long term 
As previously mentioned, failure to identify an effect of miR-21 on the proliferation of cell lines could reflect 
the cell line environment and its effect may only be evident within the context of the tumour. To explore 
this, nanoparticles could be used to transfect pre-miR-21 into tumours in vivo, and the tumour could be 
monitored for changes such as in growth, metastasis, and resistance to treatment, as has been utilised in 
the study of the miR-200 family (Pecot et al., 2013). 
Cell lines could be transfected with pre-miR-21 or pre-miR-neg, and then analysed by total RNA-
sequencing, as has been performed using transfected kidney cancer cells (Lichawska-Cieslar et al., 2018), 
and the differentially expressed genes analysed by pathway analysis (such as DAVID, or Ingenuity Pathway 
Analysis) as a top-down approach to identifying novel functions of miR-21. 
Given the prominent function of miR-21 in the inflammatory response, it is tempting to speculate that RhoB 
mediates some of its effects, and thus the regulation of RhoB by miR-21 could be important in other disease 
settings such as inflammatory disorders or autoimmune diseases; regulation of RhoB could be tested in cell 
line models of these diseases to confirm this. It also invites the question of whether secreted miR-21 from 
cancer cells could modulate macrophage function via RhoB, to mediate immunosuppression during hypoxic 
conditions. This could be tested by applying the pre-miR-21 mimic to macrophages and monitoring their 
intracellular levels of RhoB to show that the cells import and/or respond to miR-21. This would confirm 
miR-21 as a key mediator of the tumour microenvironment.  
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Kaplan-Meier plots generated using the KM plotter tool (http://kmplot.com/analysis/) revealed that when 
expression of miR-21 was dichotomised into “high” and “low”, high expression was significantly associated 
with reduced survival time in other cancer types (Supplementary Figure 1)(data for PCa was not available). 
The role of miR-21 in these cancer types could be a worthwhile avenue for further research.  
Finally, as we demonstrated in the simple example shown in Figure 13, bioinformatics can be used to 
combine genomic information with clinical parameters for precision medicine based approaches. As 
mentioned previously our model requires validation by testing on further datasets, and other models could 
be explored, such as the use of RHOB levels, or investigating the ability to identify additional parameters 
such as tumour hypoxia. Potentially the expression levels of miRNAs such as miR-21 and miR-210 could be 
added to Gleason grading or another clinical parameter to identify the most hypoxic tumours, which may 
benefit from specific therapies such as oxygen perfusion or a hypoxia-activated prodrug as reviewed in 






Supplementary Figure 1. High expression of miR-21 is significantly associated with reduced survival. In A) breast 
cancer, B) clear cell renal carcinoma, C) liver hepatocellular carcinoma, D) testicular germ cell tumour, E) lung 
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Chapter 5. Identifying novel genes, pathways, and epigenetic changes 
























5. 1. Introduction 
5. 1. I. Omics data in cancer research 
Cancer is a disease based on the accumulation of genetic abnormalities, contributed to by both germline 
mutations that predispose the individual, and somatic mutations that trigger and propel it. Our 
understanding of inherited variants and somatic occurrences that drive cancer have been vastly expanded 
by technological advances in next-generation sequencing (NGS) techniques, which have been used to 
characterise the genomics, epigenomics, and proteomics of diseased states (or predisposed individuals). 
Germline susceptibilities have been uncovered by genome-wide association studies across populations, 
and key somatic mutations in tumours have been characterised by whole-exome sequencing, whole-
genome sequencing, RNA sequencing (RNA-seq), and probe-based arrays such as methylation arrays. Such 
“-omics” studies have thus been a key focus of cancer research for the last 20 years. Furthermore, massive 
international collaborative projects have facilitated the curation and organisation of omics data, such as 
The Cancer Genome Atlas (TCGA) database, which provide publicly available repositories of datasets that 
are hugely powerful in identifying critical genomic alterations. NGS discoveries have thus clarified the 
genetic basis of many cancers and have identified novel drug targets, and have also provided advances in 
stratifying patients, which has been used to improve diagnosis, prognosis, and to inform treatment 
strategies in many diseases. It is therefore an extremely important aspect of cancer research.  
5. 1. II. Aims and hypothesis 
The focus of this thesis is to characterise somatic events that drive PCa progression, namely, the 
dysregulation of miRNAs following hypoxia. The previous chapters have used prior knowledge of miRNAs 
that would make them likely to be involved in PCa hypoxia. This chapter includes genomic and epigenomic 
techniques to offer an unbiased approach to identify novel genetic abnormalities that are involved in 
hypoxia and tumour progression.  
The chapter is split into three parts, which will be presented as mini-papers with Introduction, Results and 
Discussion sections. Part 1 utilises RNA-seq and miRNA-seq to analyse the prostatectomy samples and 
identify a novel hypoxia-regulated miRNA in PCa. Part 2 explores the effect of hypoxia on global DNA 
methylation; the R package “RnBeads” was employed to compare DNA methylation patterns in hypoxic 
tumours using a publicly available dataset from the NCBI Gene Expression Omnibus (GEO) database. Part 
3 applies the in vitro method pyrosequencing to measure the methylation levels of DNA at individual miRNA 
loci in PCa cell lines, to investigate the regulation of their expression by DNA methylation. The overarching 
hypothesis of this chapter is that bioinformatics tools can identify novel differentially expressed and 
differentially methylated genomic loci, to direct wet-lab discoveries.  
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5. 2. Part 1: RNA-sequencing based approach to identifying a novel miRNA involved in 
PCa development 
5. 2. I Introduction 
To explore PCa-associated miRNAs, RNA-sequencing (mRNA-seq and miRNA-seq) was performed on the 
cohort of prostatectomy specimens obtained from Altnagelvin Area Hospital (n=19). The sequencing work 
was performed in collaboration with Biospyder Technologies (CA, USA). As outlined in Methods section 
2.3.I, RNA was extracted from formalin-fixed specimens followed by amplification and sequencing. The 
expression data was normalised using the DESeq2 method (Love, Huber and Anders, 2014), to identify 
differentially expressed mRNAs and miRNAs in the cancer specimens relative to paired non-cancer tissue. 
Next, the regulation of differentially expressed miRNAs by hypoxia was examined followed by in vitro 
functional studies of the effect of miRNA overexpression on behaviours associated with tumour 
progression, and potentially important downstream mRNA targets.  
5. 2. II. Results 
5. 2. II. a) Differentially expressed miRNAs in the prostatectomy cohort 
For RNA-seq transcriptome data, the effect size is estimated by the log2 fold-change (log2FC) value (the 
logarithm in base 2 of the ratio between normalised counts in the test and control conditions). Figure 1 
presents volcano plots of the data, which enable visualisation of each gene in terms of its effect size and 
statistical significance. Genes that are significantly differentially expressed (adjusted p-value < 0.1) are 
highlighted in red.  
Of the screen performed, thirteen miRNAs and 175 mRNAs were differentially expressed (DE) in the tumour 
tissue compared to matched adjacent normal tissue (Table 1). Interestingly, among the 13 miRNAs 
identified were members of the miR-200 family, which our lab and others  had previously shown to be 
important in PCa (Lynch et al., 2016a)(Kumar, Nag and Mandal, 2015). In light of the results from chapters 
3 and 4, it was interesting to note that miR-21 and miR-210 were not DE overall in this small set of samples, 
although miR-21 was upregulated with relatively high significance, whereas miR-210 was downregulated 
with relatively low statistical significance. Plotting the mean+SEM of the miRNA levels in tumour versus 
non-tumour samples showed increased expression of miR-210 and miR-21 in the tumour samples as 
measured by RNAseq, confirming the qPCR results from chapters 3 and 4. A two-tailed t-test indicated that 
that miR-21 levels were significantly upregulated in the tumour samples (Figure 2A-B), which contrasted 
with the statistical test performed by BioSpyder.  
The most significantly DE was miR-23a, and moreover there was limited evidence that its expression 
positively correlated with tumour aggressiveness in the TCGA Regulome Explorer dataset 
(http://explorer.cancerregulome.org/). MiR-23a was increased in tumours of TNM stage T3b vs T4 (-
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log10p=2, R=0.28, n=88), higher in patients whose lymph nodes were examined (-log10p=2.5, R= -0.16, 
n=326), and lower in T1c tumours compared to other stages (-log10p= 2.6, R=-0.19, n=256)  
MiR-30a expression was significantly reduced in the tumour samples. This reflected the TCGA data, in which 
miR-30a negatively correlated with Gleason Score (R=-0.22, -log10p=4.2, n=330), higher in tumours which 
showed complete remission response (-log10p=3.9, n=237), lower in progressive disease (-log10p=3.8, 
n=246), and decreased in tumour pT2c vs pT3b (-log10p=4.5, n=194). This suggested that miR-30a may be 
a tumour suppressor in PCa. 
Therefore, miR-30a and miR-23 were selected for further investigation as potential hypoxamiRs. 
Furthermore, since primers were available in our stocks for miR-146a and miR-196a, these were also 



















Figure 1. Volcano plots of RNA-seq and miRNA-seq data, generated using RStudio software (version 3.5). Volcano 
(scatter) plots of the A) genes and B) miRNAs, illustrating the significantly differentially expressed genes in red 
(adjusted p-value >0.1), with upregulated genes in orange, significantly so in green. 
 
Table 1. Differentially expressed miRNAs after DESeq2 normalisation. Padj: adjusted p value.  
Rank  Gene name log2FoldChange pvalue padj 
1 miR-23a 1.589327206 7.80E-08 7.72E-06 
2 hsa-miR-146a-5p 1.160470593 2.03E-06 0.000101 
3 hsa-miR-200c-3p 0.894925383 7.02E-06 0.000232 
4 hsa-mir-664 0.969208828 0.00045 0.011141 
5 hsa-miR-17-5p 2.328991692 0.001485 0.02563 
6 hsa-miR-200a-3p 0.535626255 0.001807 0.02563 
7 hsa-miR-30a-5p -0.251709487 0.002071 0.02563 
8 miR-4539 1.560949137 0.001862 0.02563 
9 hsa-miR-200b-3p 0.419178352 0.002571 0.025827 
10 miR-200c 1.008562632 0.002609 0.025827 
11 hsa-let-7c-5p 0.585124726 0.003686 0.033175 
12 hsa-miR-221-3p -0.63918125 0.00432 0.035643 
13 hsa-miR-196a-5p 1.284004995 0.005683 0.043275 
 -------------------- ------------------- -------------- ------------ 
20 hsa-miR-21-5p 0.550821518 0.075228 0.334625 





5. 2. II. b) The effect of hypoxia on the differentially expressed miRNAs 
In order to determine if the DE miRNAs were also involved in the hypoxic response, their expression level 
was measured in PCa cell lines following 24h hypoxic culture relative to normoxia, by RT-qPCR.  
The melt curves were inspected to confirm robust expression in the cell lines, and at this point miR-23a 
was excluded from the investigations since multiple peaks were observed, indicating poor primer specificity 
for the sequence. However, miR-146a, miR-196a, and miR-30a were all detected in at least one cell line. 
MiR-30a, despite being expected to have tumour-suppressive functions based on the biopsy and TCGA 
data, was increased by hypoxia, and miR-146a was slightly induced by hypoxia at 24h but no further by 48h 
suggesting it was not regulated by hypoxia in a linear fashion (data not shown). 
MiR-196a was upregulated by 24h hypoxia in PC3 and more so by 48h in 22Rv1 in a linear fashion. 
Moreover, PubMed searches revealed that miR-196a has never previously been implicated in PCa, yet gene 
ontology (GO) analysis of the predicted mRNA targets of miR-196a using the online tool DAVID v6.8 
revealed significant functional enrichment of cancer-related pathways including prostate cancer (Figure 2). 
Therefore, miR-196a was considered a potentially novel hypoxamiR of interest in PCa, and was selected for 




















Figure 2. MiR-196a implicated as a novel hypoxamiR with important functions in PCa. A) Comparison of 
normalised expression levels of miR-210, miR-21, and miR-196a in non-tumour and tumour samples. Results of 
two-way two-tailed t-tests comparing tumour with non-tumour samples’ normalised expression level: miR-196a 
p=0.216, miR-21 p=0.004, miR-210 p=0.206. B) Log2 scaled version of the graph for greater clarity. C) RT-qPCR 
detection of miR-196a in prostate cell lines. D) MiR-196a upregulated by 24h hypoxia (0.1% O2) relative to 
normoxia (20% O2). E) MiR-196a upregulated by 24h hypoxia in 22Rv1 and significantly by 48h. F) DAVID gene 
ontology analysis of the list of predicted mRNA targets of miR-196a reveals enrichment of cancer-related 
functions. The mean + SEM is shown. One-way t-tests were used to compare condition means to the control 
(hypothetical value 100) and p-values considered significant when *p<0.05, **p<0.01, ***p<0.001.  
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5. 2. II. c) Functionality of miR-196a 
To determine if hypoxia-induced miR-196a could contribute to PCa progression, cells were transfected with 
the pre-miR-196a molecule, using lipofectamine as described in Methods section 2.1.I.e. Following 
overexpression, phenotypic assays were used to evaluate its effect on cell function (XTT assay, colony 
forming assay, and Boyden chamber migration assay, as described in Methods section 2.1.III). However, 
the phenotypic assays revealed no consistent effect on cell proliferation, colony forming ability, or 
migration. Across the cell lines PC3, 22Rv1, and LNCaP, replicates were highly varied and the effects 
appeared to depend on the cell lines used, for instance miR-196a increased colony forming ability in 22Rv1 
yet reduced it in PC3 and RWPE-1 (data not shown).  
The DAVID analysis as well as Pubmed searching was used to identify a panel of specific genes considered 
to have tumour suppressive functions, or an involvement in hypoxic signalling. Three of these were 
detectable in the cell line 22Rv1 (PRUNE2, FOXO1, and BACH1) but none of these were significantly reduced 
at the mRNA level following transfection with pre-miR-196a based on three biological replicates (data not 
shown). 
Therefore, the in vitro experiments suggested that miR-196a overexpression alone did not consistently 
increase proliferation, clonogenicity, nor migration in PCa cell lines. Furthermore, investigation of several 
proposed mRNA targets did not reveal targeting of known tumour suppressors. This could mean that miR-
196a does not have a driving role in PCa disease progression. Instead, miR-196a could have been 
overexpressed in a “passenger” type effect (due to the activity of a more important upstream regulator) 
rather than a driver. Alternatively, miR-196a could have been upregulated in non-epithelial cell types in 
the tumours and contributing to their phenotypes which indirectly leads to tumour development, for 
instance, affecting the integrity of stromal or immune cells.   
However, it is important to note the limitations of these assays in determining oncogenic effect, as they 
cover relatively few behaviours and it is possible that the miRNA exerts an oncogenic only when 
dysregulated in combination with other miRNAs, or dependent on another feature of the tumour 
microenvironment. Therefore, to investigate further the potential influence of miR-196a on the tumour 
samples, the RNA-seq and miRNA-seq data was probed further by pathway analysis.  
 
5. 2. II. d) Ingenuity Pathway Analysis (IPA) analysis of the sequencing data 
The program Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics) was used to explore potential 
networks related to miR-196a to attempt to identify novel pathways or regulators in PCa 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/). Pathway analysis is an 
effective means of probing omics data to identify the biological causes of the observed changes in gene 
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expression. Furthermore, the mRNA-seq and miRNA-seq data was integrated to identify novel mRNA : 
miRNA pairs.  
IPA is a highly sophisticated software that is suitable for most forms of omics data, and what sets it apart 
from tools like DAVID is that it takes into consideration the direction and magnitude of each gene’s 
expression, as well as the statistical significance. IPA enables visualisation of the DE genes, and has 
extensive annotations such as localisation in the cell, type of molecule (i.e., enzyme, receptor, transcription 
factor), and biomarker applications. It has a rigorously curated functional database, including miRNA : 
mRNA sequence predictions and disease signalling annotations.  
The network and upstream regulator analyses did not highlight any novel pathways, only already 
characterised regulators such as Myc signalling. However, the integrative analysis of the miRNA-seq and 
mRNA-seq data revealed that several predicted mRNA targets of miR-196a were significantly inversely 
correlated. A network was built containing miR-196a and its inversely DE targets, highlighting those 
previously implicated in PCa, and linked with Apoptosis signalling (Figure 9) and angiogenesis (since hypoxia 
was not an option) (Supplementary Figure 3). This analysis suggests that the targets such as COL15A1 could 
be interesting future targets to analyse, it is involved with PCa, or TRAF6 which is involved in apoptosis 
signalling, or IGFBP3, which has been linked to both PCa and angiogenesis. None of these have previously 
been validated as targets of miR-196a in PCa. Therefore, the oncogenic effects of miR-196a could be linked 
























Figure 9. Integrative Analysis of mRNA-seq and miRNA-seq data using IPA reveals numerous predicted mRNA targets 
of miR-196a with significant inverse expression correlation. MiR-196a was significantly upregulated in the miRNA-
seq dataset, the other proteins represent mRNAs with seed-binding complementarity that were significantly 
downregulated in the mRNA-seq data. Pathway overlay with “prostate carcinoma” disease used to highlight molecules 
previously implicated in PCa (molecules highlighted in purple). Pathway build with “Apoptosis” function used to 
illustrate the molecules known to be implicated in apoptosis (connected by purple arrows in the direction of 
regulation, dashed lines indicate indirect regulation, full lines indicate direct). The shape of each icon identifies the 
type of molecule, as coded in the legend.  
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5. 2. III. Discussion  
5. 2. III. a) Summary 
This study utilised an RNA-seq approach to characterise a cohort of prostate biopsy samples. The approach 
has several strengths, such as an unbiased identification of DE molecules. Furthermore, we utilised the 
DESeq2 method for normalisation, which is a Bayesian approach that improves on several problems caused 
by the standard log fold change analysis. These are: that small changes that are statistically highly 
significant but biologically unimportant are weighted too heavily, that the number of significantly 
differentially expressed genes that are identified is affected by the number of samples being compared, 
and that the ranking by fold change is sensitive to noise from low counting genes (based on the base mean) 
(Love, Huber and Anders, 2014). Therefore, because the DESeq2 method is highly stringent it produces a 
much shorter list of significant genes than standard methods, although these changes are more likely to be 
biologically relevant. Indeed, our results were similar to TCGA data, confirming its reliability.  
5. 2. III. b) Future directions  
The RNA-seq analysis highlighted miR-196a as one of several DE miRNAs, for the first time in PCa. 
Furthermore it was upregulated by hypoxia as has previously been reported in liver cancer (Hu et al., 2018). 
Several of the targets of miR-196a are involved in the regulation of the cell cycle and other cancers, 
suggesting an effect on cancer progression. However, preliminary in vitro overexpression and functional 
studies failed to isolate a growth-promoting effect of miR-196a in PCa cell lines. Future investigations could 
perform these phenotypic assays using more replicates which may clarify an effect. However, these assays 
are limited in that they can only measure one aspect of cell behaviour, and a very drastic effect must be 
elicited for the cells to behave significantly differently. Additionally, the activity of miR-196a could depend 
on other miRNAs or genes that are modulated in the context of the tumour but absent from this model. 
Therefore, it may be best to focus on a different feature of carcinogenesis, such as regulation of apoptosis, 
to determine how miR-196a may contribute to PCa development. MiR-196a’s involvement in apoptosis 
signalling could be investigated experimentally by methods similar to those suggested for miR-21 in chapter 
4 section (4.3.II).   
Another benefit of the RNA-seq approach was the large amount of data that was provided. I chose to 
investigate miR-196a, although there are numerous other miRNAs that were DE and may be interesting to 
focus on for further research. Pathway analysis using IPA was used to integrate the miRNA-seq and mRNA-
seq data and highlighted inversely DE mRNA: miRNA target pairs, of which some mRNAs are known 
regulators of apoptosis or angiogenesis, but have never been validated experimentally as targets in PCa. 
These could be explored in the manner shown in chapter 3, using RT-qPCR and Western blot to initially 
monitor the effect on the target levels, followed by luciferase reporter assay. Alterantively, an unbiased 
approache to miRNA taret identification could be used, such as CLASH (crosslinking ligation and sequencing 
of hybrids), which involves crosslinking miRNAs to their targets in vitro or in vivo, followed by 
immunoprecipitation of the miRNA and sequencing, to identify novel targets (Helwak and Tollervey, 2014). 
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Another option for future research would be to obtain samples of benign prostatic hyperplasia (BPH) tissue, 
which as mentioned in General Introduction section 1.1. V., is non-cancerous but often mistaken for PCa 
during screening. Identifying DE miRNAs or mRNAs in the PCa samples relative to BPH could help identify 
the most important miRNAs contributing to PCa development, and could be useful additions to screening 
panels to distinguish the cancer cases.  
Finally, it is important to acknowledge that this is a relatively small sample size, and a large number of 
samples would presumably be more powerful. The study could be replicated on a larger population, or 
perhaps including more aggressive, metastatic, or therapy-resistant tumours. However, this was useful as 
an exploratory pilot project, to illustrate the potential of the approach. Overall, the use of RNA-seq to 



















5. 3. Part 2:  The effect of hypoxia on global and regional methylation as measured by 
methylation array 
5. 3. I. Introduction 
As mentioned in the General Introduction section 1.1. VII., gene expression is regulated by epigenetic 
modifications, of which the most widely studied is DNA methylation on cytosine residues. Certain tumour-
suppressors have been reported to be silenced in PCa due to hypermethylation of the promoter region, 
such as GSTP1, which has been thoroughly examined as a methylation-based biomarker for PCa in tissues 
and liquids and can be detected by methylation specific PCR (Martignano et al., 2016). MiRNA expression 
is also governed by DNA methylation in PCa, for instance miR-200c and miR-141 (Lynch et al., 2016b). 
However, to the best of my knowledge the regulation of miRNA expression by DNA methylation during 
hypoxia in PCa has never been investigated.  
A previous project from our laboratory showed that in the prostatectomy cohort, the expression of miR-
200c and miR-141 was regulated by DNA methylation, using the wet-lab technique pyrosequencing (Lynch 
et al., 2016b). However, the use of this method proved laborious across the many samples. A powerful 
method of assessing genome-wide changes in DNA methylation is by methylation array, in which probes 
specific to the methylated and unmethylated forms of DNA at specific CpGs are used to quantify 
methylation. Several methylation arrays have been developed, such as the Illumina Infinium Human DNA 
Methylation 27k, 450k and 850k (EPIC) arrays, which contain approximately the respective number of 
probes covering the genome (Stirzaker et al., 2014).  
To explore the effect of hypoxia on genome-wide DNA methylation changes, the NCBI Gene Expression 
Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) was searched in order to obtain a publicly 
available dataset of hypoxic and normoxic cancer samples. Unfortunately, there were no methylation array 
datasets available including hypoxic PCa cell lines or tumours, which highlights that this is an understudied 
area. 
However, a dataset was found containing the DNA methylation and hydroxymethylation profiles of non-
small cell lung cancer (NSCLC) tumours, obtained using the Illumina Infinium 450k array from DNA extracted 
from fresh-frozen tumour samples (GEO identifier: GSE71403)(Thienpont et al., 2016). The tumours had 
been classed as hypoxic or normoxic based on an established hypoxic gene signature (Buffa et al., 2010). 
In the absence of a suitable PCa dataset, this data was selected to illustrate a proof-of-principle approach 
to the exploration of hypoxia-related genetic datasets.   
Levels of DNA methylation (5mc) had been measured by BeadChip v1.2 Array and hydroxymethylation 
(5hmc, its oxidative product representing demethylated cytosine) by TAB-Chip array. The authors described 
a global reduction in 5hmc in the hypoxic tumour samples, and confirmed that it was due to reduced 
activity of the TET enzymes that catalyse DNA demethylation, indicating that they are oxygen-dependent 
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(which they subsequently validated by wet-lab methods). However, the authors had not reported the 
effects of hypoxia on 5mc levels in the manuscript. 
5. 3. II. Results  
5. 3. II. a) Download and preview of a publicly-available dataset 
The dataset was downloaded from GEO using RStudio v3.5 and the TAB-chip data was removed from the 
BeadChip data using the ‘remove samples’ function. The data was visually inspected by box and whisker 
plot, which suggested that it may contain an outlier (sample 14, Figure 11, later removed). The β-value 
reports the ratio of intensities between methylated and unmethylated alleles, where a β=0 value means 
the sites were invariably unmethylated on all fragments assayed, and β=1 where the sites were fully 
methylated.  
Next, the RnBeads package and Ghostscript interpreter software were downloaded for Exploratory and 
Differential analyses (Assenov et al., 2014), which has previously been used successfully to characterise 
genome-wide methylation profiles (see Methods section 2. 4. III.)(Mackin, O’Neill and Walsh, 2018a)(Irwin 
et al., 2019). The Exploratory analysis enables visualisation of overall difference in methylation level 
between the conditions and by type of genomic region (such as at CpG islands, as described General 
Introduction section 1.1. VII.). The Differential analysis quantifies the difference in methylation at each 
probe between the conditions, and maps the differentially methylated CpGs to specific genomic regions, 
























Figure 11. Box and whisker display of methylation distribution per sample in the NSCLC dataset (GEO identifier: 
GSE71403). Samples 1-12 represent the hypoxic tumours and 13-24 the normoxic tumours, as pre-determined by the 
authors using a hypoxia metagene score. The whiskers depicts the minimum and maximum methylation values in the 
sample and the box depicts the median with first and third quartile (interquartile range). The data was from the 
BeadChip 450k human methylation array, which measures 5mc (methylation) levels, provided as the β-level which 
reports ratio of intensities between unmethylated and methylated alleles, where 0 is unmethylated and 1 fully 
methylated. Y-axis: methylation β level, x-axis: patient sample. The graph reveals abnormal methylation levels in 
sample 14 which could be an outlier. Colours: rainbow pattern, not corresponding to any sample characteristic. Welch 




5. 3. II. b) RnBeads Exploratory Analysis 
5. 3. II. b) i) Multivariate analysis 
First, multidimensional scaling (MDS) and principal component analysis (PCA) methods were used to 
inspect the dataset for clustering of the methylation profiles. These are methods of “dimension reduction” 
and involve mapping the data to a lower dimensional space which maximises (and allows visualisation of) 
the most evident source of variance between them (Li, 2010). PCA and MDS differ based on their input; the 
PCA input is the original vectors in n-dimensional space with the data projected in the direction with the 
most variance (i.e., based on the angles between vectors), which roughly maintains the spread of data and 
is best for large datasets. The MDS input is the pairwise distances between points (i.e. based on distances 
between points) transformed into 2-dimensional space, which preserves the distance between points and 
thus better represents their multivariate dissimilarity (Lacher and O’donnell, 1988). Both of these 
approaches produced a faint clustering of the normoxic samples compared with hypoxic at the second PCA 
component, with the exception of one (hypoxic sample number 7) which clustered with the normoxic 
(Figure 12). This indicated that the normoxic and hypoxic samples had distinct relatedness based on their 
methylation profiles. At this point, the outlier sample 14 had been removed using RStudio (remove 
function), as it had indeed appeared to be skewing the data as evident by dimension reduction 




Figure 12. Principal component analysis (PCA) and multidimensional scaling (MDS) methods of dimension reduction.  
Sample 14 has been excluded. Euclidean distance used as a dissimilarity metric. Each point represents a sample, colour and 
shape distinguish hypoxic status where green circles are tumours classed as hypoxic and orange triangles normoxic. A) MDS 
applied to the dataset reveals clustering of the hypoxic samples with the exception of one (identifier: sample 7). B) PCA 
applied to the dataset similarly segregates hypoxic samples, with the exception of one sample (identifier: sample 7).  
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5. 3. II. b) ii) Methylation value distributions 
The multivariate analysis indicated variance between the methylation profiles of the hypoxic and normoxic 
data. To compare their overall methylation levels, methylation density plots were used to quantify the 
densities of probes with high and low methylation values. The data was separated based on 4 types of 
genomic regions covered: promoter regions, genes, CpG islands, and tiling (units of approximately 5000 
base pairs). Interestingly, the methylation density plots revealed global hypomethylation of the hypoxic 
data compared with normoxic data. Figure 13 illustrates the reduced density of highly methylated probes 
(indicating hypomethylation) across total probes, tiling regions, and promoter and gene regions in the 





Figure 13. Methylation Value Densities by Hypoxic Status. Y-axis represents the density of probes detected 
corresponding to the degree of methylation status (x-axis).  Hypoxic data is represented by the green lines, normoxic 
by the orange lines. A) Methylation densities across all probes, showing slightly higher densities of lowly methylated 
probes and a lower density of highly methylated probes in the hypoxic data, suggesting global hypomethylation due 
to hypoxia. B) Hypomethylation of tiling regions (genomic units) in hypoxic samples compared with normoxic. C) 
Hypomethylation of gene regions in hypoxic samples compared with normoxic. D) Hypomethylation of promoter 
regions in hypoxic samples compared with normoxic. E) Very slight hypomethylation of CpG islands in the hypoxic 
samples compared with normoxic samples.  
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5. 3. II. c) RnBeads Differential analysis 
Next, a differential analysis was executed, to map DM probes to specific CpGs of the genome and estimate 
the differential methylation at each locus between the conditions (based on the absolute difference in 
methylation and the relative ratio β-value, and the statistical significance). RnBeads ranks differentially 
methylated CpGs across the genome where the first ranked sites are those with highest probability of 
differential methylation. The “combined rank” combines absolute and relative effect size with the p-value 
by statistical modelling to produce a single score.  
Figure 14A depicts the differentially methylated sites across the genome, based on the combined rank, 
with the top 100 highlighted in red. This indicated that while the density of hypomethylated probes had 
been increased in the hypoxic samples, the top ranking DM sites in the hypoxic samples were gains in 
methylation. However, regarding promoter and gene regions, there was a mixture of gains and losses 
although the most significantly DM promoters were gains in methylation which could be associated with 
gene silencing. Figure 14B-C illustrates that at specifically promoters and gene regions (respectively) there 
was a comparable degree of gains and losses in methylation.  
This highlighted that while there was broad losses in methylation across all the probes, the change in 
methylation was regionally specific and site specific, indicating that the regulation of the methylation of 
individual CpGs could be dependent on the type of locus, and thus represent altered activity of epigenetic 






Figure 14. Differentially methylated sites in the hypoxic data relative to normoxic data. The difference in mean β 
value for hypoxic versus normoxic samples by CpG site, the top 100 differentially methylated sites highlighted in red 
according to rank. A) Top 100 combined rank sites (all probes) enriched for gains in methylation. B) Top 100 combined 
rank sites (promoters alone) containing a mixture of gains and losses with slight emphasis on gains, C) Top 100 









5. 3. II. d) Functional analysis of the DM promoters and genes 
Since there were different proportions of gains and losses depending on the type of genomic region, I 
wanted to investigate the functions of the most highly ranked DM sites.  
The lists of DM genes and promoters were downloaded and functional annotation was performed using 
DAVID v6.8, analysing the top 100 ranking DM promoters and genes.  
The top 100 ranking DM genes and promoters (after excluding probes not mapped to a known gene region) 
were split into those representing losses and gains in methylation and functional annotation used to 
identify subsets with similar functions (Tables 2-5). The full functional annotation charts containing 
significantly enriched gene ontologies for promoters and genes with losses and gains in methylation are 
available in Supplementary Tables 1-3. 
Intriguingly, DAVID revealed that the promoters associated with losses in methylation were significantly 
enriched with GO functions “Inflammatory response”, “Signalling”, and “Cell membrane”. These could 
potentially be upregulated if DNA methylation was a mechanism governing expression. Promoters with 
gains in methylation were enriched with the GO functions “homeodomain” and “DNA-binding”. Likewise, 
it is possible that the gains in methylation could here pre-empt gene suppression.  
Interestingly, there was a similar pattern regarding the gene regions, DM sites representing losses in 
methylation were enriched for the GO terms “G-protein coupled receptor activity”, “Inflammatory 
response”, and “Membrane”; while DM sites representing gains in methylation were enriched for 
“Homeodomain/homeobox”, “DNA-binding”, “Positive regulation of transcription from RNA Pol II 
promoter” and “Negative regulation of transcription from RNA Pol II promoter”.  
Finally, the miRNAs alone were analysed. The DM miRNAs from both the DM promoter and DM gene lists 
were extracted and ranked by combined rank, and then stratified by methylation status in hypoxia (hypo 
or hyper-methylated miRNAs). Interestingly, among the top 100 hypomethylated miRNAs was miR-210, 
and miR-205, miR-200c and miR-141, which have previously been shown by our group to be implemental 
in PCa (Lynch et al., 2016b). According to the probes associated with both the miR-21 gene (n=2 sites 
analysed) and promoter (n=7 sites analysed), miR-21 was hypomethylated but was not in the top 100 
combined rank positions. MiR-196a was hypermethylated based on data from both the promoter and gene 
lists.  
The top 100 combined rank hypo- and hyper- DM miRNAs were analysed by DAVID, which highlighted that 
numerous were implicated in the pathway “MicroRNAs in Cancer” although no other pathways were 
enriched (Table 6). 
Overall, the differential analysis and DAVID GO indicated that hypoxia could influence the expression of 
cancer-associated miRNAs via changes in DNA methylation, and affect the epigenetic regulation of genes 
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involved in inflammation, cell signalling, and transcription, and a number of miRNAs including those 
previously implicated in cancers.  
 
Table 2. Functional Annotation of Promoters with losses in methylation in hypoxic samples relative to normoxic. 
From the top 100 combined rank promoters, n=44. 
Inflammatory response Signalling Cell membrane 
complement C3a receptor 1(C3AR1) ADAM metallopeptidase domain 
28(ADAM28) 
ADAM metallopeptidase domain 
28(ADAM28) 
secreted phosphoprotein 1(SPP1) calcitonin receptor like receptor(CALCRL) GRB2 binding adaptor protein, 
transmembrane(GAPT) 
toll like receptor 1(TLR1) cystatin F(CST7) calcitonin receptor like receptor(CALCRL) 
toll like receptor 6(TLR6) ecotropic viral integration site 2B(EVI2B) complement C3a receptor 1(C3AR1) 
 
granzyme A(GZMA) synaptotagmin like 1(SYTL1) 
 
secreted phosphoprotein 1(SPP1) toll like receptor 1(TLR1) 
 
toll like receptor 1(TLR1) toll like receptor 6(TLR6) 
 










Table 3. Functional Annotation of Promoters with gains in methylation in hypoxic data relative to normoxic. From 
the top 100 combined rank promoters, n=56. 
Homeodomain DNA-binding  
NK1 homeobox 1(NKX1-1) NK1 homeobox 1(NKX1-1) 
NK2 homeobox 3(NKX2-3) NK2 homeobox 3(NKX2-3) 
homeobox A11(HOXA11) T-box 1(TBX1) 
homeobox A3(HOXA3) T-box 20(TBX20) 
homeobox B7(HOXB7) T-box 4(TBX4) 
homeobox D9(HOXD9) T-box 5(TBX5) 








iroquois homeobox 2(IRX2) 
 
zinc finger protein 132(ZNF132) 
 





Table 4. Functional Annotation of Genes with Losses in methylation in hypoxic data relative to normoxic. From the 
top 100 combined rank promoters, n=51.   
G-protein coupled receptor activity Inflammatory response Membrane 
olfactory receptor family 4 subfamily C 
member 12(OR4C12) 
CD163 molecule(CD163) CD163 molecule(CD163) 
olfactory receptor family 4 subfamily C 
member 3(OR4C3) 
S100 calcium binding protein A8(S100A8) S100 calcium binding protein A8(S100A8) 
olfactory receptor family 5 subfamily AN 
member 1(OR5AN1) 
pyrin domain containing 2(PYDC2) carcinoembryonic antigen related cell 
adhesion molecule 4(CEACAM4) 




olfactory receptor family 8 subfamily B 
member 12(OR8B12) 
 
glycophorin A (MNS blood group)(GYPA) 
olfactory receptor family 8 subfamily H 
member 2(OR8H2) 
 
myc target 1(MYCT1) 
purinergic receptor P2Y10(P2RY10) 
 
olfactory receptor family 4 subfamily C 
member 12(OR4C12) 
taste 2 receptor member 1(TAS2R1) 
 
olfactory receptor family 4 subfamily C 
member 3(OR4C3) 
  
olfactory receptor family 5 subfamily AN 
member 1(OR5AN1) 
  
olfactory receptor family 51 subfamily A 
member 2(OR51A2) 
  
olfactory receptor family 8 subfamily B 
member 12(OR8B12) 
  
olfactory receptor family 8 subfamily H 
member 2(OR8H2) 
  
purinergic receptor P2Y10(P2RY10) 
  
solute carrier family 9 member A7(SLC9A7) 
  
taste 2 receptor member 1(TAS2R1) 
  

















Table 5. Functional Annotation of Genes with Gains in methylation in hypoxic data relative to normoxic. From the 
top 100 combined rank promoters, n=49.   
Homeodomain, homeobox DNA-binding Positive regulation of 
transcription from RNA Pol II 
promoter 
Negative regulation of 
transcription from RNA Pol II 
promoter 
ISL LIM homeobox 2(ISL2) Fer3 like bHLH transcription 
factor(FERD3L) 
NK2 homeobox 3(NKX2-3) Fer3 like bHLH transcription 
factor(FERD3L) 
NK1 homeobox 2(NKX1-2) ISL LIM homeobox 2(ISL2) achaete-scute family bHLH 
transcription factor 1(ASCL1) 
SRY-box 14(SOX14) 
NK2 homeobox 3(NKX2-3) NK1 homeobox 2(NKX1-2) homeobox D10(HOXD10) achaete-scute family bHLH 
transcription factor 1(ASCL1) 
T-cell leukemia homeobox 
1(TLX1) 
NK2 homeobox 3(NKX2-3) homeobox D9(HOXD9) homeobox D9(HOXD9) 
homeobox B13(HOXB13) SRY-box 14(SOX14) orthodenticle homeobox 
2(OTX2) 
 
homeobox D10(HOXD10) T-cell leukemia homeobox 
1(TLX1) 
paired box 7(PAX7) 
 
homeobox D9(HOXD9) achaete-scute family bHLH 
transcription factor 1(ASCL1) 
  






paired box 7(PAX7) homeobox D9(HOXD9) 
  
 











paired box 7(PAX7) 
  
 
zinc finger protein 132(ZNF132) 
  
 
zinc finger protein 418(ZNF418) 
  
 















Table 6. Analysis of DM miRNAs only. From the list of DM genes and promoters, the miRNAs were extracted, and 
then the top 100 combined rank miRNAs were split by methylation status (hypermethylated (italicised) and 
hypomethylated). Those highlighted by DAVID as involved in the KEGG pathway “microRNAs in Cancer” are highlighted 
in bold.  
Hypomethylated (from 
promoter list, n=82) 
Hypermethylated (from 
promoter list n=18) 
Hypomethylated (from gene 
list n=70) 
Hypermethylated (from 
gene list n=30) 
miR-4437 miR-4646 miR-205hg miR-184 
miR-4513 miR-5691 miR-128-1 miR-145 
miR-2053 miR-641 miR-382 miR-551a 
miR-4760 miR-125b-1 miR-485 miR-1306 
miR-1298 miR-99b-1 miR-54812 miR-130b 
miR-887 miR-224 miR-1298 miR-1908 
miR-181b-1 miR-452 miR-181a-1 miR-302a 
miR-181a-1 miR-320c-1 miR-214 miR-663a 
miR-718 miR-30d miR-489 miR-let-7f-2 
miR-3714 miR-126 miR-181b-1 miR-542 
miR-214 miR-196a-2 miR-100 miR-503 
miR-770 miR-629 miR-543 miR-503hg 
miR-320d-2 miR-124-2 miR-592 miR-143hg 
miR-653 miR-3170 miR-379 miR-346 
miR-4897 miR-3185 miR-181a-1hg miR-25 
miR-548f-2 miR-3622a;mir3622b-8 miR-139 miR-193a 
miR-205hg miR-let-7a-1 miR-595 miR-3663 















































































Hypomethylated (from promoter 
list, n=82) 
Hypermethylated (from 
promoter list n=18) 
Hypomethylated (from gene 
list n=70) 
Hypermethylated (from 


























































































































   
miR-7-2 
   
miR-567 
   
miR-541 
   
miR-4801 
   
miR-2113 
   
miR-3907 
   
miR-5708 
   
miR-122 
   
miR-4664 
   
miR-3917 
   
miR-5588 




5. 3. III. Discussion  
5. 3. III. a) Summary 
A link between hypoxia and DNA methylation has been emerging, as emphasised by a recent review on the 
effect of hypoxia on epigenetics, which can partly be attributed to the reduced activity of key enzymes such 
as the demethylating TETs, or reduced expression of enzymes such as DNMT1 due to HIF signalling (Camuzi 
et al., 2019). Accordingly, my analysis indicates a profound effect of hypoxia on DNA methylation.  
The initial exploratory analysis suggested that hypoxia was associated with global hypomethylation in this 
NSCLC dataset, with particular hypomethylation of promoters and gene regions while CpG islands were 
largely unaffected. However, this could reflect the natural hypomethylated state of CpG islands (with the 
exception of CpG islands that regulate imprinted regions) which endured little changes while suggesting 
that hypoxia was inducing hypomethylation specifically at regions that regulate somatic gene expression. 
This hypomethylation could be due to a reduction in levels of the methyl donor S-adenosylmethionine, as 
occurred during hypoxia in liver cells (Liu et al., 2011). 
The Differential Analysis was used to identify individual promoters and genes that were differentially 
methylated between the hypoxic and normoxic conditions. The gene ontology analysis revealed that 
hypoxia was associated with hypomethylation of promoters regulating “Inflammatory response”, 
“Signalling”, and “Cell membrane”, and hypermethylation of promoters regulating “homeodomain” and 
“DNA-binding”. Therefore, hypoxia may induce inflammatory signalling or morphological changes via 
hypomethylation, and suppress development-associated transcription via hypermethylation of Hox-genes 
and other transcription factors. The enrichment of inflammatory associated genes was particularly 
intriguing, since cancer cells are known to modulate inflammatory pathways following hypoxia (and indeed 
the two pathways often go hand-in-hand, as outlined in General Introduction section 1.2. II), although very 
few studies have linked this to changes in DNA methylation. One similar report comes from a group 
studying systemic hypoxia and cardiovascular disease, who have recently showed that systemic hypoxia in 
antenatal mice was associated with hypomethylation of CGIs and CPG-island shores around the 
transcription start sites of genes involved in inflammatory signalling (Huang et al>, 2019). Taken together 
these findings suggest that hypoxia could regulate inflammation via DNA methylation, in a conserved 
mechanism that is not specific to the cancer state. Likewise, the hypermethylation of HOX gene promoters 
(and others involved in development) suggests that hypoxia may regulate the acquisition of a stem-like 
phenotype through modulation of DNA methylation, which has not been largely explored. One recent study 
showed that demethylation of the CXCR4 promoter occurred following hypoxia in lung cancer cell lines and 
its resulting expression induced EMT (Kang et al., 2019). Although the promoter of CXCR4 was not 
significantly DM in this dataset, my results similarly point towards a regulation of de-differentiation and 
stemness by DNA methylation.  
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Interestingly, analysis of DM gene regions similarly indicated hypomethylation of gene regulating “G-
protein coupled receptor activity”, “Inflammatory response”, and “Membrane” and hypermethylation of 
genes regulating “Homeodomain/homeobox”, “DNA-binding”, “Positive regulation of transcription from 
RNA Pol II promoter” and “Negative regulation of transcription from RNA Pol II promoter”.  
It must be noted that the DM promoter regions may provide a clearer picture than the DM genes, since 
DNA methylation at promoters is more consistently associated with transcriptional repression, whereas 
methylation of gene bodies can have activating or inhibitory effects on expression, depending on the CpG 
(as described in General Introduction section 1.1. VII., gene body CpGs can be used to regulate splicing, 
elongation, or transcription factor recruitment). It nevertheless points towards epigenetic changes 
occurring at these types of genes, perhaps suggesting altered activity of transcriptional regulators that 
govern these subsets of genes. For instance, a chromatin modifying enzyme localised to these genes could 
be influencing higher-order structures that then affects the activity of DNA methyltransferases, or vice 
versa. Therefore, regardless of the effect on transcription, it seems clear that there are profound epigenetic 
alterations occurring at genes involved in development, transcription and inflammation, with a potential 
mixture of activating and silencing methylation patterns that suggests that these pathways are being 
epigenetically modulated and are involved in the hypoxic response. From these results we can conclude 
that there is an epigenetic regulator controlling DNA methylation at these subsets of genes, that is 
somehow responsive to hypoxia.  
5. 3. III. b) Future directions 
It would be important to investigate if the expression of these genes correlates with the changes in 
methylation, by integrating the methylation array data with an expression analysis such as RNA-seq or RT-
qPCR. An another interesting future experiment could be to determine what the overall effect on pathway 
activation would be using IPA (which I unfortunately could not achieve since I had been using the free trial 
which has limited analyses). Perhaps the top 100 combined rank promoters and genes could be analysed 
(without considering the degree of hypo/hyper methylation) although on such a small number, the results 
may not be particularly powerful or informative. Alternatively, one could input the mean.diff (absolute 
difference in methylation between conditions) of the top 1000 combined rank. To do this, the mean.diff 
signs (i.e. positive and negative for hyper and hypomethylation respectively) should be reversed so that a 
positive mean.diff could be used to approximate reduced expression. This would be based on the 
assumption that hyper and hypo-methylation associate with down and up-regulation of expression. It could 
nevertheless be useful for network and pathway analysis.   
To explore whether hypomethylation is important for inflammatory gene activation, inflammation 
signalling could be activated by treating the cells with stimulants such as lipopolysaccharide or IFN-γ, to 
upregulate inflammation signalling as has previously been published (Kämpfer et al., 2017). If this is also 
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associated with hypomethylation, it could support the regulation of inflammation by DNA methylation and 
indicate how hypoxia helps subvert immune surveillance. 
To monitor the activity of these pathways, methylation could be monitored across a time course. Since in 
this dataset, the key genes affected were HOX/inflammatory, these could be specifically investigated on a 
smaller scale than whole-genome array, by wet-lab techniques such as methylation specific PCR, COBRA, 
or Pyrosequencing. To monitor methylation changes with increasing hypoxia or increasing time spent in 
hypoxia, a hypoxic chamber could be used and DNA extracted over short time points to measure the 
methylation of specific genes over time, combined with expression analysis.  
To explore potential epigenetic regulators, a list of HIF-1a response genes could be compiled, and those 
involved in chromatin regulation be assessed. Then, ChIP or ChIP-seq could be used to discover if they 
localise to the DM sites.  
There were no methylation array datasets from hypoxic PCa cell lines or tumours available on the GEO 
database, reflecting the lack of study in the area, and so a similar experiment could be performed to create 
a PCa dataset.   
Finally, the key DM genes such as the HOX genes or inflammatory genes could be explored in hypoxia across 
a number of different cancer types, using the previously mentioned wet-lab techniques. An illustration of 















5. 4. Part 3: Regulation of miRNA expression by DNA methylation in prostate cancer 
5. 4. I. Introduction 
In vitro methylation analysis has been an essential tool for investigating the methylation status of individual 
loci, as it is quicker and more cost-effective than whole-genome array. It has been successfully used to 
analyse imprinted regions (Thakur et al., 2016), monitor changes in methylation status during processes 
such as adipogenesis (Flores et al., 2019), and been used to demonstrate cancer-associated changes in 
methylation (Lynch et al., 2016a). 
Part 2 demonstrated how hypoxia exerted profound effects on the DNA methylation of the genome in 
NSCLC. Interestingly, the miR-210 gene locus was identified as hypomethylated in the hypoxic samples, and 
one of the more statistically significant. MiR-21 was also hypomethylated although not significantly, 
inviting the question of whether hypomethylation of these regions could be a means of inducing their 
expression during hypoxia. However, miR-196a was hypermethylated following hypoxia, which was not in 
keeping with its observed expression level. Interestingly, analysis of the TCGA Regulome Explorer dataset 
revealed that a CpG site in the gene body of the pri-miR-21 gene was significantly inversely correlated with 
its expression (Figure 15). Moreover, as mentioned in chapter 4 discussion section 4.3.II b), DNA 
methylation has been suggested to regulate miR-21 (in thyroid cancer, and myelodysplastic syndromes) 
and miR-210 expression (in schwannoma, gastric cancer, and neural progenitor cells) (Ortiz et al., 
2018)(Kim et al., 2014)(Wang et al., 2017)(Kiga et al., 2014)(Xiong et al., 2012).  
For this reason, Part 3 investigates whether miR-210 and miR-21 expression could be regulated by DNA 
methylation in PCa cell lines. 
 
 
Figure 15. Association between methylation and expression of miR-21 in TCGA data. In the Regulome Explorer 
dataset (n=330), methylation of probe cg15759721 in the gene body of pri-miR-21 was significantly inversely 




A series of pyrosequencing experiments were designed to investigate the transcriptional regulation of miR-
21 and miR-210 expression by DNA methylation. Pyrosequencing is a quantitative in vitro method of 
assessing DNA methylation at specific CpGs (cytosines next to guanines), based on the use of sodium 
bisulfite (hereafter referred to as bisulfite). Bisulfite is a chemical that deaminates unmethylated cytosines 
to uracils by hydrolysis, thus providing a means of distinguishing between methylated and unmethylated 
cytosines (Delaney, Garg and Yung, 2015). Pyrosequencing has been shown to be the most reproducible 
method of DNA methylation quantification (Bock et al., 2016). The Method is outlined in section 2.1.IV.  
 
5. 4. II. Results 
5. 4. II. a) Assay design 
Two CpG islands cover the pri-miR-210 gene (CpG islands 149 and 179). As expected, the region was littered 
with CpGs which made primer design difficult since there were very few regions without CpGs for over 15 
nucleotides (the minimal length of a primer) that would also be suitable as primers due to their sequence 
(size of the amplicon, specificity, CG content, C/G ends, etc). However, 1 pair of primers were successfully 
obtained that amplified a non-CpG island region including 14 CpGs (Figure 16) of which 10 were successfully 
sequenced.  
Fewer CpGs were present around the pri-miR-21 gene, so two regions were assayed each containing 3 CpGs  
(assay 1 and assay 2); assay 1 was upstream of the pri-miR-21 gene and assay 2 downstream. Figure 17 
contains the UCSC depiction of the pri-miR-210 and pri-miR-21 genes, highlighting the regions assayed, and 
including tracks annotating nearby CpG islands and CpG probe identifiers from NGS arrays such as the 






Figure 16. MiR-210 pyrosequencing assay. DNA depicted with CpGs covered by the assay highlighted in relation to 
transcription start site (TSS) of the gene encoding pri-miR-210. The sequence paired against its bisulfite-converted 
form (above and below, respectively) is shown as predicted by MethPrimer software, assuming that all CpGs are 
unmethylated and all cytosines converted to thymine. PCR primers suggested by methprimer are depicted as greater 
than/ less than symbols and the primers that were finally selected using PyroMark software are highlighted (yellow as 
forward and reverse PCR primers and green as sequencing primer). The forward primer was biotinylated as the 
sequencing primer binds the reverse strand. Black arrows indicate CpG sites of potential methylation that were 




Figure 17. Genomic location of regions assayed relative to gene, neighbouring CpG islands, and CpG array probes. 
Sequencing was performed on regions amplified from bisulfite-treated DNA. Primers were designed that would 
amplify the regions (illustrated on UCSC) relative to the gene (regions illustrated by black boxes labelled “YourSeq”). 
Nearby CpGs with probes covered by various arrays shown on the cg tracks. A) First primer set for miR-21 designed to 
amplify region upstream, covers three CpGs (Assay 1). B) Second primer set for miR-21 designed to amplify region 
downstream, covers three CpGs (Assay 2). C) Primer set for miR-210 designed to amplify region upstream of the gene 
(miR-210 is on the reverse strand so region is to the right of the gene). 
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5. 4. II. b) DNA methylation at miR-210 and miR-21 loci and the relationship with gene expression  
First, the methylation levels of the assayed CpGs was measured in untreated cells, to examine the basal 
level of methylation, and this was compared with basal expression level (Figure 18 and 19). Interestingly, 
this revealed consistent patterns of methylation in multiple cell lines, which could indicate a conserved 
function, such as increased methylation at the 7th CpG in the miR-210 assay compared to the 6th (Figure 
18). Moreover, the methylation levels of the regions inversely correlated with the expression levels of the 
miRNA transcripts, suggesting that DNA methylation may regulate gene expression. Another striking 









Figure 18. Methylation of CpGs in the promoter region of miR-210 inversely correlates with its expression level. A) 
Pyrosequencing demonstrates conserved pattern of methylation across the region assayed, cancer cell lines LNCaP, 
22Rv1 and PC3 displaying increased methylation per CpG site compared to RWPE-1, and B) significantly increased 
mean methylation across the region. C) Accordingly, RT-qPCR reveals significantly lower expression of miR-210 in PCa 
cell lines compared to RWPE-1. One-way t-tests were used to compare condition means to the control (hypothetical 















Figure 19. Methylation of the promoter region of miR-21 inversely correlates with its expression level. A) 
Pyrosequencing demonstrates increased methylation of individual CpGs in the PCa cell lines compared to RWPE-1, in 
Assay 1 and B) Assay 2. C) Mean percentage methylation across the region is increased in PCa cell lines compared with 
RWPE-1 in Assay 1 and D), Assay 2. E) Accordingly, RT-qPCR reveals reduced expression of miR-21 in PCa cell lines 
relative to RWPE-1. One-way t-tests were used to compare condition means to the control (hypothetical value 100) 




5. 4. II. c) The effect of Aza-dc treatment on DNA methylation and gene expression 
However, to prove that DNA methylation was regulating the miRNAs expression, the increased methylation 
the cancer cell lines should be reduced (with a demethylating agent) and the effect on expression level be 
reversed accordingly. Therefore, LNCaP, 22Rv1 and PC3 were treated with a pharmacological inhibitor of 
DNA methyltransferase (DNMT), 5-Aza-2′-deoxycytidine (hereafter referred to as Aza-dc). Aza-dc is a 
cytosine analogue with a nitrogen replacing the fifth carbon, which is incorporated into DNA in place of 
endogenous cytosine. DNMT binds Aza-dc but cannot catalyse its methylation, and so remains bound and 
is eventually degraded due to activation of a DNA-damage response pathway, which is particularly evident 
in the case of the maintenance methylation enzyme DNMT1 but also true for the de novo methylation 
enzymes DNMT3A/B (Palii et al., 2008).  
The cells were either untreated or treated with 5µM Aza-dc for 72h, as has been shown effective in these 
cell lines by another research group (Li et al, 2015). After 72h, PC3 were almost confluent and were 
harvested, while 22Rv1 and LNCaP were left to grow an additional 24h to maximise cell number. During 
harvesting, cells were split into two pellets for RNA and DNA extraction of the same population. The efficacy 
of the dose on the cell lines was confirmed by upregulation of the genes SYPC3 and DAZL by RT-qPCR (Figure 
20), which are germline genes known to be regulated by DNA methylation (Maatouk et al., 2006). Of note, 
the cell line 22Rv1 appeared to be most sensitive to Aza-dc as shown by the vast upregulation of these 
markers and that by 72h of treatment the cells had acquired a senescent phenotype (wide and squashed 
looking, with faint membranes).  
Encouragingly, Aza-dc treatment increased the levels of miR-21 and miR-210 in some cell lines (miR-21 in 
PC3 and 22Rv1, and miR-210 in 22Rv1 and LNCaP), suggesting that their expression may be regulated by 
DNA methylation (Figure 21).  
Next, the methylation status of the Aza-dc treated cells was measured by Pyrosequencing, with the view 
to correlate the methylation status of each sample with the expression level of the miRNAs. Curiously 
however, Aza-dc treatment did not demethylate the DNA at the miR-210 and miR-21 assayed regions, and 
in fact the miR-21 assay 1 results show increased methylation in Aza-dc treated 22Rv1 and LNCaP (Figure 
7). The miR-210 assay showed reduced methylation in all cell lines after Aza-dc treatment at one specific 
CpG (depicted as CpG number 4, Figure 7C). Furthermore, the mean methylation of the whole miR-210 
assay region was slightly lower in Aza-dc treated cells (Figure 8). Although small, this could potentially be 
biologically relevant, particularly if it produced a cumulative effect across a large region. However, miR-
210 expression was not upregulated by Aza-dc in PC3 and so the degree of demethylation did not correlate 
with degree of expression across the cell lines, and the effect of DNA methylation on transcription could 













Figure 20. Confirmation of the efficacy of 5µM Aza-dc for 72h on PCa cell lines, and measurement of miRNA 
expression in Aza-dc treated cells. Upregulation of germline genes SYPC3 and DAZL following aza-dc treatment of A) 
PC3 and B) 22Rv1. C) MiRNA RT-qPCR results showing upregulated miR-21 expression in Aza-dc treated PC3. D) 
Upregulated miR-21 and miR-210 expression in Aza-dc treated 22Rv1. E) Upregulated miR-210 expression in Aza-dc 
treated LNCaP. Mean + SEM of two biological replicates shown with the exception of LNCaP due to RNA degradation 
of one Aza-dc treated sample. One-way t-tests were used to compare condition means to the control (hypothetical 






Figure 21. Pyrosequencing results showing the effect of Aza-dc treatment on DNA methylation of the promoter 
regions of miR-21 and miR-210, in PCa cells either untreated (black lines) or treated with 5µM Aza-dc treatment 
(red lines) for 72h. From left to right, graphs depict PC3, 22Rv1 and LNCaP. A) Assay 1 (miR-21). B) Assay 2 (miR-21) 
C) miR-210 assay. D) Analysis of the mean percentage methylation across the whole assayed regions of miR-21 gene, 
showing increase in percentage methylation in Aza-dc treated cells (white bars) compared to untreated cells (black 
bars). E) Mean percentage methylation of the miR-210 assay showing slight reduction in mean methylation in all cell 
lines. Mean + SEM of two biological replicates shown. Two-way t-tests (one-tailed, homoscedastic) were used to 
compare each set of means and p-values considered significant when *p<0.05, **p<0.01, ***p<0.001. No error bars 
where identical values were obtained for both replicates.  
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5. 4. II. d) Hypoxia and DNA methylation of LINE1 and pri-miR-21 and pri-miR-210 
Part 2 indicated that hypoxia had influenced the methylation of DNA at promoters and gene regions in 
NSCLC. I wanted to explore the effect of hypoxia on DNA methylation in PCa, overall and specifically at the 
miR-210 and miR-21 loci, to determine if perhaps hypoxia would affect these regions. 
The methylation status of long interspersed nuclear element 1 (LINE1) is considered representative of 
global methylation (Ehrlich, 2002), so this was used as a measure of the global methylation associated with 
hypoxia.  
One biological replicate was conducted culturing LNCaP in hypoxia (0.1% O2 relative to 20% O2) which 
produced no change in methylation of LINE1 at the CpGs assayed, potentially suggesting that hypoxia did 
not affect DNA methylation across the genome. Likewise, analysis of the pri-miR-21 and pri-miR-210 genes 
did not demonstrate a consistent effect of hypoxia on the assayed CpGs, although at some CpGs at the 
miR-210 region, methylation was reduced in the hypoxic versus normoxic conditions (Figure 22). However, 




























Figure 22. The effect of hypoxia on the DNA methylation of long interspersed nuclear element 1 (LINE1) and miR-21 
and miR-210 in LNCaP as measured by Pyrosequencing. Hypoxic culture was 0.1% O2 relative to normoxia 20% O2 
for 48h. One biological replicate (hypoxia) and two technical replicates (independent PCR amplifications) shown (mean 
+ SEM). A) No effect of hypoxia on the percentage methylation of most CpGs in a LINE1 element assay, which is 
representative of global methylation status. B) Mean percentage methylation of the whole assayed region showing 
no change mean percentage methylation of the LINE1 assay region in hypoxic cells. Two-way t-test (two-tailed, 
homoscedastic) were used to compare each set of means and p-values considered significant when *p<0.05, **p<0.01, 
***p<0.001. C) No effect of hypoxia on the DNA methylation of regions proximal to pri-miR-21 assay 1, nor D) pri-miR-





 5. 4. III. Discussion  
5. 4. III. a) Summary 
The initial experiments demonstrated that the DNA methylation levels of the miR-21 and miR-210 genes 
was increased in the cancer cell lines compared with RWPE-1, and this inversely correlated with their 
expression level, suggesting that these miRNAs could be regulated by DNA methylation. Indeed, in some 
cell lines, Aza-dc treatment upregulated their expression. However, Aza-dc did not significantly reduce the 
methylation of the assayed regions. The fact that the percentage methylation at the individual CpGs was 
conserved across the three cell lines could indicate an essential function of the methylation of these sites, 
but from my data I cannot conclude that it is to regulate gene expression, since I could not remove the 
methylation and correlate that with an increase in expression.  
Potentially, the concentration of Aza-dc was insufficient, although this is perhaps unlikely, since DAZL and 
SYPC3 were induced and 22Rv1 (which was most sensitive to Aza-dc) was not more demethylated that the 
other cell lines. However, potentially the 24h of extra growth time after the end of the Aza-dc treatment 
could have facilitated some re-methylation, and in fact PC3 were harvested immediately after 72h of Aza-
dc treatment (as they had been almost confluent) and this cell line had slightly lower methylation levels. 
This suggests that cells should always be harvested at the end of the treatment. 
It is also important to note that methylation patterns are highly abnormal in cancer, and the increased 
methylation of miR-21 and miR-210 could simply reflect abnormal establishment of methylation patterns 
and be unrelated to expression regulation. Furthermore, if methylation were governing these miRNAs 
expression, one might expect them to be hypomethylated in the cancer state rather than hypermethylated, 
considering their oncogenic properties. A more interesting question is whether the abnormal methylation 
at these genes somehow primes them to respond differently to hypoxia. A preliminary experiment in LNCaP 
showed that hypoxia did not affect the methylation of these promoter regions. However, in these samples 
hypoxic culture did not significantly affect LINE1 methylation. This was surprising, as it was in contrast to 
the NSCLC dataset in which hypoxia associated with global hypomethylation. Hypomethylation of repetitive 
elements (such as LINE1) is associated with increased chromosomal instability and rearrangements and is 
common in cancers (Imperatori et al., 2017) (Baba et al., 2010), so it would have made more sense if 
hypoxia had reduced methylation at this element. However, more replicates would obviously be needed. 
Furthermore, the conditions are immensely different. Firstly the NSCLC dataset analysed DNA extracted 
from 24 different tumour specimens whereas this is a single cell line replicate. Secondly, the tumours were 
classified based on a hypoxia metagene score, whereas the LNCaP replicate was cultured for 24h at 0.1% 
O2. It could be that the degree of hypoxic was too intense (i.e. oxygen levels too low) for cell replication 
and so changes in methylation-mediating enzymes (e.g. DNMT1) cannot be observed. Perhaps, culturing 
at 1% or 5% O2 would permit replication and differences in methylation would become clear. Finally, since 
the tumour samples were heterogeneous cell populations and it is not possible to confirm that the changes 
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occurred in the carcinoma cells themselves, but could be partly due to changes in infiltrating immune cells 
or stromal cells.  
There was an unexpectedly small demethylating effect of Aza-dc. Perhaps, a difference of just 5% could 
have biological effects if it was a critical CpG or had an additive effect across many CpGs in the region. 
Indeed, in PC3 the Aza-dc induced hypomethylation was significant across the miR-210 assayed region (9 
CpGs). Bizarrely, there was no demethylating effect of Aza-dc at the miR-21 regions (in fact there was an 
occasional increase in methylation at some CpGs). This may suggest that some regions more readily 
incorporate Aza-dc rather than endogenous cytosine, or it could simply be chance. In fact, a lack of 
demethylation at certain genes following Aza-dc treatment has been previously reported in a study by the 
Walsh lab, comparing methylation changes in Aza-dc treated and siRNA DNMT1 treated cells. The authors 
demonstrated that Aza-dc caused hypermethylation at the promoter regions of certain genes, which DAVID 
analysis revealed was enriched for genes encoding G-protein coupled receptors and particularly olfactory 
receptors (Mackin, O’Neill and Walsh, 2018b). Potentially, DNA-associated proteins at these regions 
somehow inhibit the incorporation of Aza-dc into DNA, although it is difficult to imagine how. Alternatively, 
de novo methylation (by DNMT3A and DNMT3B enzymes) could be particularly important at these regions 
and the maintenance methylation enzyme DNMT1 less important, and thus its inhibition does not affect 
methylation. However, in the study comparing Aza-dc with siRNA DNMT1, gains in methylation were only 
observed in the Aza-dc treated cells. It could be that in these cells, DNMT3A/B were affected by off-target 
gene silencing.  
5. 4. III. b) Future directions 
To address the issue of lack of demethylation due to Aza-dc, a future experiment could involve measuring 
the methylation levels using the miR-21 and miR-210 assays, in cells treated with siRNA DNMT1 to have a 
better chance of observing demethylation. Alternatively, a CRISPR/Cas9 system could be used to guide 
DNMT1 to these regions for it to dememthylate them, as a CRISPR/Cas9/DNMT1 system has recently been 
published (Lu et al., 2019). 
There was a discrepancy between the Aza-dc demethylation and Aza-dc induced expression (e.g. 
demethylation of the miR-210 region in PC3 was not associated with upregulation of miR-210). This could 
suggest that the gene is not governed by DNA methylation at the region assayed. However, this is an 
oversimplification since it may be almost impossible to ever fully isolate the effect of DNA methylation on 
cancer-associated gene expression using Aza-dc. This is firstly because there is interplay between many 
epigenetic mechanisms, and perhaps artificial demethylation by Aza-dc is insufficient alone, and also 
requires modification of histones (such as histone deacetylase inhibition) or chromatin. Furthermore, Aza-
dc induces a DNA damage response (DDR) pathway that could confound its effects. That is, the activated 
DDR could have knock-on effects on genes like miR-21 and miR-210 since they have pleiotropic, 
homeostatic functions. Similarly, we also have to be conscious that Aza-dc has potent anti-cancer effects, 
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and it could be that the changes in miRNA expression that were observed following Aza-dc treatment were 
in fact a result of cell death pathway activation. Based on this, and since methylation patterns are abnormal 
in cancer cells, future experiments analysing this mechanism could use a different cell line to unpick the 
regulation of the gene regions by methylation, such as a normosomic, nontransformed fibroblast cell line 
as has been successfully utilised by other researchers (Rutledge et al., 2014). 
Interestingly, a number of miRNAs have been shown to be regulated by DNA methylation and in turn, many 
regulate epigenetic processes; these “epi-miRNAs” – regulate the translation of enzymes including DNMT, 
polycomb repressive complex 1/2 (PRC1/2), retinoblastoma like protein 2 (RBL2), histone deacetylase 
(HDAC), heterochromatic protein-1 (HP1). This produces feedback loops that finely tune epigenetic 
regulation (Ramassone et al., 2018). Therefore, a mutation in one of the miRNA processing machinery can 
affect global epigenetics and vice versa, a mutation in an epigenetic regulator can affect global miRNA 
function. Interestingly, miRNAs have also been detected bound to DNA, recruiting epigenetic and 
transcription factors (Ramassone et al., 2018). It could be interesting in the future to examine if either miR-



















5. 5. IV. Overall discussion and future perspectives 
5. 5. IV. a)  Summary  
This chapter has applied omics methods to study genomic and epigenomic profiles. The RNA-seq 
characterisation of the prostatectomy cohort successfully informed the discovery of miR-196a as a 
hypoxia-regulated miRNA in PCa, and pathway analysis was used to suggest how it may operate within a 
network of its targets and may drive tumour progression. Next, the methylation profiles of hypoxic and 
normoxic NSCLC tumours were analysed using the R package “RnBeads”, which revealed global and 
regional hypomethylation associated with hypoxia and changes in the methylation patterns of promoters 
and genes governing inflammation, cell signalling, and development. Finally, the regulation of miR-21 and 
miR-210 by DNA methylation was examined using a bisulfite conversion and sequencing approach. 
Therefore, this chapter has demonstrated how different types of molecular data can contribute to 
understanding the biology of diseases or conditions. The NGS and array approaches were especially 
powerful since they produced quantitative data for many transcripts/genomic loci in parallel, with a 
significance score based on the effect size across multiple samples. In contrast, the in vitro analysis of 
miR-21 and miR-210 methylation was more laborious and eventually rather inconclusive. 
5. 5. IV. b)  Applications for personalised medicine 
In the future, personalised medicine approaches will probably consist of a mixture of these types of 
approache (multi-omics). For example, as sequencing becomes more affordable for clinical labs, specimens 
may be sequenced and analysed for specific patterns or panels, to characterise a tumour or serum. 
Methylation profiling could be used to indicate hypoxia, or other cell features, for patient stratification. For 
example, methylation profiling could predict if lung cancer patients would respond to demethylating 
agents, which have been used to treat myelodysplastic syndromes for decades (Santini, 2019). Several 
studies in the literature have reported growth inhibiting effects of either 5-azacytidine or 5-aza-
2’deoxyazacytidine on NSCLC cell lines and concluded that it could be a treatment option for patients in 
the future (Lai et al., 2018)(Desjobert et al., 2019)(Yang et al., 2017). This data would suggest that hypoxic 
tumours already display hypomethylation and if this was shown to contribute to tumour development then 
these agents may do more harm than good.  
5. 5. IV. c) Benefits and challenges of omics data in cancer research 
When the human euchromatic genome was published in 2004, the bottleneck in omics data was the 
limitations of the available technologies for generating data. Since then, high-throughput technologies 
have advanced and become increasingly efficient and affordable, and the bottleneck has now shifted 
from data generation to data processing and interpretation. As this chapter has exemplified, despite 
ready access to omics data it remains difficult to untangle the complex molecular mechanisms that 
underlie a disease. This is because the dynamics of the cell are intricate and complex, plus the type of 
data that comes from biological samples is noisy due to cellular heterogeneity, and there are limitations 
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of the applied statistics such as false positives (Alyass, Turcotte and Meyre, 2015). On top of that, the 
data represents a snapshot in time. Transcription and decay are dynamic and stochastic, and genes can 
be expressed briefly to influence numerous downstream effects before being rapidly degraded, although 
methylation profiling may be less susceptible to fluctuations, as global changes in methylation may 
require multiple cell divisions to become evident whereas proteins and RNAs can be rapidly turned over. 
Overall, detecting legitimate interactions and networks remains very challenging. However, many 
sophisticated programs are available that can be used to characterise gene expression patterns to 
uncover biological processes (and are helpfully based on pre-designed workflows that are suitable for the 
inexperienced bioinformatician). Using the programs IPA and DAVID, specific pathways were indicated as 
being enriched (such as apoptosis signalling in the prostatectomy cohort and inflammatory genes in the 
hypoxic lung tumours). Another issue in omics analysis is the difficulty in integrating multiple types of 
data. Indeed, the miRNA-seq and mRNA-seq pathway analyses indicated rather different pathway 
profiles, and even when integrated the results were no clearer. It is also important to note the caveat of 
such functional annotation and network analyses is they are based on curated data, and the networks are 
extrapolated based on information generated from many different cell types. Overall this highlights that 
pathway analysis must be interpreted with caution, although it was very useful for revealing inversely 
correlated miRNA : mRNA pairs. There is also the caveat of tumour analysis that the cell type of origin 
cannot be proven. Indeed, the difficulty in finding a miRNA that was expressed robustly in the PCa cells 
lines, may reflect the heterogenous sample and highlights the need for validation in vitro. 
In summary, omics data is immensely powerful in identifying novel genes, pathways, and epigenetic 
features in cancers. The global transition to personalised medicine depends on omics approaches to 
direct new research avenues and for patient stratification. Multiple types of omics data, such as RNA-seq 
and methylation array, will be involved. However, the effective integration of different types of omics 
data is an important bottleneck to consider.  
5. 5. IV. d)  Future directions 
It would be interesting to examine the proteomics of the hypoxic tumour samples or the prostatectomy 
cohort, to explore if the results reflected the epigenomic or transcriptomic profiles respectively. The 
proteomic profiles could be investigated by quantitative mass spectrometry, which has recently been used 
to characterise protein biomarkers in colon cancer (Atak et al., 2018).  
Alternatively, to address the issue of cellular heterogeneity, the tumours could be separated into single 
cells by flow cytometry activated cell sorting (FACS) and single cell RNA sequencing or single cell 
methylation analysis could be performed. This would provide a high resolution picture of the differences 
across cells in the microenvironment, and help decipher the behaviour and contribution of individual cells.  
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There was unexpected discordance between the mRNA-seq and miRNA-seq data. Apparently, integrative 
analyses of transcriptomic and proteomic data often reveals low level of correlation between the two, 
which has been attributed to regulation at the post-transcriptional and post-translational levels. If a 
proteomic analysis was used, the pathway analysis of the integrated data could be improved by accounting 
for regulating factors, by including in the model a network analysis of protein-protein and DNA-protein 
interactions, such as by Bayesian network models, although this would require statistical modelling 
expertise (Alyass, Turcotte and Meyre, 2015).  
Throughout this chapter I have referred to the use of miRNA or methylation based biomarkers of disease, 
however, these would need to be obtained by biopsy. Prostate biopsies are not ideal since they are invasive 
and only provide data from a snapshot in time. It would be better to characterise biomarkers taken from a 
liquid, perhaps a future experiment could involve extracting circulating RNA or DNA and repeating the 
analyses. Serum is a commonly used liquid for biomarkers, although urine may be more appropriate for 
PCa, and has already been investigated and some cohorts of PCa patients have been shown to have specific 
urine miRNA profiles and DNA methylation patterns such as GSTP1 methylation (Fredsøe et al., 
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5. 7. Supplementary figures 
Supplementary Figure 1. Analyses of mRNAseq data. Normalised by DESeq2 method.   
 
Figure 1A. Unsupervised clustering of all samples based on DESeq2 normalised mRNAseq data. Produced with the base 





Figure 1B. Unsupervised clustering of tumour samples based on DESeq2 normalised mRNAseq data. Produced with the 
base function heatmap() using DESeq2 normalised data.  
 
 
Figure 1C. Supervised clustering of all samples, comparing tumour with non-tumour status, based on DESeq2 normalised 




Figure 1D. PCA analysis comparing tumour with non-tumour status, based on DESeq2 normalised mRNAseq data with 
log2 transformed data by the variance stabilising transformation method. Produced using pretty heatmap (pheatmap) 






Figure 1E. Supervised clustering of tumour samples by patient age shows distinctness between older and younger 
patients (age shown after patient number on x-axis), based on DESeq2 normalised mRNAseq data. Produced with the 
base function heatmap() using DESeq2 normalised data.  
 
 
Figure 1F. PCA analysis of tumour samples, modelling patients over 60 years versus under 60 years, based on DESeq2 
normalised mRNAseq data with log2 transformed data by the variance stabilising transformation method. Produced 







Figure X. Heatmap using supervised clustering of tumour samples by PSA level (shown in ng/µL following patient 
number on x-axis) based on DESeq2 normalised mRNAseq data. Produced with the base function heatmap() using 
DESeq2 normalised data.  
 
 
Figure 1G. PCA analysis of tumour samples by PSA level group (Low: ≤5ng/µL, Medium: 5-7ng/µL, High 7-10ng/µL, Very 
High: ≥10ng/µL), based on DESeq2 normalised mRNAseq data with log2 transformed data by the variance stabilising 









Figure 1H. Heatmap showing supervised clustering of tumour samples by Gleason score (shown following patient 
number on the x-axis) based on DESeq2 normalised mRNAseq data. Produced with the base function heatmap() using 
DESeq2 normalised data.  
 
 
Figure 1I. PCA analysis of tumour samples by Gleason score groups (Low: 6, Intermediate: 3 + 4 =7, High ≥4 +  3 = 7). 





Figure 1J. Distances matrix by patient similarity, including patient characteristics. Produced using pretty heatmap 










Supplementary Figure 2. Analyses of mRNAseq data. Normalised by DESeq2 method.   
 
Figure 2A. Unsupervised clustering of all samples. Produced with the base function heatmap() using DESeq2 normalised 




Figure 2B. Supervised clustering of all samples by tumour versus non-tumour status. Produced with the base function 






Figure 2C. PCA analysis comparing tumour versus non-tumour samples. Produced using pretty heatmap (pheatmap) 




Figure 2D. Heatmap showing unsupervised clustering of tumour samples. Produced with the base function heatmap() 





Figure 2. Heatmap showing supervised clustering of tumour samples by patient age. Produced with the base function 




Figure 2F. PCA analysis of tumour samples by patient age. Produced using pretty heatmap (pheatmap) package in 






Figure 2G. Heatmap showing supervised clustering of tumour samples by patient PSA level (ng/µL, shown after the 
patient number on x-axis). Produced with the base function heatmap() using DESeq2 normalised data.  
 
 
Figure 2H. PCA analysis of tumour samples by patient PSA level in ng/µL (Low: ≤5ng/µL, Medium: 5-7ng/µL, High 7-








Figure 2I. Heatmap showing supervised clustering of tumour samples by patient Gleason score (shown after the patient 




Figure 2J. PCA analysis of tumour samples by Gleason score groups (Low: 6, Intermediate: 3 + 4 =7, High ≥4 +  3 = 7). 








Figure 2K. Heatmap of all samples, including all patient characteristics. Produced using pretty heatmap (pheatmap) 





Figure 2L. Distances matrix of all tumour samples by patient similarity, including patient characteristics. Produced using 








Supplementary Figure 3. Integrative Analysis of mRNA-seq and miRNA-seq data using IPA reveals numerous predicted 
mRNA targets of miR-196a with significant inverse expression correlation. MiR-196a (left-hand side, coloured grey) was 
significantly upregulated in the miRNA-seq dataset, the other proteins represent mRNAs with seed-binding complementarity 
that were significantly downregulated in the mRNA-seq data. Those which have been validated as mRNA targets (among all 
other cell types) are connected with arrows. Pathway overlay with “prostate carcinoma” disease used to highlight molecules 
previously implicated in PCa (molecules highlighted in purple). Pathway build with “angiogenesis” pathways used to illustrate 
the molecules previously implicated in this process, which may have relevance for hypoxia (connected by purple arrows in 
the direction of regulation, dashed lines indicate indirect regulation, full lines indicate direct). The shape of each icon 








Supplementary Figure 4. Principal component analysis (PCA) and multidimensional scaling (MDS) methods of dimension 
reduction, including sample 14. Each point represents a sample, colour and shape represents hypoxic status. A) MDS applied 
to the dataset reveals some clustering of the normoxic samples. B) PCA applied to the dataset does not cluster by hypoxic 
status.  
 
Supplementary Table 1. Functional Annotation Chart of the Promoters with Losses in methylation. From the top 100 
combined rank promoters, promoters analysed n=44. 
Category Term Count % P-Value Benjamini 
GOTERM_MF_DIRECT Toll-like receptor 2 binding 2 6.1 3.20E-03 1.60E-01 
INTERPRO Toll-like receptor 2 6.1 4.30E-03 2.40E-01 
PIR_SUPERFAMILY toll-like receptor, 1/2/4/6/10 types 
[Parent=PIRSF800008] 
2 6.1 4.70E-03 9.40E-03 
KEGG_PATHWAY Toll-like receptor signaling pathway 3 9.1 6.20E-03 1.40E-01 
GOTERM_BP_DIRECT inflammatory response 4 12.1 8.40E-03 8.00E-01 
GOTERM_MF_DIRECT lipopeptide binding 2 6.1 8.50E-03 2.10E-01 
UP_SEQ_FEATURE signal peptide 10 30.3 8.60E-03 5.40E-01 
GOTERM_BP_DIRECT positive regulation of interleukin-6 biosynthetic process 2 6.1 9.00E-03 5.80E-01 
UP_SEQ_FEATURE site:Reactive site 2 6.1 1.00E-02 3.70E-01 
GOTERM_BP_DIRECT immune response 4 12.1 1.10E-02 5.20E-01 
GOTERM_BP_DIRECT regulation of cytokine secretion 2 6.1 1.20E-02 4.50E-01 
UP_SEQ_FEATURE short sequence motif:Secondary area of contact 2 6.1 1.40E-02 3.40E-01 
GOTERM_BP_DIRECT megakaryocyte development 2 6.1 1.80E-02 5.00E-01 
INTERPRO Proteinase inhibitor I25, cystatin 2 6.1 1.90E-02 4.60E-01 
GOTERM_BP_DIRECT platelet formation 2 6.1 2.10E-02 5.00E-01 
SMART CY 2 6.1 2.20E-02 3.70E-01 
INTERPRO Toll/interleukin-1 receptor homology (TIR) domain 2 6.1 2.80E-02 4.50E-01 
UP_SEQ_FEATURE domain:TIR 2 6.1 2.80E-02 4.70E-01 
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UP_KEYWORDS Thiol protease inhibitor 2 6.1 2.90E-02 8.90E-01 
SMART TIR 2 6.1 2.90E-02 2.60E-01 
UP_KEYWORDS Signal 10 30.3 2.90E-02 6.70E-01 
GOTERM_BP_DIRECT toll-like receptor signaling pathway 2 6.1 3.00E-02 5.70E-01 
GOTERM_MF_DIRECT cysteine-type endopeptidase inhibitor activity 2 6.1 3.60E-02 4.90E-01 
GOTERM_BP_DIRECT MyD88-dependent toll-like receptor signaling pathway 2 6.1 3.70E-02 5.90E-01 
UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 10 30.3 3.80E-02 4.90E-01 
KEGG_PATHWAY Neuroactive ligand-receptor interaction 3 9.1 3.90E-02 3.80E-01 
UP_KEYWORDS Glycoprotein 10 30.3 4.90E-02 7.20E-01 
UP_KEYWORDS Cell membrane 8 24.2 5.30E-02 6.40E-01 
GOTERM_CC_DIRECT phagocytic vesicle membrane 2 6.1 6.90E-02 9.50E-01 
UP_KEYWORDS Disulfide bond 8 24.2 7.50E-02 7.00E-01 
INTERPRO Cysteine-rich flanking region, C-terminal 2 6.1 8.60E-02 7.60E-01 
GOTERM_CC_DIRECT integral component of plasma membrane 5 15.2 8.60E-02 8.40E-01 
UP_SEQ_FEATURE topological domain:Extracellular 7 21.2 8.90E-02 7.50E-01 
 
Supplementary Table 7. Functional Annotation Chart of the Promoters with Gains in methylation. From the top 100 
combined rank promoters, promoters analysed n=56. 
Category Term Count % P-Value Benjamini 
INTERPRO Homeodomain, metazoa 6 13.6 6.70E-07 6.60E-05 
INTERPRO Homeobox, conserved site 7 15.9 1.10E-06 5.60E-05 
GOTERM_MF_DIRECT sequence-specific DNA binding 9 20.5 2.40E-06 1.50E-04 
UP_SEQ_FEATURE DNA-binding region:T-box 4 9.1 3.20E-06 4.00E-04 
INTERPRO Transcription factor, T-box, conserved site 4 9.1 3.80E-06 1.20E-04 
INTERPRO Transcription factor, T-box 4 9.1 3.80E-06 1.20E-04 
INTERPRO Homeodomain 7 15.9 6.30E-06 1.60E-04 
UP_KEYWORDS Homeobox 7 15.9 9.20E-06 6.70E-04 
SMART TBOX 4 9.1 1.00E-05 2.40E-04 
GOTERM_BP_DIRECT anterior/posterior pattern specification 5 11.4 1.40E-05 4.10E-03 
UP_SEQ_FEATURE DNA-binding region:Homeobox 6 13.6 2.50E-05 1.60E-03 
INTERPRO Homeodomain-like 7 15.9 3.00E-05 5.80E-04 
SMART HOX 7 15.9 3.40E-05 4.00E-04 
INTERPRO p53-like transcription factor, DNA-binding 4 9.1 7.10E-05 1.20E-03 
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA 
binding 
9 20.5 2.00E-04 6.50E-03 
UP_KEYWORDS DNA-binding 13 29.5 2.80E-04 1.00E-02 
UP_KEYWORDS Developmental protein 9 20.5 3.40E-04 8.30E-03 
GOTERM_BP_DIRECT regulation of transcription, DNA-templated 10 22.7 1.20E-03 1.70E-01 
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GOTERM_BP_DIRECT embryonic forelimb morphogenesis 3 6.8 1.60E-03 1.50E-01 
GOTERM_CC_DIRECT nucleus 20 45.5 2.00E-03 8.00E-02 
GOTERM_BP_DIRECT embryonic skeletal system morphogenesis 3 6.8 2.30E-03 1.60E-01 
GOTERM_BP_DIRECT embryonic limb morphogenesis 3 6.8 2.50E-03 1.40E-01 
UP_KEYWORDS Transcription regulation 12 27.3 3.20E-03 5.60E-02 
UP_KEYWORDS Transcription 12 27.3 3.90E-03 5.60E-02 
GOTERM_BP_DIRECT transcription, DNA-templated 10 22.7 7.10E-03 3.10E-01 
GOTERM_BP_DIRECT angiogenesis 4 9.1 7.90E-03 2.90E-01 
GOTERM_BP_DIRECT positive regulation of transcription from RNA 
polymerase II promoter 
7 15.9 8.20E-03 2.70E-01 
UP_KEYWORDS Cardiomyopathy 3 6.8 1.00E-02 1.20E-01 
GOTERM_BP_DIRECT parathyroid gland development 2 4.5 1.30E-02 3.50E-01 
INTERPRO Beta tubulin 2 4.5 1.60E-02 2.10E-01 
INTERPRO Beta tubulin, autoregulation binding site 2 4.5 1.60E-02 2.10E-01 
GOTERM_BP_DIRECT atrial septum morphogenesis 2 4.5 2.40E-02 5.20E-01 
GOTERM_BP_DIRECT morphogenesis of an epithelium 2 4.5 2.60E-02 5.10E-01 
UP_KEYWORDS Atrial fibrillation 2 4.5 2.60E-02 2.40E-01 
GOTERM_BP_DIRECT endocardial cushion morphogenesis 2 4.5 2.90E-02 5.30E-01 
GOTERM_BP_DIRECT cellular response to cadmium ion 2 4.5 3.10E-02 5.20E-01 
GOTERM_BP_DIRECT positive regulation of chondrocyte differentiation 2 4.5 3.50E-02 5.30E-01 
INTERPRO Homeobox protein, antennapedia type, conserved 
site 
2 4.5 3.60E-02 3.60E-01 
INTERPRO Tubulin/FtsZ, 2-layer sandwich domain 2 4.5 4.00E-02 3.60E-01 
GOTERM_BP_DIRECT positive regulation of cardiac muscle cell 
proliferation 
2 4.5 4.00E-02 5.60E-01 
INTERPRO Tubulin, C-terminal 2 4.5 4.10E-02 3.40E-01 
INTERPRO Tubulin, conserved site 2 4.5 4.10E-02 3.40E-01 
INTERPRO Tubulin/FtsZ, C-terminal 2 4.5 4.10E-02 3.40E-01 
UP_SEQ_FEATURE short sequence motif:Antp-type hexapeptide 2 4.5 4.20E-02 8.30E-01 
GOTERM_BP_DIRECT outflow tract septum morphogenesis 2 4.5 4.20E-02 5.60E-01 
INTERPRO Tubulin 2 4.5 4.30E-02 3.30E-01 
GOTERM_BP_DIRECT proximal/distal pattern formation 2 4.5 4.30E-02 5.50E-01 
INTERPRO Tubulin/FtsZ, GTPase domain 2 4.5 4.50E-02 3.20E-01 
GOTERM_BP_DIRECT thyroid gland development 2 4.5 4.50E-02 5.40E-01 
GOTERM_BP_DIRECT pattern specification process 2 4.5 5.00E-02 5.60E-01 
UP_KEYWORDS Nucleus 16 36.4 5.10E-02 3.80E-01 
GOTERM_MF_DIRECT RNA polymerase II regulatory region sequence-
specific DNA binding 
3 6.8 5.20E-02 6.80E-01 
GOTERM_BP_DIRECT cellular response to fibroblast growth factor 
stimulus 
2 4.5 5.40E-02 5.70E-01 
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SMART SM00865 2 4.5 5.50E-02 3.70E-01 
GOTERM_BP_DIRECT blood vessel remodeling 2 4.5 5.70E-02 5.80E-01 
GOTERM_BP_DIRECT dorsal/ventral pattern formation 2 4.5 5.70E-02 5.80E-01 
SMART SM00864 2 4.5 6.00E-02 3.10E-01 
GOTERM_BP_DIRECT microtubule-based process 2 4.5 6.40E-02 6.00E-01 
KEGG_PATHWAY Pathogenic Escherichia coli infection 2 4.5 6.50E-02 6.80E-01 
GOTERM_BP_DIRECT positive regulation of transcription, DNA-templated 4 9.1 6.80E-02 6.10E-01 
GOTERM_BP_DIRECT multicellular organism development 4 9.1 7.00E-02 6.00E-01 
GOTERM_BP_DIRECT thymus development 2 4.5 7.60E-02 6.20E-01 
GOTERM_BP_DIRECT blood circulation 2 4.5 8.00E-02 6.20E-01 
GOTERM_BP_DIRECT cellular response to transforming growth factor beta 
stimulus 
2 4.5 8.70E-02 6.40E-01 
GOTERM_BP_DIRECT odontogenesis of dentin-containing tooth 2 4.5 9.70E-02 6.70E-01 
 
Supplementary Table 2. Functional Annotation Chart of the Genes with Losses in methylation. From the top 100 combined 
rank promoters, promoters analysed n=51. 
Category Term Count % P-Value Benjamini 
GOTERM_MF_DIRECT G-protein coupled receptor activity 8 22.2 1.60E-05 6.10E-04 
UP_KEYWORDS Glycoprotein 17 47.2 3.30E-05 2.50E-03 
UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 16 44.4 5.00E-05 4.60E-03 
UP_SEQ_FEATURE topological domain:Extracellular 13 36.1 7.30E-05 3.40E-03 
UP_KEYWORDS G-protein coupled receptor 8 22.2 8.10E-05 3.00E-03 
UP_KEYWORDS Sensory transduction 7 19.4 1.10E-04 2.80E-03 
UP_KEYWORDS Transducer 8 22.2 1.20E-04 2.30E-03 
GOTERM_MF_DIRECT olfactory receptor activity 6 16.7 1.50E-04 3.00E-03 
GOTERM_BP_DIRECT detection of chemical stimulus involved in sensory 
perception of smell 
6 16.7 1.90E-04 2.00E-02 
INTERPRO Olfactory receptor 6 16.7 1.90E-04 9.80E-03 
INTERPRO G protein-coupled receptor, rhodopsin-like 7 19.4 2.40E-04 6.20E-03 
UP_KEYWORDS Olfaction 6 16.7 2.50E-04 3.70E-03 
INTERPRO GPCR, rhodopsin-like, 7TM 7 19.4 2.80E-04 4.70E-03 
KEGG_PATHWAY Olfactory transduction 6 16.7 5.60E-04 9.50E-03 
UP_SEQ_FEATURE disulfide bond 12 33.3 5.60E-04 1.70E-02 
UP_SEQ_FEATURE topological domain:Cytoplasmic 13 36.1 5.90E-04 1.30E-02 
UP_KEYWORDS Disulfide bond 13 36.1 6.70E-04 8.30E-03 
GOTERM_BP_DIRECT G-protein coupled receptor signaling pathway 7 19.4 8.20E-04 4.40E-02 
UP_KEYWORDS Receptor 9 25 9.30E-04 9.90E-03 
GOTERM_CC_DIRECT integral component of membrane 15 41.7 3.40E-03 8.70E-02 
UP_SEQ_FEATURE transmembrane region 14 38.9 5.60E-03 9.80E-02 
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GOTERM_MF_DIRECT odorant binding 3 8.3 5.80E-03 7.20E-02 
UP_KEYWORDS Transmembrane helix 15 41.7 6.00E-03 5.50E-02 
UP_KEYWORDS Transmembrane 15 41.7 6.20E-03 5.00E-02 
UP_KEYWORDS Antimicrobial 3 8.3 8.80E-03 6.40E-02 
GOTERM_CC_DIRECT plasma membrane 12 33.3 1.40E-02 1.80E-01 
UP_KEYWORDS Cell membrane 10 27.8 1.60E-02 1.10E-01 
UP_KEYWORDS Inflammatory response 3 8.3 1.70E-02 1.00E-01 
UP_KEYWORDS Sialic acid 2 5.6 2.60E-02 1.40E-01 
UP_KEYWORDS Signal 11 30.6 3.20E-02 1.60E-01 
UP_KEYWORDS Membrane 16 44.4 3.30E-02 1.50E-01 
UP_KEYWORDS Secreted 7 19.4 3.90E-02 1.70E-01 
UP_KEYWORDS Innate immunity 3 8.3 4.60E-02 1.90E-01 
GOTERM_BP_DIRECT antibacterial humoral response 2 5.6 5.60E-02 8.80E-01 
GOTERM_BP_DIRECT inflammatory response 3 8.3 8.70E-02 9.20E-01 
 
Supplementary Table 3. Functional Annotation Chart of the Genes with Gains in methylation. From the top 100 combined 
rank promoters, promoters analysed n=49. 
Category Term Count % P-Value Benjamin
i 
INTERPRO Homeobox, conserved site 10 25.6 1.80E-12 9.60E-11 
INTERPRO Homeodomain 10 25.6 2.60E-11 7.00E-10 
UP_KEYWORDS Homeobox 10 25.6 8.70E-11 5.60E-09 
INTERPRO Homeodomain-like 10 25.6 3.00E-10 5.30E-09 
UP_SEQ_FEATURE DNA-binding region:Homeobox 9 23.1 3.80E-10 3.40E-08 
SMART HOX 10 25.6 4.20E-10 5.00E-09 
UP_KEYWORDS DNA-binding 17 43.6 3.30E-09 1.10E-07 
GOTERM_MF_DIREC
T 
sequence-specific DNA binding 10 25.6 3.00E-08 1.10E-06 
UP_KEYWORDS Developmental protein 12 30.8 4.60E-08 1.00E-06 
INTERPRO Homeodomain, metazoa 5 12.8 6.60E-06 8.80E-05 
GOTERM_BP_DIRECT regulation of transcription, DNA-templated 11 28.2 4.50E-05 1.00E-02 
GOTERM_BP_DIRECT transcription, DNA-templated 12 30.8 7.50E-05 8.50E-03 
GOTERM_BP_DIRECT peripheral nervous system neuron development 3 7.7 1.00E-04 7.80E-03 
UP_KEYWORDS Transcription regulation 12 30.8 2.70E-04 4.40E-03 
UP_KEYWORDS Nucleus 18 46.2 2.70E-04 3.50E-03 
UP_KEYWORDS Transcription 12 30.8 3.50E-04 3.70E-03 
GOTERM_CC_DIRECT nucleus 17 43.6 2.30E-03 7.60E-02 
GOTERM_MF_DIREC
T 
transcription factor activity, sequence-specific DNA 
binding 
7 17.9 2.30E-03 4.20E-02 
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INTERPRO Myc-type, basic helix-loop-helix (bHLH) domain 3 7.7 1.10E-02 1.10E-01 
GOTERM_BP_DIRECT spinal cord motor neuron cell fate specification 2 5.1 1.10E-02 4.60E-01 
GOTERM_BP_DIRECT hindlimb morphogenesis 2 5.1 1.20E-02 4.30E-01 
UP_SEQ_FEATURE domain:Helix-loop-helix motif 3 7.7 1.40E-02 4.60E-01 
GOTERM_BP_DIRECT positive regulation of transcription from RNA polymerase 
II promoter 
6 15.4 1.60E-02 4.50E-01 
GOTERM_BP_DIRECT spinal cord association neuron differentiation 2 5.1 2.00E-02 4.80E-01 
SMART HLH 3 7.7 2.10E-02 1.20E-01 
GOTERM_BP_DIRECT neuromuscular process 2 5.1 2.30E-02 4.80E-01 
UP_SEQ_FEATURE compositionally biased region:Poly-Gln 3 7.7 2.40E-02 5.20E-01 
GOTERM_BP_DIRECT neuron fate commitment 2 5.1 2.60E-02 4.90E-01 
GOTERM_BP_DIRECT proximal/distal pattern formation 2 5.1 3.70E-02 5.70E-01 
GOTERM_MF_DIREC
T 
RNA polymerase II regulatory region sequence-specific 
DNA binding 
3 7.7 3.80E-02 3.80E-01 
GOTERM_BP_DIRECT negative regulation of transcription, DNA-templated 4 10.3 4.10E-02 5.80E-01 
GOTERM_BP_DIRECT multicellular organism development 4 10.3 4.60E-02 5.90E-01 
GOTERM_BP_DIRECT response to nicotine 2 5.1 5.60E-02 6.30E-01 
GOTERM_BP_DIRECT embryonic skeletal system morphogenesis 2 5.1 5.90E-02 6.30E-01 
UP_SEQ_FEATURE compositionally biased region:Poly-Gly 3 7.7 7.40E-02 8.20E-01 
GOTERM_BP_DIRECT skeletal muscle tissue development 2 5.1 7.60E-02 7.00E-01 
GOTERM_BP_DIRECT adult locomotory behavior 2 5.1 7.80E-02 6.80E-01 
GOTERM_BP_DIRECT odontogenesis of dentin-containing tooth 2 5.1 8.20E-02 6.80E-01 
GOTERM_BP_DIRECT negative regulation of neuron differentiation 2 5.1 8.30E-02 6.70E-01 
GOTERM_MF_DIREC
T 
transcriptional repressor activity, RNA polymerase II 
transcription regulatory region sequence-specific binding 
2 5.1 8.40E-02 5.60E-01 
GOTERM_BP_DIRECT single fertilization 2 5.1 8.80E-02 6.70E-01 
GOTERM_MF_DIREC
T 
DNA binding 6 15.4 9.50E-02 5.20E-01 
GOTERM_MF_DIREC
T 
RNA polymerase II core promoter proximal region 
sequence-specific DNA binding 
3 7.7 9.60E-02 4.60E-01 
UP_SEQ_FEATURE domain:KRAB 3 7.7 9.80E-02 8.40E-01 
GOTERM_BP_DIRECT negative regulation of transcription from RNA polymerase 
II promoter 



































7. 1. Introduction 
7.1. I. Collaboration with the Institute of Genetics and Molecular and Cellular Biology, University 
of Strasbourg.  
This chapter is a report of my collaboration with researchers at the University of Strasbourg, on a study 
investigating the effect of the expression of pathological AR variants in PCa.  
In December 2017, I was awarded a scholarship provided by Ulster University’s Department for Research 
and Impact. The scheme was called “Global Research Opportunities for Ulster Postgraduate Researchers: 
Internationalising your Networks (GRO-Ur-Networks)” and comprised a £2,000 grant to fund a 1-3 week 
research stay at a foreign institution with the objective of acquiring new skills and connections. 
My host was Dr Jocelyn Céraline from the Institut de Génétique et de Biologie Moléculaire et Cellulaire 
(IGBMC) in Ilkirch, France, which is affiliated with the nearby University of Strasbourg. I had approached 
three different PIs working on PCa research and in the end chose to write the grant with Dr Céraline 
because he had an upcoming project involving RNA-seq analysis, which I was keen to develop skills in. 
Dr Céraline’s research focuses on the pathological androgen receptor (AR) variants. As discussed in the 
General Introduction Section 1.1. VII b), one way in which PCa cells evade AR inhibitors is by upregulating 
AR mutants, such as splice variants that lack the entire or vast parts of the C-terminal (ligand-binding) 
domain, which when unbound auto-inhibits AR’s transcription factor activity. The mutants are thus 
constitutively active transcription factors regardless of circulating androgen levels or the presence of AR 
antagonists like bicalutamide or enzalutamide that bind this domain. AR variant 7 (AR-V7) is the most 
prevalent AR splice variant, and has a specific C-terminus encoded by the cryptic (alternatively spliced) 
exon 3 that contains a stop codon at the hinge region thus truncating further expression (Hu et al., 2009). 
This project investigated this variant as well as another one, AR variant Q641X (formerly AR-Q641X), which 
contains a nonsense mutation that produces a premature stop codon instead of the glutamine at position 
641 resulting in a similar truncation (Céraline et al., 2004).  
A previous study published by Dr Céraline’s group reported that the gene encoding N-cadherin (CHD2) was 
upregulated by the AR variant AR-V7, demonstrating one mechanism through which PCa cells expressing 
this mutant may gain mesenchymal features to acquire increased malignancy. This study involved lentiviral 
transduction of LNCaP cells with plasmids encoding the wild-type AR (AR-WT) and AR-V7, and then 
sequencing total RNA (mRNA-seq and miRNA-seq) (Cottard et al., 2017). When reading this paper I noticed 
in their paper that one of the genes upregulated significantly by AR-V7 was miR-210-3p, further supporting 
a distorted link between hypoxia and AR signalling in CRPC. It was this link with miR-210 as well as a keen 
interest in his research, that lead me to approached Dr Céraline in the first place. Initially, the project had 
planned to include more miRNA-related analysis although the focus later shifted to concentrate primarily 
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on AR variants. Nevertheless, as discussed below, there is a link between hypoxia and AR variants that is 
worthy of investigation, and it was an excellent opportunity to gain experience in RNA-seq analysis. 
The project that I collaborated on builds on their previous study; again, they overexpressed AR-WT and AR-
V7 in LNCaP, this time including AR-Q641X and using a doxycycline-inducible vector plasmid, meaning that 
they could capture the immediate response to AR variant expression. The cells were transfected and then 
treated with doxycycline to induce expression of the variants, and then sequenced to explore the 
transcriptional effects of the variants’ expression. My role in the project would be to shadow and possibly 
perform some of the analysis of the sequencing data and to contribute to writing the publication. 
Author Contributions: 
 Pauline Ould Madi Berthelemy: Performed laboratory work, performed all bioinformatics 
analysis, contributed to study design, wrote the manuscript.  
 Jocelyn Ceraline: Contributed to study design.  
 C. Zoe Angel: Shadowed bioinformatics analysis and performed a small portion to repeat and 
validate Pauline’s analysis, performed one of the IPA analyses, carried out a literature review on 
one of the groups of significantly differentially expressed genes, contributed to writing the 
manuscript.  
 
7. 1. II. Project Overview 
The plasmids had been generated by cloning AR variant genes (AR-WT, AR-V7 or AR-Q641X) into the vector 
(known as C3) downstream of a doxycycline-inducible promoter, and then transfected into LNCaP by a 
lentiviral method. The vector also contained enhanced GFP (eGFP) to confirm transfection efficiency. 
The cells were treated for 24 hours with 20ng/ml of doxycycline to induce the promoter. It is important to 
note that LNCaP cells express an endogenous AR that is full-length (AR-FL) but distinct from the wild-type 
version as it is mutated at T878A (Veldscholte et al>, 1990). The cells were therefore also treated with 
10nM of DHT to activate AR (FL and/or WT) or vehicle alone (ethanol, EtOH). The eGFP-expressing cells 
were selected by FACS and sequenced at the IGBMC bioinformatics core. Table 1 recaps the treatments.  
Relative to the negative control eGFP+dox+vehicle, the log2(fold change) was calculated in the following 
conditions: eGFP+dox+DHT, AR-WT+dox+DHT, AR-Q641X+dox+vehicle, and AR-V7+dox+vehicle. These 
ratios indicated the impact of endogenous AR-FL, AR-WT, AR-Q641X and AR-V7, respectively. To compare 
the transcriptional effects of the pathological AR variants, the genes differentially expressed in the AR-WT 
condition were compared with those differentially expressed (DE) in the AR-Q641X and AR-V7 conditions 
(Figure 1). Pathways analysis was performed using Ingenuity Pathway Analysis (IPA) software on the lists 

















Table 1. LNCaP conditions used in the study. All received 20ng/ml doxycycline (Dox) to induce the promoter. DHT at 
10nM for 24 hours or vehicle alone (ethanol). The log2(fold change) of gene expression between conditions 1 and 2-
6 were calculated.  
Condition Plasmid Doxycycline Treatment (24h) Represents 
1 eGFP + Dox + Vehicle Effect of the plasmid 
2 eGFP + Dox + DHT  Endogenous AR-FL (T8784) 
3 eGFP-AR-WT + Dox + DHT AR-WT + endogenous AR-FL 
4 eGFP-AR-Q641X + Dox + Vehicle AR-Q641X 










Figure 1. Results of the ARV sequencing. A) Heatmap showing significantly different gene expression pattern for the 
AR-Q641X and AR-V7 conditions. B) Significantly up- or down-regulated genes in the AR variant conditions were 
identified, relative to expression level in the AR-WT condition.  
 
 
7. 2. Tasks 
In the end, I contributed three tasks during my internship. After being trained in the program Jupyter and 
being given the datasets, I produced a list of DE genes in the AR-Q641X condition relative to AR-WT (to 
repeat and validate Pauline’s earlier analysis). I also performed the IPA analysis on this gene list. Since 
returning, I also performed some preliminary analysis of publically-available chromatin 
immunoprecipitation sequencing (ChIP-seq) data, to see if I could validate any of the genes, although this 
part was for my own interest and not a part of the collaboration. These four tasks are outlined below.  
7. 2. I. RNA-seq analysis 
Jupyter Notebook (a python-based command line environment) was used to produce tables containing 
genes significantly deregulated in the AR variant conditions but not in the AR-WT condition, and then to 
compare them with each other to identify genes deregulated by each variant and those deregulated by 
both.  
Below is an excerpt of code that I wrote for the analysis, using the Jupyter Notebook software with the 
packages: pandas, numpty and matplotlib.pyplot. Most of the functions were previously designed by 
members of the Céraline group and are stored on a network folder, where they can be re-used and refined 
for different applications. I designed an analysis and put some of the functions together and did some 
troubleshooting when functions hadn’t worked. This analysis produced a list of genes that were 
significantly DE in the AR-Q641X (+EtOH) condition but not in the AR-WT (+DHT) condition, and this list was 




Table 2. Identification of commonly deregulated genes by AR-Q641X expression but not AT-WT expression. Code 
written in Jupyter Notebook using the packages pandas, numpty and matplotlib.pyplot. Lines beginning with hash 
symbols are annotations for the reader (ignored by the program). Gene list tables depict the first few genes only. 
 
Identification of genes deregulated by AR-Q641X compared to AR-WT 
# Import the required packages, specify the path (directing Jupyter to the correct folder)  
import pandas as pd 
import numpy as np 
import matplotlib.pyplot as plt 
%matplotlib notebook 
path = "./" 
 
# Choose the desired files and import the data to Jupyter kernel in the form of tables 
fname1 = "Q641X_EtOH_WT_EtOH.xlsx"  
fname2 = "WT_DHT_WT_EtOH.xlsx" 
t1=pd.read_excel(path+fname1,index_col="Ensembl gene id") 
t2=pd.read_excel(path+fname2,index_col="Ensembl gene id") 
 
# Change column names to something readable 
t1.columns = ["Gene_name","log2","pvalue"] 
t2.columns = ["Gene_name","log2","pvalue"] 
 
# Filter significant fold changes 
t105 = t1[t1["pvalue"] < 0.05] 
t205 = t2[t2["pvalue"] < 0.05] 
 
# Make tables containing the up and down regulated genes 
gene1_up = t105[t105["log2"]>1.] 
gene1_down = t105[t105["log2"]<-1.] 
gene2_up = t205[t205["log2"]>1.] 
gene2_down = t205[t205["log2"]<-1.] 
 
# Have a look at genes upregulated in AR-WT 
print (gene2_up) 
 
Ensembl gene id Gene_name log2_WT pvalue_WT 
ENSG00000134216 CHIA 4.046172   2.648248e-09 
ENSG00000175040 CHST2 2.370637   1.709631e-04 




# make tables of all deregulated using the Append function 
gene1_all = gene1_up.append(gene1_down) 
gene2_all = gene2_up.append(gene2_down) 
 
# Find genes deregulated in both datasets AR-WT and AR-Q641X using the merge function 
gene_common = gene1_all.merge(gene2_all,left_index=True, right_index=True, how='inner') 
 
# Drop the column for “gene name” that appears twice 




# Rename columns 
gene_common.columns = ["Gene_name","log2_Q641X","pvalue_Q641X", "log2_WT", "pvalue_WT"] 
 
# Have a look at the common genes in a table format 
gene_common 
 
Ensembl gene id Gene_name log2_Q641X pvalue_Q641X log2_WT pvalue_WT 
ENSG00000134216 CHIA 2.680970 7.787479e-04 4.046172 2.648248e-09 
ENSG00000229314 ORM1 3.785498 1.377485e-13 3.355856 2.257708e-10 
ENSG00000258926 RP11-47I22.1 3.481220 1.516913e-07 3.199291 2.412471e-06 
 
 
# Find genes upregulated in both AR-WT and AR-Q641X 
gene_up = gene1_up.merge(gene2_up,left_index=True, right_index=True, how='inner') 
gene_up = gene_up.drop("Gene_name_y",1) 
gene_up.columns = ["Gene_name","log2_Q641X","pvalue_Q641X", "log2_WT", "pvalue_WT"] 
 
# Find genes downregulated in both AR-WT and AR-Q641X  
gene_down = gene1_down.merge(gene2_down,left_index=True, right_index=True, how='inner') 
gene_down = gene_down.drop("Gene_name_y",1) 
gene_down.columns = ["Gene_name","log2_Q641X","pvalue_Q641X", "log2_WT", "pvalue_WT"] 
 
# Find genes deregulated in Q641X but not in AR-WT 
gene_Q641X = gene1_all.merge(gene2_all,left_index=True, right_index=True, how='left',indicator=True) 
gene_Q641X = gene_Q641X[gene_Q641X["_merge"] == "left_only"] 
 
# Drop columns 
gene_Q641X = gene_Q641X.drop(["Gene_name_y","pvalue_y","log2_y","_merge"],1) 
 
# Rename columns 




Ensembl gene id Gene_name log2_Q641X pvalue_Q641X 
ENSG00000142319 SLC6A3 3.916246 3.451926e-16 
ENSG00000166828 SCNN1G 2.068318 1.062004e-03 
ENSG00000136867 SLC31A2 1.520619 1.118436e-06 
ENSG00000070182 SPTB 2.253254 2.868471e-04 
 
# Save this table as an Excel sheet 
from pandas import ExcelWriter 






7. 2. II. Ingenuity Pathway Analysis 
After obtaining a list of deregulated genes from each AR variant, we used Ingenuity Pathway Analysis (IPA) 
software to identify known signalling pathways enriched in each condition. There were 59 genes 
deregulated by both the variants compared with AR-WT, and these were also analysed. The IGBMC institute 
has an annual subscription to IPA and it was there that I was trained in this program, which as shown in 
chapter 5 I have since applied to my own project.  
The below figures contain some of my IPA analyses, exploring the lists of genes specifically DE in the AR 
variant conditions (NB: since there are a limited number of images that can be downloaded on IPA, 
screenshots were used instead). First, I showed using a heat map that specific pathways and functions were 
enriched by AR-WT, but not by either of the AR variants (such as “Invasion of Cells”, and “Transport of 
Molecule”). Surprisingly, AR-V7 was most dissimilar to the others in terms of the types of genes that were 
deregulated. For instance, while AR-WT and AR-Q641X had strongest upregulation of “Cell movement” and 
“Synthesis of Lipid”, AR-V7 did not (Figure 2). This seemed peculiar since AR-V7 and AR-Q641X have similar 
protein structures due to the truncated CTD. Next, I compared the IPA core analysis profiles of the AR-V7 
and AR-Q641X conditions, which were indeed strikingly different. The AR-Q641X condition was associated 
with several growth-promoting pathways such as STAT3 signalling, VEGF signalling, and interestingly, HIF-
mediated glucocorticoid regulation which could point towards a link between hypoxic signalling (Figure 3). 
The AR-V7 gene list was enriched for metabolic pathways: Thyroid hormone metabolism, Nicotine 
degradation, NAD salvage pathway, Serotonin degradation, and Coagulation system. Finally, there were 
some interesting networks highlighted by IPA based on the AR-Q641X list, revealing that the subsequent 
effect of AR-Q641X expression could include Erk, Akt, and NF-κβ, which could suggest how these variants 










                
Figure 2. IPA heatmaps of diseases and biological functions, and pathways enriched in each condition. AR-V7 data 





Figure 3. Canonical pathways enrichment chart. Pathways enriched by Q641X expression relative based on the ratio 
between the number of genes from that pathway that are significantly deregulated, out of the total number of genes 
known to be involved in the pathway. Top enriched pathway is STAT3 signalling; 4 genes were significantly deregulated 
in this dataset out of a total of 74 genes known to be involved in STAT3 signalling (hence the small ratio) although it is 




          
Figure 4. Two networks highlighted by IPA, based on the significantly DE genes specific to the AR-Q641X 
conditions. Right-hand network suggests that ERK1/2 could be activated as a result of these genes, while left-hand 




7. 2. III. Literature review  
The IPA analysis provided some hints as to how the AR variants could promote cancer progression, although 
we wanted to understand better the long term effects of their expression. This experiment had produced 
much shorter lists of specific DE genes for each condition than their previous study, perhaps because of 
the new dox-inducible system (previously they had harvested the cells 72h after transfection, this time 24h 
after dox treatment). One of my tasks was to take half of the DE genes and perform a literature review on 
them, and I proposed that many were transcription factors that could shape the long-term response. We 
therefore highlighted all of the transcription factors from the gene lists and produced a table, which has 
been included in the manuscript. There were 24 transcription factors upregulated by AR-Q641X and 12 by 
AR-V7 but not by the endogenous AR-FL of eGFP condition nor the AR-WT, and 10 of these were 
upregulated by both AR variants (Table 3). Some of them have already been characterised in relation to 
cancer, such as the orphan nuclear receptor nuclear receptor subfamily 5 group A member 2 (NR5A2), 
CCAAT/enhancer-binding protein delta (CEBPD), Hes family BHLH transcription factor 1 (HES1), the 
nucleoside diphosphate kinase 2 (NME2), and ETS proto-oncogene 2 (ETS2). However, this is the first time 
that they have been implicated in the response to AR variant activation.  
 
 
Table 3. Transcription factors upregulated in each condition. Blue: transcription factors upregulated by both variants, 





7. 2. IV. ChIP-seq analysis 
I was invited to be part of the group discussions regarding the manuscript and in one of the last meetings 
that I attended; a paper that had just been published was discussed and had a similar study design. The 
authors had also overexpressed AR-WT and AR-V7 using plasmid vectors in 22Rv1 yet they had also 
included a ChIP-seq analysis to examine precisely which genes the AR variants were regulating (He et al., 
2018). When I returned home I uploaded this dataset from GEO using Integrative Genomics Viewer (IGV, 
https://software.broadinstitute.org/software/igv/) to explore if the DE genes from my list were indeed 
shown to be enriched in the ChIP-seq data. However, I did not observe any enrichment for the genes that 
I searched. As an example, I compared the chitinase acidic (CHIA) locus in the 22Rv1 AR-WT and AR-V7 
datasets, since this was the most significantly upregulated gene in the LNCaP AR-WT dataset but was not 
induced by the variants, although there was no different (Figure 5).  However, this was a different cell line 
and when I uploaded two other ChIP-seq datasets using AR-WT in LNCaP, there were peaks at the CHIA 


























Figure 5. ChIP-seq analysis of the CHIA locus. No difference between the peaks at CHIA locus in the AR-WT and AR-





Figure 6. Binding of AR-WT to the CHIA promoter. Based on data from two independent ChIP-seq studies, peaks 
observed at the CHIA promoter locus, suggesting CHIA may be a direct target of AR in LNCaP that is not expressed by 
the AR variants.  
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7. 3. Discussion 
7. 3. I. Summary of findings 
This study confirms that the AR variants have distinct transcriptional activity compared to the wild-type. 
There were many genes, and even entire signalling pathways, that were activated by the AR variants that 
were not activated by wild-type nor endogenous full-length AR. Furthermore, we reported a number of 
transcriptional factors induced that may shape an increasingly malignant cell state. The variants lack the 
LBD meaning that they are constitutively active, however, this study also highlights that it changes AR’s 
transcription factor activity; there were fewer pathways activated by the AR variants than AR-WT and AR-
FL, suggesting they have decreased transcriptional activity. However, we highlighted some known 
oncogenes that were overexpressed exclusively by the variants, which could contribute to the increased 
aggressiveness that is associated with their expression. The different transcriptional activity could reflect 
different binding partners or transcriptional co-regulators, due to the change in the structure of the AR 
protein.  
7. 3. II. Strengths and limitations of the study 
This study reports some interesting findings and the study design was novel. Most published studies have 
used a cell line like 22Rv1 or PC3 that have a deleted or mutated AR. Here, LNCaP was chosen because it 
has an active endogenous AR-FL and is sensitive to AR signalling and so this is the first study of its kind in 
LNCaP. This was designed to be a more accurate representation of the situation in a prostate tumour in 
which AR-WT is expressed and at the same time, the variants are upregulated, resulting in a mixture of 
wild-type and mutant AR in the cell. Furthermore, LNCaP does not have endogenous expression of most of 
the AR variants, unlike 22Rv1 (Wadosky and Koochekpour, 2017). The effect of AR-WT was distinguished 
from AR-FL by comparing the transcriptome of cells expressing only eGFP and treated with DHT, which has 
not been shown previously. Furthermore, the study included AR-Q641X which is a relatively unstudied 
variant, and utilised a novel dox-inducible system. However, in my opinion one limitation is that the AR-V7 
condition should have been excluded from the analysis since it has a suspiciously different expression 
profile from AR-Q641X when the proteins are structurally highly similar, and including AR-V7 could have 
biased the list of commonly deregulated genes. I noticed when performing the literature review of the 
deregulated genes, that some of the most significantly deregulated were pseudogenes, which have no 
known function. This highlighted the inherent limitation of all RNA-seq based studies in that we may 
mistakenly attribute a change in RNA levels to be biologically relevant because the p-value happens to be 
significant. As with all cell line studies, this experiment is limited in that the overexpression of the variants 
was out of the context of a tumour. However, it was a valuable model to dissect the pathway in a 
homogenous population to improve reproducibility and without the noise of other cell types. Finally, IPA 
was used for pathway analysis, which has a wealth of information on gene ontology and it incorporated 
the effect size and significance. However, the graphs such as the network analysis must be interpreted 
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cautiously since the information is based on published discoveries from numerous cell types and the 
interactions and functions that it attributed here may not exist or be relevant in a PCa setting.  
7. 3. III. Future directions 
To confirm their differential expression in the AR variant conditions, the key deregulated genes could be 
validated by another technology such as RT-qPCR, and their oncogenic effects could be confirmed by 
phenotypic assays. For instance, the IPA analysis suggested that proliferation may be reduced in the variant 
conditions, due to the downregulation of E2F targets, G2M checkpoint and PI3K/AKT/mTOR signalling. This 
could be confirmed by growth curves or MTT assay. To confirm that the IPA predicted interactions between 
co-expressed genes occur in this system, these could be confirmed by co-immunoprecipitation.  
An RT-qPCR or Western blot for the AR-WT, AR-V7 and AR-Q641X in the cells could be used to confirm the 
integrity of the plasmid and gene. This could additionally give an indication of the expression level produced 
by the dox-inducible system, to ensure it is effective but not too high. We observed far fewer genes induced 
after 24h of dox treatment than they previously observed; in future, collecting cells over a time-course 
could to map the progressive effects of AR variant expression. Immunoprecipitation-based studies could 
examine the non-genomic functions of AR, such as its scaffolding functions as loss of the CTD would change 
its interacting partners, which could underlie the differing transcriptional effects. If a critical structural 
difference between the AR variants and AR-WT is identified, such as a binding site for another protein, it 
could inform the development of an agent to inhibit the variants. Binding partners could be predicted by 
the database POSSUM and validated by co-immunoprecipitation and mass spectrometry, or de novo using 
BioID (an IP-based assay for identifying interacting proteins) (Roux, Kim and Burke, 2013). It would also be 
valuable to determine whether the variants are heterodimerising with endogenous AR-FL or each other 
(since active AR is a homodimer), which would have implications for its transcription factor activity. Similar 
to the 22Rv1 study by He et al., integrating the RNA-seq data with ChIP-seq data could determine which 
genes are direct transcriptional targets of AR and the variants (He et al., 2018).  
The previous study highlighted miR-210 as induced by AR-V7, a ChIP experiment could confirm this and if 
so the effect of the variants on other mediators of the hypoxic response could be explored. Alternatively, 
perhaps overexpression of the variants confers increased resistance or different transcriptional effects 
during hypoxia. Then, miRNA-seq could be performed on the variant expressing cells, to examine their 
effect on miRNA profiles during normoxia and hypoxia. This could reveal critical miRNAs that mediate 
increased malignancy following expression of the variants, either in the basal state or during hypoxia. 
Androgen receptor variant behaviour in hypoxia and the effect of miRNAs remains unexplored and could 
have significance in understanding the response to therapy and how resistance develops. 
216 
 
7. 3. IV. Concluding remarks 
In conclusion, this internship was extremely interesting and useful, as I gained insight into another field of 
PCa research and gained understanding and skills in analysis of omics data, which I have been able to apply 
to my own project.  
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Chapter 8. Systematic Review and Exploratory Meta-Analysis: the 
Appetite-Regulating Hormones – Leptin, Adiponectin and Ghrelin – and 





























7. 1. Foreword 
This chapter consists of a systematic review that I lead authored, which broadly addresses the relationship 
between obesity and prostate cancer development. It was written because the opportunity arose for me 
to collaborate with the WHO International Agency for Research in Cancer (IARC), based in Lyon in France, 
as a follow-on from an internship that I completed there before starting my PhD. Although this was not 
strictly aligned with the scope of my PhD, it was still in the field of PCa and was an excellent chance for 
international collaboration, so it was worked into the overall PhD schedule. 
My review was a collaboration between the Nutritional Epidemiology and the Screening groups, as the two 
PIs were scientists from those groups. The PIs were Inge Huybrechts PhD who is an expert in nutrition and 
epidemiology, and Vitaly Smelov MD PhD who is a practicing urologist and PCa researcher. I was given 
primary responsibility for designing and executing a systematic review and meta-analysis related to both 
nutrition and cancer screening. Since my PhD investigates PCa, and I was collaborating with a Nutrition 
group, I chose the timely topic of obesity-related hormones in PCa, with the specific title “Appetite-
Regulating Hormones – Leptin, Adiponectin and Ghrelin – and the Development of Prostate Cancer: A 
Systematic Review and Exploratory Meta-Analysis”.  
The scope of the review was to combine the results of observation studies that  have compared the levels 
of these hormones in PCa patients and controls, to determine if the hormone levels associated with disease 
incidence or progression to an advanced stage. Many such studies have been published over the last 30 
years although the conclusions have been mixed. The aim of the review was to elucidate the relationship 
between obesity and PCa, and to assess their reliability as biomarkers for diagnosis or prognosis.  
The review was accepted for publication in the Nature Publishing Group journal Prostate Cancer and 
Prostatic Diseases (PCAN) in April 2019. The completed published version of the manuscript follows this 
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7. 2. Afterword 
7. 2. I. Summary 
As outlined in the review, leptin levels were not associated with PCa incidence or advancement. However, 
I concluded that adiponectin levels may be inversely associated with advanced stage disease. Too little 
evidence was available on ghrelin levels for an association to be determined.  
This type of epidemiological research evidences association only and cannot be used to evidence causation, 
and so a tumour suppressive effect of adiponectin cannot be confirmed. However, as cited in the paper, 
some in vitro functional studies have reported growth-inhibiting effects of adiponectin on PCa cell lines. 
Therefore, the review supports other evidence that obesity may create systemic effects which prostate 
tumours may be sensitive to, in this case, low levels of adiponectin. This suggests that the prostate tumour 
is a dynamic entity that is responsive to the systemic as well as the local environment (e.g. hypoxia), and 
that a holistic approach to PCa research is important, considering the influence of lifestyle risk factors as 
well as inherited and sporadic genomic abnormalities and the tumour microenvironoment.  
Overall, I found this experience extremely valuable as I gained experience in reading and reviewing 
published research, in epidemiology statistics, and scientific writing, as well as collaborating within a multi-
disciplinary team. The review has also helped me to structure my literature searches when preparing my 
general introduction and chapters.   
7. 2. II. Future directions 
The systematic review approach described here could easily be expanded to the topics of miRNAs in PCa 
and/or obesity. Indeed, as the number of publications in this area increases, a structured meta-
analysis/review would be very timely and useful. There are currently many reports of miRNAs being 
dysregulated during obesity, either in metabolic tissues or in circulation (the PubMed search: miRNA AND 
obesity NOT review, reveals over 800 research articles). For many of the implicated miRNAs, a functional 
role has been determined, for example regulating adipogenesis, insulin resistance, or glucose uptake (Xie, 
Sun and Lodish, 2009)(del Carmen Martínez-Jiménez, Méndez-Mancilla and Portales-Pérez, 2018). It would 
therefore be interesting to focus on obesity-related miRNAs that influence PCa development. A couple of 
publications are available that have addressed this issue, although too few for review and mainly 
implicating inflammation mediating miRNAs which are likely dysregulated due to the systemic subclinical 
inflammation that is associated with obesity. It therefore appears that this area requires further 
investigation. To explore this, perhaps the serum or PCa tissue of men with differing BMIs could be analysed 
for miRNA expression by miRNA-seq (matching the case and control groups for tumour stage and patient 
age and family history).  
Interestingly, this review highlighted the difficulties in assessing the use of serum hormone biomarkers. 
The study designs were highly heterogeneous, for example the different types of protein quantification 
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assays (such as ELISA, or RIA). Indeed, unexpected variation was observed in the absolute hormone levels 
across the different cohorts, perhaps reflecting assays of different sensitivities. It would be simpler to use 
a biomarker such as a small RNA, which are reliably detected by PCR methods, using smaller amounts of 
starting material, and may be less varied due to the type of assay used. An important next stage of this 
research would be to perform a similar systematic review investigating the association between obesity-
related miRNAs and PCa, however, as mentioned above this will not be possible until more literature is 
available (that is, more observation studies have been carried out, measuring miRNA levels in PCa patients). 
Alternatively, a list of miRNAs that regulate leptin or adiponectin could be compiled and measured in PCa 
patients as these could be more consistent as biomarkers.  
Finally, one implication of this research is that body size and potentially diet, have the ability to influence 
cancer incidence. This could be further dissected at the molecular level, for instance by investigating the 
effect of diet on epigenetics or miRNA expression. As mentioned in the General Introduction section 1.1. 
III., PCa incidence varies widely between populations which could partially be due to their varying diets. As 
an example, Asian men have a relatively low incidence compared with European and North American men 
which could be linked with their higher consumption of soy products (Perabo et al., 2008). It has been 
shown that genistein (a soy-derived isoflavone and phytoestrogen) influences PCa cell behaviour; it 
inhibited migration and invasion in vitro (Pavese, Krishna and Bergan, 2014). Similar observational and in 
vitro studies have linked polyphenols and other antioxidants with a tumour suppressive effects in PCa 
(Patel, 2014). Previous work in our laboratory demonstrated that treatment of PCa cells with genistein 
caused demethylation of the promoter CpG sites closest to the miR-200c loci, resulting in increased miR-
200c expression (Lynch et al, 2016), and suggesting a potentially important relationship between diet and 
epigenetic regulation of miRNAs.  With this in mind, it could be interesting to use an observation study to 
correlate dietary or exercise habits with miRNA expression or DNA methylation patterns in PCa, for instance 
by comparing the transcriptome or epigenome of PCa patients of different BMI groups, types of diet, or 
exercise patterns. Then, GO functional enrichment or network analysis would be used to characterise the 
differences, as demonstrated in chapter 5. Intriguingly, one study found that genistein modulated 
epigenetic profiles when given as a supplement to PCa patients (30mg daily); it was associated with 
differential DNA methylation of genes regulating development, proliferation, transcription, and stem cell 
markers, with enrichment analysis indicating overall reduction in Myc and increased PTEN activity (Bilir et 
al., 2017). Similarly, an intervention study could be used, giving PCa patients a supplement such as 
antioxidants or polyphenols, and then performing methylation array or miRNA-seq to explore differences 
in methylation or miRNA expression patterns.  
In summary, properly conducted systematic reviews are important tools for effectively appraising and 
evaluating the evidence that is rapidly accumulating in relation to the complex causative factors of PCa 
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development and progression. Such reviews and meta-analyses can help prioritise the areas to focus on, 
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8. 1. Overall summary of findings 
This thesis has focused on characterising the expression and function of miRNAs during hypoxia in PCa, 
while touching on other important influences such as gene regulation by DNA methylation, expression of 
pathological splice variants, and the interaction between obesity-related hormones and PCa outcome. 
Taken together, these chapters illustrate the complexity of the disease and highlight the utility of 
personalised medicine approaches, such as monitoring hypoxia or other patient-specific variables.  
8. 2. HypoxamiRs in prostate cancer 
Hypoxia is common in prostate tumours and is a known driver of tumour progression, so it is therefore 
important to understand its effects at the cellular level. Furthermore, hypoxia can be exacerbated by 
chemotherapies such as bicalutamide, as demonstrated in chapter 3. Hypoxic stress exerts widespread 
effects, through the activation of the master transcription factor HIF, plus the reduced activity of oxygen 
dependent enzymes. At the transcriptional level, hypoxia responsive miRNAs (“hypoxamiRs”) may play a 
critical role in the hypoxic adaptation of cancer cells and subsequently increase malignancy. Numerous in 
vitro and NGS studies have previously shown that acute or chronic hypoxia affected the expression of 
swathes of miRNAs, and for many of them a functional role was confirmed. This thesis provides new data 
to evidence how hypoxia can contribute to tumour progression through its impact on miRNAs. Chapters 3, 
4 and 5 have demonstrated that miR-210, miR-21, and miR-196a were induced by hypoxia in PCa models. 
In some cases we presented how it may contribute to PCa progression. For instance, in vitro phenotypic 
assays highlighted an ability of miR-21 overexpression alone to increase the cells’ clonogenicity and 
migration, and miR-210 was shown to regulate the neural cell adhesion molecule. Therefore, our findings 
are in accordance with previous research on these miRNAs while adding novel data.  
8. 3. MicroRNA biomarkers in prostate cancer 
In addition to elucidating the aetiology of PCa, miRNAs such as these could be clinically valuable as 
biomarkers. Biomarkers are an essential component of personalised medicine as they can reveal the nature 
of the patient’s disease and allow the clinician to estimate to which treatment they will best respond. They 
can also be used to monitor specific biochemical outcomes such as tumour reduction, hypoxia, imminent 
relapse, remission, or metastasis (Hayes, Peruzzi and Lawler, 2014). Potentially, in the future levels of miR-
210 and/or miR-21 could be used to indicate PCa hypoxia, which would suggest that additional hypoxia-
targeting treatment is necessary, such as addition of a hypoxia-activated prodrug or oxygen perfusion, or 
direct the clinician to choose surgery over radiotherapy alone. Chapter 4 reported that miR-21 was also 
upregulated in the serum of mice, suggesting that it may be a useful addition to liquid biopsy panels to 
monitor tumour hypoxia. Fluid based or circulating miRNAs can make diagnosis less invasive for the patient, 
and can easily provide longitudinal measurements across a period of “watchful waiting” or treatment. 
Moreover, in TCGA Regulome Explorer cohort of 333 patients, miR-21 tumour levels (in addition to miR-
210 levels) improved the ability of Gleason scoring (a clinical parameter) to predict a patient’s response to 
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therapy. It is important to note that miRNAs are particularly appropriate molecules for biomarker use as 
they are abundant and stable due to their short size, and their position within the RNAi machinery or within 
exosomes. Exosomal miRNAs from blood were found to be stable even after several freeze/thaw cycles 
and long periods at room temperature where longer RNA transcripts or proteins would have been 
degraded, emphasising their unique capacity as biomarkers (Mitchell et al., 2008). However, although the 
potential of miRNA profiling seems great, more research is required to identify the best miRNAs, or 
combinations of miRNAs, that should be profiled for PCa and other diseases. 
8. 4. MicroRNAs in prostate cancer therapeutics 
Naturally, the use of miRNAs in therapeutics has been slower to emerge than in diagnostics, as an extra 
dimension of research is required to evaluate off-target effects and optimise effective delivery and stability 
of the molecule in its tissue. Nevertheless, RNAi based therapies are already entering the clinic (Bouchie, 
2013). The major bottleneck has been efficient delivery of the molecule (i.e., foreign RNA) into living cells 
without it being destroyed, but new improved conjugates that mask them from the cell’s innate response 
are being finalised (Springer and Dowdy, 2018). Another limitation to miRNA-based therapies is off target 
effects, since miRNAs operate within intricate networks. This reflects the inherent limitation of miRNA 
functional studies, as the majority involve a simplified model in which the targeting of a specific mRNA is 
validated in vitro, as reported in chapters 3 and 4. These studies are essential to confirm the biological 
function of the miRNA as a regulator of the mRNA in question. However in complex organisms, mRNAs are 
regulated by the simultaneous and coordinated action of numerous miRNAs operating within a network of 
interactions. Likewise, miRNAs are promiscuous and may regulate many other mRNAs, which may 
positively or negatively regulate each other (or act differentially on multiple nodes of the same pathway), 
and thus the net effect of a miRNA’s overexpression can be difficult to ascertain (Figure 1). This was 
illustrated in chapter 3, in which in several replicates, miR-210 did not significantly reduce the mRNA level 
of NCAM although the luciferase reporter assay confirmed the targeting. In this way, miRNA promiscuity 
poses an issue in terms of therapeutics, as for example, using a miRNA inhibitor (antagomiR) could have 
unanticipated effects on diverse secondary targets. An alternative for miRNA inhibitors are “target 
protectors” (morpholinos), a similar molecule that binds to the mRNA target at its miRNA binding site (with 
14-15 nucleotides in specificity) blocking miRNA-binding yet permitting translation (Ho et al., 2012). This 
approach would be suitable if a miRNA had a single deleterious effect of suppressing a key target. For 
instance if a key target of miR-196a was identified (e.g. an apoptosis inducer) then a morpholino could be 
appropriate to singularly disrupt this interaction, whereas considering the many tumour-suppressors 
targeted by miR-21, an antagomiR inhibitor molecule would be more useful. Another issue with miRNA 
based therapies is resistance, although combinatorial miRNA modulation has been suggested to overcome 
this (Hayes, Peruzzi and Lawler, 2014). As an example, dual inhibition of miR-21 and miR-210 could be a 
viable strategy to suppress the deleterious effects of hypoxia. Similarly, resistance has been observed to 
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occur due to the redundancy between numerous miRNAs, or through different family members, although 
sequences can be designed that target the whole family. A benefit of miR-21 and miR-210 would be that 
they do not have known family members.  
 
 
Figure 1. MiRNAs operate in networks with varying degrees of complexity. Networks based on a similar figure from 
(Hayes, Peruzzi and Lawler, 2014). A) The basic sequence of a single miRNA targeting a single mRNA, modulating an 
effect. B) MiRNA promiscuity, one miRNA has multiple mRNA targets thus modulating multiple effects, the sum of 
which may determine a phenotype. C) A miRNA may regulate multiple targets that are functionally related and thus 
interact with each other to produce a phenotype. D) A miRNA (or related miRNAs such as from a cluster) target 
multiple nodes in a pathway, potentially via other molecules (miRNAs or mRNAs). E) The potential structural 
complexity is amplified, considering the number of potential targets of each miRNA. Network of validated targets of 
miR-210 (in all cell types) from miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php), highlighting NCAM 
as a target among many other targets, which additionally has other known regulators.  
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8. 5. Multi-omics approaches in prostate cancer research and healthcare 
This thesis has focused mainly on in vitro and in vivo methods, but I had the opportunity to work with some 
NGS datasets through collaborations with the BioSpyder company in California and a research group in 
Strasbourg. Furthermore, I replicated an RnBeads methylation analysis workflow process using a publicly-
available methylation array dataset, which is a method that has been described by the Colum Walsh group 
at Ulster University. These collaborations allowed me to explore the immense utility of large datasets, and 
develop some introductory skills in bioinformatics. Multi-omics approaches are important in research and 
healthcare, and can involve screening for differentially expressed molecules, differentially methylated 
genomic regions, the pathological AR variants, or obesity-related signalling. However, to supplement omics 
analysis, wet-lab investigations remain essential to prove the functional roles of genes and this is 
particularly important for translating biomarkers into therapeutic targets. For functional analysis, 
phenotypic screens are useful, although as reported in chapter 5 they assess a limited number of cell 
behaviours, and may miss key interactions that take place in the context of the tumour. 
8. 6. The value of miRNAs in personalised medicine 
Investigating hypoxia-associated transcriptional or epigenetic changes is particularly impactful because it 
can be applied to many cancer settings, and perhaps beyond to diseases that similarly involve deregulated 
hypoxic signalling such as cardiovascular disease or stroke. Furthermore, miRNA or DNA based biomarkers 
are more stable and may be more cost-effective to analyse than protein markers since primers are 
generally cheaper than antibodies. While the extensive use of omics data for personalised medicine 
approaches has been hailed for patient stratification, it has also received criticism for failing to consider 
cost-effectiveness. A seminal meta-review highlighted that most studies that have investigated 
personalised medicine tests, had not included an economic assessment during the evaluation of their 
utility; they concluded that while many tests did prove to be cost-effective, remarkably few were cost-
saving (Phillips et al., 2014). As outlined in the chapter 5 discussion, personalised medicine will comprise a 
medley of approaches, although it is crucial that impact and applicability be considered to ensure that the 
eventual test or product will be viable. Already, only 12% of global health spending occurs in low and 
middle-income countries, despite containing 84% of the world’s people, and the transition to personalised 
medicine (i.e. increasingly complicated and specific tests) will compound the widening gap (Gottret and 
Schieber, 2006). PCR based methods of detection are cheap, simple and reliable, which increases the 
chances that they can be utilised across the world, compared with other diagnostic tools such as multiplex 
assays for protein biomarker detection. So, as a final comment it is important to emphasise approaches 
such as simple PCRs or genomic arrays (for miRNAs, or methylation specific PCR) compared with proteomics 
or whole-genome NGS analyses. Figure 2 illustrates a multi-omics integrated approach to personalised 



















Figure 2. Towards a personalised medicine approach to prostate cancer diagnosis and management. A combination 
of genomics, clinicopathological, and patient specific characteristics will be used to accurately inform PCa diagnosis 
and determination of tumour characteristics such as hypoxia or AR variant status. This will thus inform the choice of 
treatment; co-morbidities such as cardiovascular disease (CVD) would suggest surgery is not suitable for the patient, 
AR variant expression could indicate androgen inhibiting chemotherapy is unsuitable, and hypoxia may indicate that 
radiotherapy is unsuitable or indicate the need for hypoxia targeting treatments like a hypoxia-activate prodrug or 
oxygen perfusion. The patient’s response to treatment, and subsequent biochemical outcomes, will also be monitored 
by standard clinicopathological measurements (i.e. biopsy or PSA levels) supplemented by specific markers such as 




8. 7. Future directions: 
There are many broad areas for future investigation that could be pursued to build upon the data and ideas 
presented in this thesis, in addition to the focused suggestions already outlined in the discussion of each 
chapter. The study design could also be improved in several ways.  
8. 7. I) Study design improvements 
The RT-qPCR approach used throughout this thesis could have benefited from complete adherence to the 
“MIQE” guidelines (the Minimum Information for Publication of Quantitative Real-Time PCR Experiments) 
(Bustin et al., 2009). These aim to improve the reliability and reproducibility of RT-qPCR results across 
laboratories, and include a checklist of the essential features of an RT-qPCR experiment. One guideline 
which I did not adhere to was to computationally determine which housekeeping gene was most stable 
and thus best for each experiment, for which there are several algorithms available such as Bestkeeper 
(Pfaffl et al., 2004) and geNorm (Vandesompele et al., 2002)(Mestdagh et al., 2009).  
Additionally, I used luciferase reporter assay to explore the regulation of NCAM by miR-210, which is 
frequently described as the “gold standard” in validating miRNA : mRNA interactions (Lewis et al., 2003). 
However, a newer approach such as CLIP-seq would be best as it will highlight novel interactors in an 
unbiased way. CLIP-seq involves immunoprecipitating miRNAs after crosslinking them to mRNA targets, 
and sequencing the targets (Chi et al., 2009). 
It is vital to note that this thesis has made use of cell line models to explore the aetiology and progression 
of cancer, models in which there are profound limitations of cell lines. These cell lines provided a limited 
model of in vivo cancer as they are homogenous populations of epithelial cells, which were purified from 
tumours years (often decades) previously and have been subject to in vitro culture and freeze/thaw cycles 
since. Especially in the case of cancer as a disease, cell lines may be inappropriate since their genomes are 
unstable and they thus have increased propensity to mutate, adapt and evolve and at the point of 
laboratory measurement they may be incomparable to the original genotype. Moreover, since they were 
isolated from a small population of cells from a patients (highly heterogeneous) tumour they may not 
represent the cancer as it manifests across different patients. A more reliable way to identify gene 
expression in cancers would be to use tumours from a cohort of patients, sort the cells by FACS, and 
perform scRNAseq. However, the caveat of this approach would be that a vast number of patients would 
be required to obtain significant (i.e., non patient-specific) results and it would be enormously expensive. 
Furthermore, cell lines are most useful for pathway analysis since they are homogenous and provide a 
smaller system to model changes without interference from other cell types.  
Finally, this work made use of transient overexpression of hypoxia-associated miRNAs to explore their 
effect on cell behaviour. However, it would be more useful to have used antogomir molecules to block the 
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effects of the miRNA during hypoxia, to observe the lack of its effect. A loss of function during hypoxia 
study would have been more valuable than gain of function during normoxia.  
8. 7. I) Future research  
As mentioned, monitoring or targeting hypoxia could have uses in many tumour types. As an illustration, a 
panel of standard hypoxamiRs could be designed that effectively characterise the hypoxic tumour cell, 
perhaps including the addition of PCa-specific markers such as the long non-coding RNA PCA3 (see General 
Introduction section 1.1. V.) or AR. Ideally, a serum profile would be developed but it must be able to 
distinguish between tumour hypoxia and cardiovascular disease or an inflammatory disorder.  
The principles of profiling miRNA expression by PCR could also be extended to other non-coding RNAs, such 
as long non-coding RNAs (lncRNAs). Many researchers investigate lncRNAs as biomarkers, and several have 
been identified as biomarkers of PCa (such as PCA3) (Misawa, Takayama and Inoue, 2017). In general I 
believe miRNAs may be more valuable since their short size increases their physical stability which makes 
them more robust and suitable for simpler protocols, and thus more accessible to research groups. 
However, if reliable lncRNA biomarkers could be identified, a large panel may be useful. A number of 
lncRNAs have been identified that are expressed in response to hypoxia, in cancers such as breast, gastric 
and pancreatic cancers (Chang et al., 2016). One study has shown that a lncRNAs was hypoxia-responsive 
and in vitro studies showed it could increase the proliferation of PCa cell lines and was associated with PCa 
patient prognosis (Zhao et al., 2017). Therefore, this area could be further investigated.  
Another option could be to look for circular RNAs (circRNA), which are currently the focus of intense 
investigation since they sponge miRNAs and are incredibly stable and thus ideal as biomarkers (Rong et al., 
2017)(Li et al., 2015). CircRNAs are produced through a specific biogenesis pathway, or result from slicing 
events (Ashwal-Fluss et al., 2014). Considering that a key problem in PCa is pathological AR splice variants, 
perhaps the missing segments could produce circular fragments and could be detected as markers of 
aberrant splicing.  
As mentioned in chapter 5, DNA methylation at gene bodies is involved in the regulation of splicing, so it 
could also be interesting to investigate if methylation patterns of the AR gene body associate with 
expression of the AR variants, and perhaps if hypoxia could modulate it. Indeed, further investigation into 
the relationship between hypoxia, DNA methylation, and miRNAs would be interesting. The NSCLC study 
by Thienpont et al., demonstrated that the demethylating TET enzymes are oxygen dependent (Thienpont 
et al., 2016) as are many other epigenetic regulators such as histone deacetylases (HDAC) and sirtuins 
(Camuzi et al., 2019). The methyl donor S-adenosylmethionine is reduced during hypoxia in liver cells (Liu 
et al., 2011) and the expression of DNMT1 and DNMT3a/b have each been shown to be affected by hypoxia 
in different cell contexts (Camuzi et al., 2019). These highlight how epigenetics will be immediately 
susceptible to hypoxia. They suggest that epigenetic based therapies such as HDAC inhibitor may not be 
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effective when tumours become hypoxic; future studies of such therapies should monitor and control for 
the effect of hypoxia and patients should be stratified accordingly.  
Interestingly, miRNA biogenesis is regulated by hypoxia (via epigenetics) which could be important for the 
hypoxic response. It was reported that miRNA biogenesis is suppressed during hypoxia, as the H3K27me3 
demethylases 6A and 6B (KDM6A/B), which are required for activation of the Dicer promoter, are oxygen-
dependent (van den Beucken et al., 2014). As discussed in the General Introduction section 1.3. VII.,  
miRNAs are essential for rapid stress responses and adaptation. However, whether this influenced the 
overall activity of miRNAs has not been shown. To explore this, point mutations in Ago could be performed, 
such as mutating the region that binds the 5’ phosphate of the miRNA/siRNA. This knock-in could be 
achieved using a CRISPR/Cas9 or a cre-lox recombination system (Hagan et al., 2019)(Balligand et al., 2019). 
Then, the ability of the mutant cells to survive hypoxia could be measured.  
This thesis has touched on how androgen deprivation therapy (ADT) such as bicalutamide can influence 
hypoxia, with the view to elucidate the link between ADT and tumour progression and/or relapse. To 
further these investigations, it would be interesting to explore the effect of hypoxia-responsive miRNAs on 
the AR signalling pathway, which could modulate the pathway and mediate AR independence. A list of AR 
targets could be compiled including miRNAs that regulate them. If any of these miRNAs are hypoxia-
responsive, it could suggest a mechanism through which hypoxia facilitates AR independence.  
The effects of ADT could also be investigated by single cell RNA-seq (scRNA-seq). As mentioned in chapter 
5, scRNA-seq can be extremely powerful in characterising heterogeneous cell populations and has been 
used to discover rare and small cell populations. Here, scRNA-seq could be suitable to analyse tumours 
following ADT, using a model similar to the one presented in chapter 3. With increasing ADT treatment and 
hypoxia, tumours could be extracted and analysed by scRNA-seq. This may highlight the population of cells 
that facilitate relapse, which may have cancer stem cell like features and favour a hypoxic environment.  
To conclude, it is clear from the work presented here that hypoxia in PCa does impact upon miRNA 
signalling. This is a complex interaction that overlaps with other hypoxic response axes within the cell, but 
there is great opportunity to use this information to help improve the management of PCa. This thesis has 
added valuable, novel data to the overall global research effort to combat PCa, with impact for researchers, 
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2018). 
 Obtained £500 from Ulster University Doctoral College to fund the All Ireland Biomedical Sciences 
Postgraduate Conference.  
 Collected £1,800 funding to attend Keystone Symposium on Small Regulatory RNAs (£550 Travel Award 
- The Biochemical Society; £750 Conference Grant - The Genetics Society, £500 Travel Grant - The Royal 
Society of Biology). 
 Secured £1,000 from the Biomedical Sciences Research Institute to run social and academic events for 
the Biomedical Sciences Postgraduate Society (Sep 2017). 
 Successfully requested £1,000 from the Ulster University Research and Impact department, to organise 
and run a workshop for PhD researchers: ‘Introduction to Statistical Programming with R’ (Jun 2017).  
 Successfully applied for a £250 grant from Santander to run “Postgraduate Careers Workshop” (Sept 
2017).  
 Awarded £500 Training grant from The Genetics Society to attend ‘Introduction to RNAseq’ course 
(London, Nov 2017). 
 Awarded £60 scholarship from the School of Biomedical Sciences to attend All Ireland Biomedical 









“Appetite-Regulating Hormones - Leptin, Adiponectin and Ghrelin - and the Development of Prostate Cancer: A 
Systematic Review and Meta-Analysis”.  
C. Zoe Angel, Isabel Iguacel, Amy Mullee, Neela Guha, Rachel Wasson, Declan J. McKenna, Marc J. Gunter, Vitaly 
Smelov & Inge Huybrechts. April 2019 Prostate Cancer and Prostatic Diseases. 
 
“Serum levels of miR-199a-5p correlates with blood pressure in premature cardiovascular disease patients 
homozygous for the MTHFR 677C > T polymorphism”  
Seodhna M. Lynch, Mary Ward, Helene McNulty, C. Zoe Angel, Geraldine Horigan, J.J. Strain, John Purvis, Mike 
Tackett, Declan J. McKenna. In press, Genomics. 
 
“miR-210 is Induced by Hypoxia and Regulates Neural Cell Adhesion Molecule in Prostate Cells” C. Zoe Angel, 
Seodhna M. Lynch, Colum P. Walsh & Declan J. McKenna.  Journal of Cellular Physiology Accepted Jan 2020 
 
Submitted 
 “Transcriptional Landscapes of Constitutive Androgen Receptor Variants in Prostate Cancer”  
Pauline Ould Madi - Berthélémy, Eva Erdmann, Edwige Schreyer, Mathieu Jung, C. Zoe Angel, Bruno Kieffer & 
Jocelyn Céraline. Submitted for publication to Oncotarget. 
 
 
Conference presentations  
 
Oral presentations:  
The All Ireland Biomedical Sciences Postgraduate Conference (Sligo, 14th -15th Jun 2017) “Regulation of miR-210 
by hypoxia in prostate cancer”. C. Zoe Angel, Seodhna M. Lynch, Heather Nesbitt, Colum P. Walsh, Declan J. 
McKenna. 
 
Ulster University PhD Festival of Research (9th Apr 2019). “Investigating the role of miRNAs in the hypoxic 
response in prostate cancer”. C. Zoe Angel, Christopher J. McNally, Colum P. Walsh, Declan J. McKenna. 
 
Poster presentations:  
European Congress of Personalised Medicine, (Belfast, 27th – 30th Nov 2017) “MicroRNAs in Prostate Cancer: 
Implications for Personalised Medicine”. C. Zoe Angel, Seodhna M. Lynch, Colum P. Walsh, Declan J. McKenna. 
 
Irish Association for Cancer Research (Dublin, 22nd Feb 2018) “miR-210 is regulated by hypoxia and contributes 
to malignant progression in prostate cancer.” C. Zoe Angel, Seodhna M. Lynch, Heather Nesbitt, Declan J. 
McKenna.  
 
Androgens Meeting (Edinburgh, 3rd – 5th Sept 2018). “The Androgen Receptor Variants ARV7 and ARVQ641X 
have distinct Transcriptional Activities in Prostate Cancer Cells.” Pauline Ould Madi - Berthélémy, Eva Erdmann, 
Edwige Schreyer, Mathieu Jung, C Zoe Angel, Bruno Kieffer & Jocelyn Céraline. 
 
World Cancer Congress (Kuala Lampur, Malaysia, 1-4 Oct 2018) E-poster “The Appetite-Regulating Hormones - 
Leptin, Adiponectin and Ghrelin - and the Development of Prostate Cancer: A Systematic Review and Meta-
Analysis” (presented by Dr I. Huybrechts) C. Zoe Angel, Isabel Iguacel, Amy Mullee, Neela Guha, Rachel Wasson, 
Declan McKenna, Marc Gunter, Vitaly Smelov & Inge Huybrechts. 
 
Irish Association for Cancer Research (Dublin, 22nd Feb 2019) “miR-21 is induced by hypoxia in prostate cancer 
and targets the tumour suppressor Rho-related GTP-binding protein (RHOB)”. C. Zoe Angel, Seodhna M. Lynch, 
Colum P. Walsh, Declan J. McKenna. 
 
Keystone Symposium – D7 Small Regulatory RNAs (Daejeon, South Korea, 16th – 18th Apr 2019). “Investigating 
the role of miRNAs in the hypoxic response in prostate cancer”. C. Zoe Angel, Christopher J. McNally, Colum P. 
Walsh, Declan J. McKenna. 
